us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent us-gaap:PropertyPlantAndEquipmentNet us-gaap:LongTermDebtAndCapitalLeaseObligationsCurrent us-gaap:LongTermDebtAndCapitalLeaseObligations APTARGROUP INC 0000896622 false--12-31 2019 Q3 DE IL 0000896622 country:FR 2019-01-01 2019-09-30 0000896622 2018-10-01 2018-12-31 0000896622 atr:StockRepurchaseProgramApril182019Member 2019-04-18 0000896622 us-gaap:TreasuryStockMember 2019-09-30 0000896622 us-gaap:RetainedEarningsMember 2019-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-09-30 0000896622 us-gaap:CommonStockMember 2019-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0000896622 us-gaap:TreasuryStockMember 2019-06-30 0000896622 us-gaap:RetainedEarningsMember 2019-06-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-06-30 0000896622 us-gaap:CommonStockMember 2019-06-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000896622 2019-06-30 0000896622 us-gaap:TreasuryStockMember 2018-12-31 0000896622 us-gaap:RetainedEarningsMember 2018-12-31 0000896622 us-gaap:NoncontrollingInterestMember 2018-12-31 0000896622 us-gaap:CommonStockMember 2018-12-31 0000896622 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000896622 us-gaap:TreasuryStockMember 2018-09-30 0000896622 us-gaap:RetainedEarningsMember 2018-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2018-09-30 0000896622 us-gaap:CommonStockMember 2018-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0000896622 us-gaap:TreasuryStockMember 2018-06-30 0000896622 us-gaap:RetainedEarningsMember 2018-06-30 0000896622 us-gaap:NoncontrollingInterestMember 2018-06-30 0000896622 us-gaap:CommonStockMember 2018-06-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0000896622 2018-06-30 0000896622 us-gaap:TreasuryStockMember 2017-12-31 0000896622 us-gaap:RetainedEarningsMember 2017-12-31 0000896622 us-gaap:NoncontrollingInterestMember 2017-12-31 0000896622 us-gaap:CommonStockMember 2017-12-31 0000896622 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2019-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2018-12-31 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-12-31 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-12-31 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2018-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2017-12-31 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2017-12-31 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2017-12-31 0000896622 us-gaap:EmployeeStockOptionMember atr:StockAwardPlansMember 2018-12-31 0000896622 us-gaap:EmployeeStockOptionMember atr:DirectorStockOptionPlansMember 2018-12-31 0000896622 us-gaap:EmployeeStockOptionMember atr:DirectorStockOptionPlansMember 2018-01-01 2018-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:StockAwardPlansMember 2019-01-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:DirectorStockOptionPlansMember 2019-01-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:StockAwardPlansMember 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:DirectorStockOptionPlansMember 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:StockAwardPlansMember 2018-01-01 2018-09-30 0000896622 atr:RestrictedStockUnitsTimeBasedMember 2019-09-30 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2019-09-30 0000896622 atr:RestrictedStockUnitsTimeBasedMember 2018-12-31 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2018-12-31 0000896622 atr:RestrictedStockUnitsTimeBasedMember atr:DirectorStockOptionPlansMember 2019-01-01 2019-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember atr:DirectorStockOptionPlansMember 2019-01-01 2019-09-30 0000896622 atr:RestrictedStockUnitsTimeBasedMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-09-30 0000896622 atr:CspTechnologiesMember 2019-01-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:PharmaMember 2019-07-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:PharmaMember 2019-07-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember 2019-07-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2019-07-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:PharmaMember 2019-01-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember 2019-01-01 2019-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2019-01-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember us-gaap:FoodAndBeverageMember 2018-07-01 2018-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:PharmaMember 2018-07-01 2018-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:BeautyAndHomeMember 2018-07-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember us-gaap:FoodAndBeverageMember 2018-07-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:PharmaMember 2018-07-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:BeautyAndHomeMember 2018-07-01 2018-09-30 0000896622 us-gaap:OperatingSegmentsMember 2018-07-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2018-07-01 2018-09-30 0000896622 us-gaap:OperatingSegmentsMember us-gaap:FoodAndBeverageMember 2018-01-01 2018-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:PharmaMember 2018-01-01 2018-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:BeautyAndHomeMember 2018-01-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember us-gaap:FoodAndBeverageMember 2018-01-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:PharmaMember 2018-01-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember atr:BeautyAndHomeMember 2018-01-01 2018-09-30 0000896622 us-gaap:OperatingSegmentsMember 2018-01-01 2018-09-30 0000896622 us-gaap:IntersegmentEliminationMember 2018-01-01 2018-09-30 0000896622 srt:NorthAmericaMember us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 srt:NorthAmericaMember atr:PharmaMember 2019-07-01 2019-09-30 0000896622 srt:NorthAmericaMember atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 srt:LatinAmericaMember atr:PharmaMember 2019-07-01 2019-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 srt:EuropeMember us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 srt:EuropeMember atr:PharmaMember 2019-07-01 2019-09-30 0000896622 srt:EuropeMember atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 srt:AsiaMember us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 srt:AsiaMember atr:PharmaMember 2019-07-01 2019-09-30 0000896622 srt:AsiaMember atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 srt:NorthAmericaMember 2019-07-01 2019-09-30 0000896622 srt:LatinAmericaMember 2019-07-01 2019-09-30 0000896622 srt:EuropeMember 2019-07-01 2019-09-30 0000896622 srt:AsiaMember 2019-07-01 2019-09-30 0000896622 srt:NorthAmericaMember us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 srt:NorthAmericaMember atr:PharmaMember 2019-01-01 2019-09-30 0000896622 srt:NorthAmericaMember atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 srt:LatinAmericaMember atr:PharmaMember 2019-01-01 2019-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 srt:EuropeMember us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 srt:EuropeMember atr:PharmaMember 2019-01-01 2019-09-30 0000896622 srt:EuropeMember atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 srt:AsiaMember us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 srt:AsiaMember atr:PharmaMember 2019-01-01 2019-09-30 0000896622 srt:AsiaMember atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 srt:NorthAmericaMember 2019-01-01 2019-09-30 0000896622 srt:LatinAmericaMember 2019-01-01 2019-09-30 0000896622 srt:EuropeMember 2019-01-01 2019-09-30 0000896622 srt:AsiaMember 2019-01-01 2019-09-30 0000896622 srt:NorthAmericaMember us-gaap:FoodAndBeverageMember 2018-07-01 2018-09-30 0000896622 srt:NorthAmericaMember atr:PharmaMember 2018-07-01 2018-09-30 0000896622 srt:NorthAmericaMember atr:BeautyAndHomeMember 2018-07-01 2018-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2018-07-01 2018-09-30 0000896622 srt:LatinAmericaMember atr:PharmaMember 2018-07-01 2018-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2018-07-01 2018-09-30 0000896622 srt:EuropeMember us-gaap:FoodAndBeverageMember 2018-07-01 2018-09-30 0000896622 srt:EuropeMember atr:PharmaMember 2018-07-01 2018-09-30 0000896622 srt:EuropeMember atr:BeautyAndHomeMember 2018-07-01 2018-09-30 0000896622 srt:AsiaMember us-gaap:FoodAndBeverageMember 2018-07-01 2018-09-30 0000896622 srt:AsiaMember atr:PharmaMember 2018-07-01 2018-09-30 0000896622 srt:AsiaMember atr:BeautyAndHomeMember 2018-07-01 2018-09-30 0000896622 srt:NorthAmericaMember 2018-07-01 2018-09-30 0000896622 srt:LatinAmericaMember 2018-07-01 2018-09-30 0000896622 srt:EuropeMember 2018-07-01 2018-09-30 0000896622 srt:AsiaMember 2018-07-01 2018-09-30 0000896622 srt:NorthAmericaMember us-gaap:FoodAndBeverageMember 2018-01-01 2018-09-30 0000896622 srt:NorthAmericaMember atr:PharmaMember 2018-01-01 2018-09-30 0000896622 srt:NorthAmericaMember atr:BeautyAndHomeMember 2018-01-01 2018-09-30 0000896622 srt:LatinAmericaMember us-gaap:FoodAndBeverageMember 2018-01-01 2018-09-30 0000896622 srt:LatinAmericaMember atr:PharmaMember 2018-01-01 2018-09-30 0000896622 srt:LatinAmericaMember atr:BeautyAndHomeMember 2018-01-01 2018-09-30 0000896622 srt:EuropeMember us-gaap:FoodAndBeverageMember 2018-01-01 2018-09-30 0000896622 srt:EuropeMember atr:PharmaMember 2018-01-01 2018-09-30 0000896622 srt:EuropeMember atr:BeautyAndHomeMember 2018-01-01 2018-09-30 0000896622 srt:AsiaMember us-gaap:FoodAndBeverageMember 2018-01-01 2018-09-30 0000896622 srt:AsiaMember atr:PharmaMember 2018-01-01 2018-09-30 0000896622 srt:AsiaMember atr:BeautyAndHomeMember 2018-01-01 2018-09-30 0000896622 srt:NorthAmericaMember 2018-01-01 2018-09-30 0000896622 srt:LatinAmericaMember 2018-01-01 2018-09-30 0000896622 srt:EuropeMember 2018-01-01 2018-09-30 0000896622 srt:AsiaMember 2018-01-01 2018-09-30 0000896622 us-gaap:EmployeeSeveranceMember 2019-09-30 0000896622 atr:OtherRestructuringCostsMember 2019-09-30 0000896622 us-gaap:EmployeeSeveranceMember 2018-12-31 0000896622 atr:OtherRestructuringCostsMember 2018-12-31 0000896622 atr:BusinessTransformationPlanMember 2019-07-01 2019-09-30 0000896622 atr:BusinessTransformationPlanMember 2018-07-01 2018-09-30 0000896622 atr:BusinessTransformationPlanMember 2018-01-01 2018-09-30 0000896622 atr:CspTechnologiesMember 2018-12-31 0000896622 us-gaap:NotesPayableToBanksMember 2017-01-01 2017-12-31 0000896622 atr:BusinessTransformationPlanMember 2018-01-01 2019-09-30 0000896622 atr:BapcoClosuresHoldingLimitedMember 2019-08-02 2019-08-02 0000896622 atr:NanopharmMember 2019-06-05 2019-06-05 0000896622 atr:GatewayAnalyticalMember 2019-05-31 2019-05-31 0000896622 atr:ReboulSasMember 2018-05-01 2018-05-01 0000896622 srt:MaximumMember atr:NobleMember atr:EarnOutProvisionMember us-gaap:SubsequentEventMember 2019-10-31 2019-10-31 0000896622 atr:NobleMember us-gaap:SubsequentEventMember 2019-10-31 2019-10-31 0000896622 us-gaap:EmployeeSeveranceMember 2019-01-01 2019-09-30 0000896622 atr:OtherRestructuringCostsMember 2019-01-01 2019-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-07-01 2019-09-30 0000896622 us-gaap:CashFlowHedgingMember 2019-07-01 2019-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2019-01-01 2019-09-30 0000896622 us-gaap:CashFlowHedgingMember 2019-01-01 2019-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-07-01 2018-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-07-01 2018-09-30 0000896622 us-gaap:CashFlowHedgingMember 2018-07-01 2018-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2018-01-01 2018-09-30 0000896622 us-gaap:CurrencySwapMember us-gaap:CashFlowHedgingMember us-gaap:OtherNonoperatingIncomeExpenseMember 2018-01-01 2018-09-30 0000896622 us-gaap:CashFlowHedgingMember 2018-01-01 2018-09-30 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedTranslationAdjustmentMember 2018-01-01 2018-09-30 0000896622 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0000896622 us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000896622 atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member 2019-09-30 0000896622 atr:FiveYearRevolvingCreditFacilityMaturingInJuly2022Member 2018-12-31 0000896622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember 2019-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-07-01 2019-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:CashFlowHedgingMember us-gaap:InterestExpenseMember 2019-01-01 2019-09-30 0000896622 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0000896622 us-gaap:TreasuryLockMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0000896622 us-gaap:InterestRateSwapMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0000896622 atr:BusinessTransformationPlanMember 2019-01-01 2019-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0000896622 us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember 2019-07-01 2019-09-30 0000896622 us-gaap:MinistryOfTheEconomyFinanceAndIndustryFranceMember 2019-01-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-07-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-07-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2019-01-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2019-01-01 2019-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-07-01 2018-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-07-01 2018-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2018-01-01 2018-09-30 0000896622 us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember 2018-01-01 2018-09-30 0000896622 us-gaap:PreferredStockMember 2019-01-01 2019-09-30 0000896622 us-gaap:PreferredStockMember 2018-01-01 2018-12-31 0000896622 us-gaap:OperatingSegmentsMember us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:PharmaMember 2019-01-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember us-gaap:FoodAndBeverageMember 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:PharmaMember 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember atr:BeautyAndHomeMember 2019-09-30 0000896622 atr:CspTechnologiesMember us-gaap:FoodAndBeverageMember 2019-09-30 0000896622 atr:CspTechnologiesMember atr:PharmaMember 2019-09-30 0000896622 us-gaap:CorporateNonSegmentMember 2019-09-30 0000896622 atr:CspTechnologiesMember 2019-09-30 0000896622 us-gaap:OperatingSegmentsMember us-gaap:FoodAndBeverageMember 2018-12-31 0000896622 us-gaap:OperatingSegmentsMember atr:PharmaMember 2018-12-31 0000896622 us-gaap:OperatingSegmentsMember atr:BeautyAndHomeMember 2018-12-31 0000896622 us-gaap:CorporateNonSegmentMember 2018-12-31 0000896622 country:BR us-gaap:ReductionInTaxesMember 2019-09-30 0000896622 country:FR 2019-09-30 0000896622 country:BR us-gaap:ReductionInTaxesMember us-gaap:InterestIncomeMember 2019-03-31 0000896622 country:BR us-gaap:ReductionInTaxesMember us-gaap:CostOfSalesMember 2019-03-31 0000896622 country:BR us-gaap:ReductionInTaxesMember 2019-03-31 0000896622 country:BR us-gaap:ReductionInTaxesMember 2018-12-31 0000896622 srt:WeightedAverageMember us-gaap:TrademarksAndTradeNamesMember 2019-01-01 2019-09-30 0000896622 srt:WeightedAverageMember us-gaap:PatentsMember 2019-01-01 2019-09-30 0000896622 srt:WeightedAverageMember us-gaap:PatentedTechnologyMember 2019-01-01 2019-09-30 0000896622 srt:WeightedAverageMember us-gaap:CustomerRelationshipsMember 2019-01-01 2019-09-30 0000896622 srt:WeightedAverageMember atr:LicensingAgreementsAndOtherProductMember 2019-01-01 2019-09-30 0000896622 srt:WeightedAverageMember 2019-01-01 2019-09-30 0000896622 us-gaap:TrademarksAndTradeNamesMember 2019-09-30 0000896622 us-gaap:PatentsMember 2019-09-30 0000896622 us-gaap:PatentedTechnologyMember 2019-09-30 0000896622 us-gaap:CustomerRelationshipsMember 2019-09-30 0000896622 atr:LicensingAgreementsAndOtherProductMember 2019-09-30 0000896622 us-gaap:TrademarksAndTradeNamesMember 2018-12-31 0000896622 us-gaap:PatentsMember 2018-12-31 0000896622 us-gaap:PatentedTechnologyMember 2018-12-31 0000896622 us-gaap:CustomerRelationshipsMember 2018-12-31 0000896622 atr:LicensingAgreementsAndOtherProductMember 2018-12-31 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2019-09-30 0000896622 us-gaap:TreasuryStockMember 2019-07-01 2019-09-30 0000896622 us-gaap:RetainedEarningsMember 2019-07-01 2019-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-07-01 2019-09-30 0000896622 us-gaap:CommonStockMember 2019-07-01 2019-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:TreasuryStockMember 2019-01-01 2019-09-30 0000896622 us-gaap:RetainedEarningsMember 2019-01-01 2019-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2019-01-01 2019-09-30 0000896622 us-gaap:CommonStockMember 2019-01-01 2019-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2019-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2019-07-01 2019-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2019-01-01 2019-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2018-07-01 2018-09-30 0000896622 us-gaap:ForeignExchangeContractMember 2018-01-01 2018-09-30 0000896622 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-09-30 0000896622 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2018-12-31 0000896622 us-gaap:AccountsPayableAndAccruedLiabilitiesMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000896622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-09-30 0000896622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:CrossCurrencyInterestRateContractMember us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000896622 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2019-09-30 0000896622 us-gaap:DesignatedAsHedgingInstrumentMember 2019-09-30 0000896622 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeContractMember us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2018-12-31 0000896622 us-gaap:NotDesignatedAsHedgingInstrumentEconomicHedgeMember 2018-12-31 0000896622 us-gaap:DesignatedAsHedgingInstrumentMember 2018-12-31 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember 2017-12-31 0000896622 us-gaap:ForeignPlanMember 2019-09-30 0000896622 srt:MinimumMember us-gaap:NotesPayableOtherPayablesMember 2019-09-30 0000896622 srt:MaximumMember us-gaap:NotesPayableOtherPayablesMember 2019-09-30 0000896622 srt:MinimumMember us-gaap:NotesPayableOtherPayablesMember 2018-12-31 0000896622 srt:MaximumMember us-gaap:NotesPayableOtherPayablesMember 2018-12-31 0000896622 us-gaap:NotesPayableToBanksMember 2017-12-31 0000896622 us-gaap:NotesPayableOtherPayablesMember 2019-09-30 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2026Member 2019-09-30 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2025Member 2019-09-30 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2024Member 2019-09-30 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2023Member 2019-09-30 0000896622 atr:SeniorUnsecuredNotes3.4PercentDue2024Member 2019-09-30 0000896622 atr:SeniorUnsecuredNotes3.2PercentDue2022Member 2019-09-30 0000896622 atr:SeniorUnsecuredNotes1.17DueIn2024Member 2019-09-30 0000896622 atr:SeniorUnsecuredNotes0.98DueIn2023Member 2019-09-30 0000896622 atr:FinanceLeaseLiabilityObligationsMember 2019-09-30 0000896622 us-gaap:NotesPayableOtherPayablesMember 2018-12-31 0000896622 us-gaap:CapitalLeaseObligationsMember 2018-12-31 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2026Member 2018-12-31 0000896622 atr:SeniorUnsecuredNotes3.6PercentDue2025Member 2018-12-31 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2024Member 2018-12-31 0000896622 atr:SeniorUnsecuredNotes3.5PercentDue2023Member 2018-12-31 0000896622 atr:SeniorUnsecuredNotes3.4PercentDue2024Member 2018-12-31 0000896622 atr:SeniorUnsecuredNotes3.2PercentDue2022Member 2018-12-31 0000896622 atr:SeniorUnsecuredNotes1.17DueIn2024Member 2018-12-31 0000896622 atr:SeniorUnsecuredNotes0.98DueIn2023Member 2018-12-31 0000896622 us-gaap:AccountingStandardsUpdate201409Member us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0000896622 us-gaap:AccountingStandardsUpdate201409Member 2018-01-01 2018-09-30 0000896622 us-gaap:PreferredStockMember 2019-08-31 0000896622 us-gaap:PreferredStockMember 2018-05-31 0000896622 srt:MaximumMember country:AR us-gaap:SalesRevenueNetMember us-gaap:GeographicConcentrationRiskMember 2019-01-01 2019-09-30 0000896622 us-gaap:CrossCurrencyInterestRateContractMember us-gaap:CashFlowHedgingMember 2019-09-30 0000896622 2017-12-31 0000896622 2018-09-30 0000896622 atr:CspTechnologiesMember us-gaap:TrademarksAndTradeNamesMember 2018-08-27 0000896622 atr:CspTechnologiesMember us-gaap:PatentedTechnologyMember 2018-08-27 0000896622 atr:CspTechnologiesMember us-gaap:CustomerRelationshipsMember 2018-08-27 0000896622 atr:CspTechnologiesMember atr:LicensingAgreementsAndOtherProductMember 2018-08-27 0000896622 atr:NanopharmMember 2019-06-05 0000896622 atr:CspTechnologiesMember 2019-01-01 2019-01-31 0000896622 atr:GatewayAnalyticalMember 2019-05-31 0000896622 atr:CspTechnologiesMember 2018-07-01 2018-09-30 0000896622 atr:CspTechnologiesMember 2018-01-01 2018-09-30 0000896622 atr:NobleMember us-gaap:SubsequentEventMember 2019-10-31 0000896622 srt:MinimumMember atr:BtyMember us-gaap:CallOptionMember us-gaap:SubsequentEventMember 2019-10-01 0000896622 srt:MaximumMember atr:BtyMember us-gaap:CallOptionMember us-gaap:SubsequentEventMember 2019-10-01 0000896622 atr:BtyMember us-gaap:SubsequentEventMember 2019-10-01 0000896622 atr:BapcoClosuresHoldingLimitedMember 2019-08-02 0000896622 atr:BapcoClosuresHoldingLimitedMember 2018-12-31 0000896622 atr:ReboulSasMember 2018-05-01 0000896622 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000896622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000896622 us-gaap:FairValueMeasurementsRecurringMember 2019-09-30 0000896622 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000896622 us-gaap:FairValueMeasurementsRecurringMember 2018-12-31 0000896622 us-gaap:PreferredStockMember 2018-10-01 2018-12-31 0000896622 us-gaap:EmployeeStockOptionMember atr:SellingResearchAndDevelopmentAndAdministrativeExpensesMember 2019-01-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember atr:SellingResearchAndDevelopmentAndAdministrativeExpensesMember 2018-01-01 2018-09-30 0000896622 atr:NewLongTermIncentiveProgramMember 2018-01-01 2018-09-30 0000896622 atr:CspTechnologiesMember us-gaap:TrademarksAndTradeNamesMember 2018-08-27 2018-08-27 0000896622 atr:CspTechnologiesMember us-gaap:PatentedTechnologyMember 2018-08-27 2018-08-27 0000896622 atr:CspTechnologiesMember us-gaap:CustomerRelationshipsMember 2018-08-27 2018-08-27 0000896622 atr:CspTechnologiesMember atr:LicensingAgreementsAndOtherProductMember 2018-08-27 2018-08-27 0000896622 atr:CspTechnologiesMember 2018-08-27 2018-08-27 0000896622 country:BR 2019-01-01 2019-09-30 0000896622 country:BR 2019-09-30 0000896622 country:BR 2017-03-31 0000896622 2019-10-25 0000896622 atr:NewLongTermIncentiveProgramMember 2019-01-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0000896622 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2019-01-01 2019-09-30 0000896622 atr:RestrictedStockUnitsPerformanceBasedMember 2018-01-01 2018-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0000896622 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0000896622 us-gaap:TreasuryStockMember 2018-07-01 2018-09-30 0000896622 us-gaap:RetainedEarningsMember 2018-07-01 2018-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2018-07-01 2018-09-30 0000896622 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0000896622 us-gaap:TreasuryStockMember 2018-01-01 2018-09-30 0000896622 us-gaap:RetainedEarningsMember 2018-01-01 2018-09-30 0000896622 us-gaap:NoncontrollingInterestMember 2018-01-01 2018-09-30 0000896622 us-gaap:CommonStockMember 2018-01-01 2018-09-30 0000896622 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-09-30 0000896622 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-09-30 0000896622 country:US atr:CspTechnologiesMember 2018-08-27 2018-08-27 0000896622 country:FR atr:CspTechnologiesMember 2018-08-27 2018-08-27 0000896622 us-gaap:IndemnificationGuaranteeMember 2019-09-30 0000896622 us-gaap:IndemnificationGuaranteeMember 2018-12-31 0000896622 srt:MaximumMember 2019-09-30 0000896622 srt:MinimumMember 2019-01-01 2019-09-30 0000896622 srt:MaximumMember 2019-01-01 2019-09-30 0000896622 srt:MinimumMember 2019-09-30 0000896622 atr:BtyMember us-gaap:SubsequentEventMember 2019-10-01 2019-10-01 0000896622 us-gaap:NotesPayableToBanksMember 2019-09-30 0000896622 us-gaap:NotesPayableToBanksMember 2018-12-31 0000896622 atr:BusinessTransformationPlanMember 2019-09-30 0000896622 atr:NewLongTermIncentiveProgramMember 2019-09-30 0000896622 us-gaap:ForeignPlanMember 2019-07-01 2019-09-30 0000896622 country:US 2019-07-01 2019-09-30 0000896622 us-gaap:ForeignPlanMember 2019-01-01 2019-09-30 0000896622 us-gaap:ForeignPlanMember 2018-07-01 2018-09-30 0000896622 country:US 2018-07-01 2018-09-30 0000896622 us-gaap:ForeignPlanMember 2018-01-01 2018-09-30 0000896622 country:US 2018-01-01 2018-09-30 0000896622 country:US 2019-01-01 2019-09-30 0000896622 country:FR 2018-07-01 2018-09-30 0000896622 country:FR 2018-01-01 2018-09-30 0000896622 2018-07-01 2018-09-30 0000896622 2019-07-01 2019-09-30 0000896622 2019-01-01 2019-09-30 0000896622 2018-01-01 2018-09-30 0000896622 atr:CspTechnologiesMember 2018-08-27 0000896622 atr:NobleMember atr:EarnOutProvisionMember us-gaap:SubsequentEventMember 2019-10-31 2019-10-31 0000896622 us-gaap:FoodAndBeverageMember 2019-07-01 2019-09-30 0000896622 us-gaap:CorporateAndOtherMember 2019-07-01 2019-09-30 0000896622 atr:PharmaMember 2019-07-01 2019-09-30 0000896622 atr:BeautyAndHomeMember 2019-07-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember 2019-01-01 2019-09-30 0000896622 us-gaap:CorporateAndOtherMember 2019-01-01 2019-09-30 0000896622 atr:PharmaMember 2019-01-01 2019-09-30 0000896622 atr:BeautyAndHomeMember 2019-01-01 2019-09-30 0000896622 us-gaap:FoodAndBeverageMember 2018-07-01 2018-09-30 0000896622 us-gaap:CorporateAndOtherMember 2018-07-01 2018-09-30 0000896622 atr:PharmaMember 2018-07-01 2018-09-30 0000896622 atr:BeautyAndHomeMember 2018-07-01 2018-09-30 0000896622 us-gaap:FoodAndBeverageMember 2018-01-01 2018-09-30 0000896622 us-gaap:CorporateAndOtherMember 2018-01-01 2018-09-30 0000896622 atr:PharmaMember 2018-01-01 2018-09-30 0000896622 atr:BeautyAndHomeMember 2018-01-01 2018-09-30 0000896622 2019-09-30 0000896622 srt:RestatementAdjustmentMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0000896622 2019-01-01 0000896622 2018-12-31 iso4217:USD xbrli:pure iso4217:USD xbrli:shares xbrli:shares iso4217:EUR atr:segment

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

​

FORM 10-Q

​

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2019

​

OR

​

☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

​

FOR THE TRANSITION PERIOD FROM TO

​

​

COMMISSION FILE NUMBER 1-11846

AptarGroup, Inc.

​

​ | ​ | ​
DELAWARE | ​ | 36-3853103
(State of Incorporation) | ​ | (I.R.S. Employer Identification No.)

​

265 EXCHANGE DRIVE, SUITE 100, CRYSTAL LAKE, ILLINOIS 60014

​

815-477-0424

​

Securities registered pursuant to Section 12(b) of the Act:

​

​ | ​ | ​
Title of each class | Trading symbol(s) | Name of each exchange on which registered
Common Stock, $.01 par value | ATR | New York Stock Exchange

​

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes þ No ◻

​

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes þ No ◻

​

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

​

Large accelerated filer þ | Accelerated filer ☐ | Non-accelerated filer ☐ | Smaller reporting company ☐ | Emerging growth company ☐

​

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

​

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ◻ No þ

​

The number of shares outstanding of common stock, as of October 25, 2019, was 63,927,079 shares.

​

​

​

​

​

​

Table of Contents

​

​

​

AptarGroup, Inc.

​

Form 10-Q

​

Quarter Ended September 30, 2019

​

INDEX

​

​

|  | ​
Part I. | FINANCIAL INFORMATION | ​
​ | ​ | ​
Item 1. | Financial Statements (Unaudited) | ​
​ | ​ | ​
​ | Condensed Consolidated Statements of Income – Three and Nine Months Ended September 30, 2019 and 2018 | 1
​ | ​ | ​
​ | Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2019 and 2018 | 2
​ | ​ | ​
​ | Condensed Consolidated Balance Sheets – September 30, 2019 and December 31, 2018 | 3
​ | ​ | ​
​ | Condensed Consolidated Statements of Changes in Equity – Three and Nine Months Ended September 30, 2019 and 2018 | 5
​ | ​ | ​
​ | Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2019 and 2018 | 6
​ | ​ | ​
​ | Notes to Condensed Consolidated Financial Statements | 7
​ | ​ | ​
Item 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 29
​ | ​ | ​
Item 3. | Quantitative and Qualitative Disclosures about Market Risk | 44
​ | ​ | ​
Item 4. | Controls and Procedures | 44
​ | ​ | ​
Part II. | OTHER INFORMATION | ​
​ | ​ | ​
Item 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 45
​ | ​ | ​
Item 6. | Exhibits | 46
​ | ​ | ​
​ | Signature | 47

​

​

​

​

​

i

Table of Contents

PART I – FINANCIAL INFORMATION

​

ITEM 1. FINANCIAL STATEMENTS (UNAUDITED)

​

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
In thousands, except per share amounts | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 | ​ | 2018 | ​ | 2019 | ​ | 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales | ​ | $ | 701,278 | ​ | $ | 665,775 | ​ | $ | 2,188,399 | ​ | $ | 2,079,733 |
Operating Expenses: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cost of sales (exclusive of depreciation and amortization shown below) | ​ |  | 444,237 | ​ |  | 435,379 | ​ |  | 1,382,810 | ​ |  | 1,355,445 | ​
Selling, research & development and administrative | ​ |  | 111,559 | ​ |  | 103,574 | ​ |  | 346,526 | ​ |  | 323,146 | ​
Depreciation and amortization | ​ |  | 49,218 | ​ |  | 41,857 | ​ |  | 144,574 | ​ |  | 123,133 | ​
Restructuring initiatives | ​ | ​ | 6,019 | ​ | ​ | 23,852 | ​ | ​ | 17,286 | ​ | ​ | 48,002 | ​
​ | ​ |  | 611,033 | ​ |  | 604,662 | ​ |  | 1,891,196 | ​ |  | 1,849,726 | ​
Operating Income | ​ |  | 90,245 | ​ |  | 61,113 | ​ |  | 297,203 | ​ |  | 230,007 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Other (Expense) Income: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest expense | ​ |  | (8,898) | ​ |  | (8,735) | ​ |  | (26,868) | ​ |  | (24,754) | ​
Interest income | ​ |  | 957 | ​ |  | 1,537 | ​ |  | 3,738 | ​ |  | 6,306 | ​
Equity in results of affiliates | ​ |  | 238 | ​ |  | (45) | ​ |  | 152 | ​ |  | (130) | ​
Miscellaneous, net | ​ |  | (269) | ​ |  | (2,928) | ​ |  | 148 | ​ |  | (4,372) | ​
​ | ​ |  | (7,972) | ​ |  | (10,171) | ​ |  | (22,830) | ​ |  | (22,950) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income before Income Taxes | ​ |  | 82,273 | ​ |  | 50,942 | ​ |  | 274,373 | ​ |  | 207,057 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Provision for Income Taxes | ​ |  | 25,504 | ​ |  | 11,920 | ​ |  | 80,684 | ​ |  | 52,966 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Income | ​ | $ | 56,769 | ​ | $ | 39,022 | ​ | $ | 193,689 | ​ | $ | 154,091 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Income Attributable to Noncontrolling Interests | ​ | $ | (19) | ​ | $ | (26) | ​ | $ | (20) | ​ | $ | (20) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Income Attributable to AptarGroup, Inc. | ​ | $ | 56,750 | ​ | $ | 38,996 | ​ | $ | 193,669 | ​ | $ | 154,071 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Income Attributable to AptarGroup, Inc. per Common Share: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | $ | 0.89 | ​ | $ | 0.63 | ​ | $ | 3.05 | ​ | $ | 2.47 | ​
Diluted | ​ | $ | 0.85 | ​ | $ | 0.60 | ​ | $ | 2.93 | ​ | $ | 2.38 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Average Number of Shares Outstanding: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Basic | ​ | ​ | 64,010 | ​ | ​ | 62,378 | ​ | ​ | 63,485 | ​ | ​ | 62,304 | ​
Diluted | ​ | ​ | 66,702 | ​ | ​ | 65,129 | ​ | ​ | 66,163 | ​ | ​ | 64,822 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Dividends per Common Share | ​ | $ | 0.36 | ​ | $ | 0.34 | ​ | $ | 1.06 | ​ | $ | 0.98 | ​

​

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

​

​

1

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
In thousands | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | 2019 | ​ | 2018 | ​ | 2019 |  | 2018 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Income | $ | 56,769 | ​ | $ | 39,022 |  | $ | 193,689 | ​ | $ | 154,091 | ​
Other Comprehensive Income: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign currency translation adjustments |  | (42,540) | ​ |  | (9,869) | ​ |  | (42,737) | ​ |  | (53,157) | ​
Changes in treasury locks, net of tax |  | — | ​ |  | 3 | ​ |  | — | ​ |  | 17 | ​
Changes in derivative gains (losses), net of tax | ​ | 279 | ​ | ​ | (1,166) | ​ | ​ | (593) | ​ | ​ | 1,046 | ​
Defined benefit pension plan, net of tax | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of prior service cost included in net income, net of tax |  | 82 | ​ |  | 90 | ​ |  | 249 | ​ |  | 278 | ​
Amortization of net loss included in net income, net of tax |  | 631 | ​ |  | 1,243 | ​ |  | 1,901 | ​ |  | 3,754 | ​
Total defined benefit pension plan, net of tax |  | 713 | ​ |  | 1,333 | ​ |  | 2,150 | ​ |  | 4,032 | ​
Total other comprehensive loss |  | (41,548) | ​ |  | (9,699) | ​ |  | (41,180) | ​ |  | (48,062) | ​
Comprehensive Income |  | 15,221 | ​ |  | 29,323 | ​ |  | 152,509 | ​ |  | 106,029 | ​
Comprehensive Income Attributable to Noncontrolling Interests |  | (7) | ​ |  | (15) | ​ |  | (8) | ​ |  | (4) | ​
Comprehensive Income Attributable to AptarGroup, Inc. | $ | 15,214 | ​ | $ | 29,308 | ​ | $ | 152,501 | ​ | $ | 106,025 | ​

​

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

​

​

2

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
In thousands | ​ | ​ | ​ | ​ | ​ | ​ |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | September 30, | ​ | ​ | December 31, |
​ | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and equivalents | ​ | $ | 270,577 | ​ | $ | 261,823 | ​
Accounts and notes receivable, less allowance for doubtful accounts of $3,775 in 2019 and $3,541 in 2018 | ​ |  | 552,289 | ​ | ​ | 569,630 | ​
Inventories | ​ |  | 383,491 | ​ | ​ | 381,110 | ​
Prepaid and other | ​ |  | 118,371 | ​ | ​ | 118,245 | ​
​ | ​ |  | 1,324,728 | ​ | ​ | 1,330,808 | ​
Property, Plant and Equipment: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Buildings and improvements | ​ |  | 479,233 | ​ | ​ | 453,572 | ​
Machinery and equipment | ​ |  | 2,432,515 | ​ | ​ | 2,368,332 | ​
​ | ​ |  | 2,911,748 | ​ | ​ | 2,821,904 | ​
Less: Accumulated depreciation | ​ |  | (1,893,520) | ​ | ​ | (1,855,810) | ​
​ | ​ |  | 1,018,228 | ​ | ​ | 966,094 | ​
Land | ​ |  | 24,511 | ​ | ​ | 25,519 | ​
​ | ​ |  | 1,042,739 | ​ | ​ | 991,613 | ​
Other Assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Investments in equity securities | ​ |  | 8,264 | ​ | ​ | 25,448 | ​
Goodwill | ​ |  | 722,070 | ​ | ​ | 712,095 | ​
Intangible assets | ​ |  | 259,712 | ​ | ​ | 254,904 | ​
Operating lease right-of-use assets | ​ | ​ | 72,481 | ​ | ​ | — | ​
Miscellaneous | ​ |  | 35,145 | ​ | ​ | 62,867 | ​
​ | ​ |  | 1,097,672 | ​ | ​ | 1,055,314 | ​
Total Assets | ​ | $ | 3,465,139 | ​ | $ | 3,377,735 | ​

​

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

​

​

3

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
In thousands, except share and per share amounts | ​ | ​ | ​ | ​ | ​ | ​ |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | September 30, | ​ | ​ | December 31, |
​ | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
Liabilities and Stockholders’ Equity | ​ | ​ | ​ | ​ | ​ | ​ | ​
Current Liabilities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Notes payable, including revolving credit facilities | ​ | $ | 46,276 | ​ | $ | 101,293 | ​
Current maturities of long-term obligations, net of unamortized debt issuance costs | ​ |  | 64,941 | ​ |  | 62,678 | ​
Accounts payable and accrued liabilities | ​ |  | 537,620 | ​ |  | 525,199 | ​
​ | ​ |  | 648,837 | ​ |  | 689,170 | ​
Long-Term Obligations, net of unamortized debt issuance costs | ​ |  | 1,075,153 | ​ |  | 1,125,993 | ​
Deferred Liabilities and Other: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Deferred income taxes | ​ |  | 36,072 | ​ |  | 53,917 | ​
Retirement and deferred compensation plans | ​ |  | 67,546 | ​ |  | 62,319 | ​
Operating lease liabilities | ​ | ​ | 55,278 | ​ | ​ | — | ​
Deferred and other non-current liabilities | ​ |  | 28,274 | ​ |  | 23,465 | ​
Commitments and contingencies | ​ |  | — | ​ |  | — | ​
​ | ​ |  | 187,170 | ​ |  | 139,701 | ​
Stockholders’ Equity: | ​ | ​ | ​ | ​ | ​ | ​ | ​
AptarGroup, Inc. stockholders’ equity | ​ | ​ | ​ | ​ | ​ | ​ | ​
Common stock, $.01 par value, 199 million shares authorized, 68.5 and 67.3 million shares issued as of September 30, 2019 and December 31, 2018, respectively | ​ |  | 685 | ​ |  | 673 | ​
Capital in excess of par value | ​ |  | 756,988 | ​ |  | 678,769 | ​
Retained earnings | ​ |  | 1,498,300 | ​ |  | 1,371,826 | ​
Accumulated other comprehensive loss | ​ |  | (351,672) | ​ |  | (310,504) | ​
Less: Treasury stock at cost, 4.6 and 4.4 million shares as of September 30, 2019 and December 31, 2018, respectively | ​ |  | (350,645) | ​ |  | (318,208) | ​
Total AptarGroup, Inc. Stockholders’ Equity | ​ |  | 1,553,656 | ​ |  | 1,422,556 | ​
Noncontrolling interests in subsidiaries | ​ |  | 323 | ​ |  | 315 | ​
Total Stockholders’ Equity | ​ |  | 1,553,979 | ​ |  | 1,422,871 | ​
Total Liabilities and Stockholders’ Equity | ​ | $ | 3,465,139 | ​ | $ | 3,377,735 | ​

​

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

​

​

4

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
In thousands | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Three Months Ended | ​ | AptarGroup, Inc. Stockholders’ Equity | ​ | ​ | ​ | ​ | ​ | ​ | ​
September 30, 2019 and 2018 |  | ​ |  | Accumulated |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ | ​
​ | ​ | ​ | ​ | Other | ​ | Common | ​ | ​ | ​ | Capital in | ​ | Non- | ​ | ​ | ​
​ | ​ | Retained | ​ | Comprehensive | ​ | Stock | ​ | Treasury | ​ | Excess of | ​ | Controlling | ​ | Total | ​
​ | ​ | Earnings | ​ | (Loss) Income | ​ | Par Value | ​ | Stock | ​ | Par Value | ​ | Interest | ​ | Equity |
Balance - June 30, 2018 | ​ | $ | 1,328,034 | ​ | $ | (291,660) | ​ | $ | 668 | ​ | $ | (336,278) | ​ | $ | 646,449 | ​ | $ | 299 | ​ | $ | 1,347,512 | ​
Net income | ​ |  | 38,996 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 26 | ​ | ​ | 39,022 | ​
Foreign currency translation adjustments | ​ | ​ | — | ​ | ​ | (9,858) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (11) | ​ | ​ | (9,869) | ​
Changes in unrecognized pension gains (losses) and related amortization, net of tax | ​ | ​ | — | ​ | ​ | 1,333 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,333 | ​
Changes in treasury locks, net of tax | ​ | ​ | — | ​ | ​ | 3 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3 | ​
Changes in derivative gains (losses), net of tax | ​ | ​ | — | ​ | ​ | (1,166) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (1,166) | ​
Stock awards and option exercises | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4 | ​ | ​ | 12,137 | ​ | ​ | 24,261 | ​ | ​ | — | ​ | ​ | 36,402 | ​
Cash dividends declared on common stock | ​ |  | (21,179) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (21,179) | ​
Balance - September 30, 2018 | ​ | $ | 1,345,851 | ​ | $ | (301,348) | ​ | $ | 672 | ​ | $ | (324,141) | ​ | $ | 670,710 | ​ | $ | 314 | ​ | $ | 1,392,058 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance - June 30, 2019 | ​ | $ | 1,464,607 | ​ | $ | (310,136) | ​ | $ | 683 | ​ | $ | (317,380) | ​ | $ | 743,332 | ​ | $ | 316 | ​ | $ | 1,581,422 | ​
Net income | ​ |  | 56,750 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 19 | ​ | ​ | 56,769 | ​
Foreign currency translation adjustments | ​ | ​ | — | ​ | ​ | (42,528) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (12) | ​ | ​ | (42,540) | ​
Changes in unrecognized pension gains (losses) and related amortization, net of tax | ​ | ​ | — | ​ | ​ | 713 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 713 | ​
Changes in derivative gains (losses), net of tax | ​ | ​ | — | ​ | ​ | 279 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 279 | ​
Stock awards and option exercises | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2 | ​ | ​ | 2,512 | ​ | ​ | 13,656 | ​ | ​ | — | ​ | ​ | 16,170 | ​
Cash dividends declared on common stock | ​ |  | (23,057) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (23,057) | ​
Treasury stock purchased | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (35,777) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (35,777) | ​
Balance - September 30, 2019 | ​ | $ | 1,498,300 | ​ | $ | (351,672) | ​ | $ | 685 | ​ | $ | (350,645) | ​ | $ | 756,988 | ​ | $ | 323 | ​ | $ | 1,553,979 | ​

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
In thousands | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended | ​ | AptarGroup, Inc. Stockholders’ Equity | ​ | ​ | ​ | ​ | ​ | ​ | ​
September 30, 2019 and 2018 |  | ​ |  | Accumulated |  | ​ |  | ​ |  | ​ |  | ​ |  | ​ | ​
​ | ​ | ​ | ​ | Other | ​ | Common | ​ | ​ | ​ | Capital in | ​ | Non- | ​ | ​ | ​
​ | ​ | Retained | ​ | Comprehensive | ​ | Stock | ​ | Treasury | ​ | Excess of | ​ | Controlling | ​ | Total | ​
​ | ​ | Earnings | ​ | (Loss) Income | ​ | Par Value | ​ | Stock | ​ | Par Value | ​ | Interest | ​ | Equity |
Balance - December 31, 2017 | ​ | $ | 1,301,147 | ​ | $ | (253,302) | ​ | $ | 667 | ​ | $ | (346,245) | ​ | $ | 609,471 | ​ | $ | 310 | ​ | $ | 1,312,048 | ​
Net income | ​ |  | 154,071 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 20 | ​ | ​ | 154,091 | ​
Adoption of revenue recognition standard | ​ | ​ | 2,937 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,937 | ​
Foreign currency translation adjustments | ​ | ​ | — | ​ |  | (53,141) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (16) | ​ | ​ | (53,157) | ​
Changes in unrecognized pension gains (losses) and related amortization, net of tax | ​ | ​ | — | ​ |  | 4,032 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 4,032 | ​
Changes in treasury locks, net of tax | ​ | ​ | — | ​ |  | 17 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 17 | ​
Changes in derivative gains (losses), net of tax | ​ | ​ | — | ​ |  | 1,046 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 1,046 | ​
Stock awards and option exercises | ​ | ​ | — | ​ | ​ | — | ​ |  | 11 | ​ |  | 26,009 | ​ | ​ | 67,705 | ​ | ​ | — | ​ | ​ | 93,725 | ​
Cash dividends declared on common stock | ​ |  | (60,989) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (60,989) | ​
Treasury stock purchased | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (3,905) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (3,905) | ​
Common stock repurchased and retired | ​ | ​ | (51,315) | ​ | ​ | — | ​ | ​ | (6) | ​ |  | — | ​ | ​ | (6,466) | ​ | ​ | — | ​ | ​ | (57,787) | ​
Balance - September 30, 2018 | ​ | $ | 1,345,851 | ​ | $ | (301,348) | ​ | $ | 672 | ​ | $ | (324,141) | ​ | $ | 670,710 | ​ | $ | 314 | ​ | $ | 1,392,058 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance - December 31, 2018 | ​ | $ | 1,371,826 | ​ | $ | (310,504) | ​ | $ | 673 | ​ | $ | (318,208) | ​ | $ | 678,769 | ​ | $ | 315 | ​ | $ | 1,422,871 | ​
Net income | ​ |  | 193,669 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 20 | ​ | ​ | 193,689 | ​
Foreign currency translation adjustments | ​ | ​ | — | ​ |  | (42,725) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (12) | ​ | ​ | (42,737) | ​
Changes in unrecognized pension gains (losses) and related amortization, net of tax | ​ | ​ | — | ​ |  | 2,150 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 2,150 | ​
Changes in derivative gains (losses), net of tax | ​ | ​ | — | ​ |  | (593) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (593) | ​
Stock awards and option exercises | ​ | ​ | — | ​ | ​ | — | ​ |  | 12 | ​ |  | 22,436 | ​ | ​ | 78,219 | ​ | ​ | — | ​ | ​ | 100,667 | ​
Cash dividends declared on common stock | ​ |  | (67,195) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (67,195) | ​
Treasury stock purchased | ​ | ​ | — | ​ | ​ | — | ​ | ​ | — | ​ |  | (54,873) | ​ | ​ | — | ​ | ​ | — | ​ | ​ | (54,873) | ​
Balance - September 30, 2019 | ​ | $ | 1,498,300 | ​ | $ | (351,672) | ​ | $ | 685 | ​ | $ | (350,645) | ​ | $ | 756,988 | ​ | $ | 323 | ​ | $ | 1,553,979 | ​

​

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

​

​

5

Table of Contents

AptarGroup, Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
In thousands, brackets denote cash outflows | ​ | ​ | ​ | ​ | ​ | ​ |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, | ​ | ​ | 2019 | ​ | ​ | 2018 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash Flows from Operating Activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net income | ​ | $ | 193,689 | ​ | $ | 154,091 | ​
Adjustments to reconcile net income to net cash provided by operations: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Depreciation | ​ |  | 124,787 | ​ |  | 113,555 | ​
Amortization | ​ |  | 19,787 | ​ |  | 9,578 | ​
Stock-based compensation | ​ |  | 18,075 | ​ |  | 14,829 | ​
Provision for doubtful accounts | ​ |  | 930 | ​ |  | 190 | ​
Loss (gain) on disposition of fixed assets | ​ |  | 303 | ​ |  | (979) | ​
Deferred income taxes | ​ |  | 5,948 | ​ |  | (5,414) | ​
Defined benefit plan expense | ​ |  | 11,517 | ​ |  | 14,466 | ​
Equity in results of affiliates | ​ |  | (152) | ​ |  | 130 | ​
Changes in balance sheet items, excluding effects from foreign currency adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Accounts and other receivables | ​ |  | 724 | ​ |  | (72,620) | ​
Inventories | ​ |  | (16,025) | ​ |  | (41,183) | ​
Prepaid and other current assets | ​ |  | (1,721) | ​ |  | (807) | ​
Accounts payable and accrued liabilities | ​ |  | 15,047 | ​ |  | 55,921 | ​
Income taxes payable | ​ |  | 6,729 | ​ |  | (7,481) | ​
Retirement and deferred compensation plan liabilities | ​ |  | (935) | ​ |  | (21,534) | ​
Other changes, net | ​ |  | 1,678 | ​ |  | (3,157) | ​
Net Cash Provided by Operations | ​ |  | 380,381 | ​ |  | 209,585 | ​
Cash Flows from Investing Activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Capital expenditures | ​ |  | (186,841) | ​ |  | (145,321) | ​
Proceeds from sale of property, plant and equipment | ​ |  | 3,658 | ​ |  | 4,056 | ​
Insurance proceeds | ​ | ​ | — | ​ | ​ | 10,631 | ​
Acquisition of business, net of cash acquired | ​ | ​ | (49,062) | ​ | ​ | (527,916) | ​
Acquisition of intangible assets, net | ​ |  | (4,621) | ​ |  | (346) | ​
Investment in equity securities | ​ | ​ | (3,530) | ​ | ​ | (10,000) | ​
Proceeds from sale of investment in equity securities | ​ |  | 16,487 | ​ |  | — | ​
Notes receivable, net | ​ |  | (89) | ​ |  | 216 | ​
Net Cash Used by Investing Activities | ​ |  | (223,998) | ​ |  | (668,680) | ​
Cash Flows from Financing Activities: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Proceeds from notes payable | ​ |  | 36,893 | ​ | ​ | 18,003 | ​
Repayments of notes payable | ​ |  | (41,145) | ​ | ​ | (6,395) | ​
Proceeds and repayments of short term credit facility, net | ​ | ​ | (47,253) | ​ | ​ | 139,384 | ​
Proceeds from long-term obligations | ​ |  | 10,524 | ​ |  | 10,092 | ​
Repayments of long-term obligations | ​ |  | (64,924) | ​ |  | (67,026) | ​
Dividends paid | ​ |  | (67,195) | ​ |  | (60,989) | ​
Proceeds from stock option exercises | ​ |  | 81,815 | ​ |  | 78,896 | ​
Purchase of treasury stock | ​ |  | (54,873) | ​ |  | (3,905) | ​
Common stock repurchased and retired | ​ | ​ | — | ​ | ​ | (57,787) | ​
Net Cash (Used) Provided by Financing Activities | ​ |  | (146,158) | ​ |  | 50,273 | ​
Effect of Exchange Rate Changes on Cash | ​ |  | (6,471) | ​ |  | (7,436) | ​
Net Increase (Decrease) in Cash and Equivalents and Restricted Cash | ​ |  | 3,754 | ​ |  | (416,258) | ​
Cash and Equivalents and Restricted Cash at Beginning of Period | ​ |  | 266,823 | ​ |  | 712,640 | ​
Cash and Equivalents and Restricted Cash at End of Period | ​ | $ | 270,577 | ​ | $ | 296,382 | ​

​

Restricted cash included in the line item prepaid and other on the Condensed Consolidated Balance Sheets as shown below represents amounts held in escrow related to the CSP Technologies Acquisition (as defined herein).

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, |  | ​ | 2019 |  | ​ | 2018 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and equivalents | ​ | $ | 270,577 | ​ | $ | 291,382 | ​
Restricted cash included in prepaid and other | ​ | ​ | — | ​ | ​ | 5,000 | ​
Total Cash and Equivalents and Restricted Cash shown in the Statement of Cash Flows | ​ | $ | 270,577 | ​ | $ | 296,382 | ​

​

​

See accompanying unaudited Notes to Condensed Consolidated Financial Statements.

​

​

6

Table of Contents

AptarGroup, Inc.

Notes to Condensed Consolidated Financial Statements

(Dollars in Thousands, Except per Share Amounts, or as Otherwise Indicated)

(Unaudited)

​

NOTE 1 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

​

BASIS OF PRESENTATION

​

The accompanying unaudited Condensed Consolidated Financial Statements include the accounts of AptarGroup, Inc. and our subsidiaries. The terms “AptarGroup”, “Aptar”, “Company”, “we”, “us” or “our” as used herein refer to AptarGroup, Inc. and our subsidiaries. All significant intercompany accounts and transactions have been eliminated.

In the opinion of management, the unaudited Condensed Consolidated Financial Statements (the “Condensed Consolidated Financial Statements”) include all normal recurring adjustments necessary for a fair statement of consolidated financial position, results of operations, comprehensive income, changes in equity and cash flows for the interim periods presented. The accompanying Condensed Consolidated Financial Statements have been prepared by the Company, pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) have been condensed or omitted pursuant to such rules and regulations, although we believe that the disclosures made are adequate to make the information presented not misleading. Also, certain financial position data included herein was derived from the audited Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December 31, 2018 but does not include all disclosures required by U.S. GAAP. Accordingly, these Condensed Consolidated Financial Statements and related notes should be read in conjunction with the audited Consolidated Financial Statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018. The results of operations of any interim period are not necessarily indicative of the results that may be expected for the year.

During the quarter ended June 30, 2018, primarily based on published estimates, which indicate that Argentina's three-year cumulative inflation rate has exceeded 100%, we concluded that Argentina has become a highly inflationary economy. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries. We have changed the functional currency from the Argentinian peso to the U.S. dollar. Local currency monetary assets and liabilities have been remeasured into U.S. dollars using exchange rates as of the latest balance sheet date, with remeasurement adjustments and other transaction gains and losses recognized in net earnings. Our Argentinian operations contributed less than 2% of consolidated net assets and revenues at and for the nine months ended September 30, 2019 and 2018.

​

ADOPTION OF RECENT ACCOUNTING STANDARDS

​

Changes to U.S. GAAP are established by the Financial Accounting Standards Board (“FASB”) in the form of Accounting Standards Updates (“ASUs”) to the FASB’s Accounting Standards Codification.

In February 2016, the FASB issued a new standard related to leases to increase transparency and comparability among organizations. Most prominent among the changes in the standard is the recognition of right-of-use (“ROU”) assets and lease liabilities by lessees for those leases classified as operating leases, as our accounting for finance leases remained substantially unchanged. Under the new standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. We adopted the standard on January 1, 2019 using a modified retrospective transition, with the effective date method. Under this method, financial results reported in periods prior to 2019 are not recast. We elected the package of practical expedients permitted under the transition guidance within the new standard, which among other things, allows companies to carry forward their historical lease classification. We also implemented internal controls and key system functionality to enable the preparation of financial information on adoption. The impact of adoption of the standard to previously reported results is shown below.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ | Balance at | ​ | ​ | ​ | ​ | ​ | Balance at | ​
​ | ​ | ​ | December 31, | ​ | ​ | ​ | ​ | ​ | January 1, | ​
​ | ​ | ​ | 2018 | ​ | ​ | Adjustments | ​ | ​ | 2019 | ​
Consolidated Balance Sheets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Operating lease right-of-use assets | ​ | $ | — | ​ | $ | 83,222 | ​ | $ | 83,222 | ​
Prepaid and other | ​ | ​ | 118,245 | ​ | ​ | (1,383) | ​ | ​ | 116,862 | ​
Property, plant and equipment | ​ | ​ | 991,613 | ​ | ​ | 5,876 | ​ | ​ | 997,489 | ​
Current maturities of long-term obligations, net of unamortized debt issuance costs | ​ | ​ | 62,678 | ​ | ​ | 2,631 | ​ | ​ | 65,309 | ​
Accounts payable and accrued liabilities | ​ | ​ | 525,199 | ​ | ​ | 20,508 | ​ | ​ | 545,707 | ​
Operating lease liabilities | ​ | ​ | — | ​ | ​ | 61,331 | ​ | ​ | 61,331 | ​
Long-term obligations, net of unamortized debt issuance costs | ​ | ​ | 1,125,993 | ​ | ​ | 3,245 | ​ | ​ | 1,129,238 | ​

7

Table of Contents

​

In February 2018, the FASB issued ASU 2018-02, which provides guidance on the reclassification of certain tax effects from accumulated other comprehensive income. This guidance allows for the reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from the Tax Cuts and Jobs Act of 2017 (“TCJA”). The new standard is effective for fiscal years and interim periods beginning after December 15, 2018. We elected to early adopt this standard in the fourth quarter of 2018. As part of this adoption, we elected to reclassify $6.7 million of stranded income tax effects of the TCJA from accumulated other comprehensive income to retained earnings at the beginning of the fourth quarter of 2018.

Other accounting standards that have been issued by the FASB or other standards-setting bodies did not have a material impact on our Condensed Consolidated Financial Statements.

LEASES

We determine if an arrangement is a lease at inception. Operating lease assets are included in operating lease ROU assets and operating lease liabilities are included in accounts payable and accrued liabilities and operating lease liabilities in our consolidated balance sheets. Finance leases are included in property, plant and equipment, current maturities of long-term obligations and long-term obligations in our consolidated balance sheets.

ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. We use the implicit rate when readily determinable. As most of our leases do not provide an implicit rate, we use our incremental borrowing rate based on the information available at the commencement date of the lease in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made as well as initial direct costs incurred and excludes lease incentives. Our lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense for operating lease payments is recognized on a straight-line basis over the lease term.

We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, we account for the lease and non-lease components as a single lease component. We have elected not to recognize right-of-use assets and lease liabilities that arise from short-term leases (a lease whose term is 12 months or less and does not include a purchase option that we are reasonably certain to exercise).

Certain vehicle lease contracts include guaranteed residual value that is considered in the determination of lease classification. The probability of having to satisfy a residual value guarantee is not considered for the purpose of lease classification, but is considered when measuring a lease liability.

GOODWILL

We believe that the accounting estimates related to determining the fair value of our reporting units is a critical accounting estimate because: (1) it is highly susceptible to change from period to period because it requires management to make assumptions about the future cash flows for each reporting unit over several years, and (2) the impact that recognizing an impairment would have on the assets reported on our balance sheet as well as our results of operations could be material. Management’s determination of the fair value of our reporting units, based on future cash flows for the reporting units, requires significant judgment and the use of estimates and assumptions related to projected revenue growth rates, the terminal growth factor, as well as the discount rate. Actual cash flows in the future may differ significantly from those forecasted.

Management believes goodwill, or the excess purchase price over the fair value of the net assets acquired in purchase transactions has continuing value. Goodwill is not amortized and must be tested annually, or more frequently as circumstances dictate, for impairment. During the third quarter of 2019, we performed a separate quantitative impairment assessment using the discounted cash flow analysis of the Active Packaging reporting unit, which was formed as a result of the CSP Technologies Acquisition in the third quarter of 2018. We calculated the fair value of the Active Packaging reporting unit and compared it with the associated carrying amount (the “step one” approach”) as of July 1, 2019. Based on this quantitative analysis, the fair value of the reporting unit exceeded the carrying value and therefore no impairment loss was recognized.

RETIREMENT OF COMMON STOCK

​

During the first nine months of 2019, we repurchased 493 thousand shares of common stock, all of which were returned to treasury stock. During the first nine months of 2018, we repurchased 668 thousand shares of common stock, of which 623 thousand shares were immediately retired. Common stock was reduced by the number of shares retired at $0.01 par value per share. We allocate the excess purchase price over par value between additional paid-in capital and retained earnings.

8

Table of Contents

INCOME TAXES

​

We compute taxes on income in accordance with the tax rules and regulations of the many taxing authorities where income is earned. The income tax rates imposed by these taxing authorities may vary substantially. Taxable income may differ from pre-tax income for financial accounting purposes. To the extent that these differences create temporary differences between the tax basis of an asset or liability and our reported amount in the financial statements, an appropriate provision for deferred income taxes is made.

All of our non-U.S. earnings are subject to U.S. taxation, either from the transition tax enacted in the U.S. by the TCJA on accumulated non-U.S. earnings as of the end of 2017 or the global intangible low-taxed income (“GILTI”) provisions on non-U.S. earnings thereafter. We maintain our assertion that the cash and distributable reserves at our non-U.S. affiliates are indefinitely reinvested. We will provide for the necessary withholding and local income taxes when management decides that an affiliate should make a distribution. These decisions are made taking into consideration the financial requirements of the non-U.S. affiliates and the global cash management goals of the Company.

We provide a liability for the amount of unrecognized tax benefits from uncertain tax positions. This liability is provided whenever we determine that a tax benefit will not meet a more-likely-than-not threshold for recognition. See Note 5 - Income Taxes for more information.

​

​

​

​

​

​

NOTE 2 – REVENUE

At contract inception, we assess the goods and services promised in our contracts with customers and identify a performance obligation for each promise to transfer a good or service (or bundle of goods or services) that is distinct. To identify the performance obligations, we consider all the goods or services promised in the contract, whether explicitly stated or implied based on customary business practices. For a contract that has more than one performance obligation, we allocate the total contract consideration to each distinct performance obligation on a relative standalone selling price basis. Revenue is recognized when (or as) the performance obligations are satisfied (i.e., when the customer obtains control of the good or service). The majority of our revenues are derived from product and tooling sales; however, we also receive revenues from service, license, exclusivity and royalty arrangements, which collectively are not material to the quarterly and year-to-date results. Revenue by segment and geography for the three and nine months ended September 30, 2019 and 2018 is as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | For the Three Months Ended September 30, 2019 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | Latin | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment | ​ | Europe | ​ | Domestic | ​ | America | ​ | Asia | ​ | Total |
Beauty + Home | ​ | $ | 188,542 | ​ | $ | 75,931 | ​ | $ | 40,261 | ​ | $ | 23,448 | ​ | $ | 328,182 | ​
Pharma | ​ | ​ | 174,252 | ​ | ​ | 78,259 | ​ | ​ | 6,366 | ​ | ​ | 10,374 | ​ | ​ | 269,251 | ​
Food + Beverage | ​ | ​ | 28,718 | ​ | ​ | 57,307 | ​ | ​ | 8,058 | ​ | ​ | 9,762 | ​ | ​ | 103,845 | ​
Total | ​ | $ | 391,512 | ​ | $ | 211,497 | ​ | $ | 54,685 | ​ | $ | 43,584 | ​ | $ | 701,278 | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Three Months Ended September 30, 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Latin | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment | ​ | Europe | ​ | Domestic | ​ | America | ​ | Asia | ​ | Total | ​
Beauty + Home | ​ | $ | 190,267 | ​ | $ | 83,353 | ​ | $ | 44,653 | ​ | $ | 23,487 | ​ | $ | 341,760 | ​
Pharma | ​ | ​ | 161,733 | ​ | ​ | 50,126 | ​ | ​ | 6,165 | ​ | ​ | 9,491 | ​ | ​ | 227,515 | ​
Food + Beverage | ​ | ​ | 29,472 | ​ | ​ | 47,870 | ​ | ​ | 7,476 | ​ | ​ | 11,682 | ​ | ​ | 96,500 | ​
Total | ​ | $ | 381,472 | ​ | $ | 181,349 | ​ | $ | 58,294 | ​ | $ | 44,660 | ​ | $ | 665,775 | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Nine Months Ended September 30, 2019 |
​ | ​ | ​ | ​ | ​ | ​ | ​ | Latin | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment | ​ | Europe | ​ | Domestic | ​ | America | ​ | Asia | ​ | Total |
Beauty + Home | ​ | $ | 607,316 | ​ | $ | 236,883 | ​ | $ | 124,352 | ​ | $ | 69,370 | ​ | $ | 1,037,921 | ​
Pharma | ​ | ​ | 549,080 | ​ | ​ | 226,073 | ​ | ​ | 21,100 | ​ | ​ | 27,638 | ​ | ​ | 823,891 | ​
Food + Beverage | ​ | ​ | 92,015 | ​ | ​ | 177,587 | ​ | ​ | 25,153 | ​ | ​ | 31,832 | ​ | ​ | 326,587 | ​
Total | ​ | $ | 1,248,411 | ​ | $ | 640,543 | ​ | $ | 170,605 | ​ | $ | 128,840 | ​ | $ | 2,188,399 | ​

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | For the Nine Months Ended September 30, 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | Latin | ​ | ​ | ​ | ​ | ​ | ​ | ​
Segment | ​ | Europe | ​ | Domestic | ​ | America | ​ | Asia | ​ | Total | ​
Beauty + Home | ​ | $ | 622,184 | ​ | $ | 252,709 | ​ | $ | 140,238 | ​ | $ | 73,338 | ​ | $ | 1,088,469 | ​
Pharma | ​ | ​ | 520,574 | ​ | ​ | 132,496 | ​ | ​ | 19,229 | ​ | ​ | 26,552 | ​ | ​ | 698,851 | ​
Food + Beverage | ​ | ​ | 90,185 | ​ | ​ | 143,005 | ​ | ​ | 23,343 | ​ | ​ | 35,880 | ​ | ​ | 292,413 | ​
Total | ​ | $ | 1,232,943 | ​ | $ | 528,210 | ​ | $ | 182,810 | ​ | $ | 135,770 | ​ | $ | 2,079,733 | ​

9

Table of Contents

​

We perform our obligations under a contract with a customer by transferring goods and/or services in exchange for consideration from the customer. The timing of performance will sometimes differ from the timing of the receipt of the associated consideration from the customer, thus resulting in the recognition of a contract asset or a contract liability. We recognize a contract asset when we transfer control of goods or services to a customer prior to invoicing for the related performance obligation. The contract asset is transferred to accounts receivable when the product is shipped and invoiced to the customer. We recognize a contract liability if the customer's payment of consideration precedes the entity's performance.

The opening and closing balances of our contract asset and contract liabilities are as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Balance as of | ​ | Balance as of | ​ | Increase/ |
​ | ​ | December 31, 2018 | ​ | September 30, 2019 | ​ | (Decrease) |
Contract asset (current) | ​ | $ | 15,858 | ​ | $ | 19,044 | ​ | $ | 3,186 | ​
Contract asset (long-term) | ​ | $ | — | ​ | $ | — | ​ | $ | — | ​
Contract liability (current) | ​ | $ | 68,134 | ​ | $ | 59,500 | ​ | $ | (8,634) | ​
Contract liability (long-term) | ​ | $ | 11,261 | ​ | $ | 12,705 | ​ | $ | 1,444 | ​

​

The differences in the opening and closing balances of our contract asset and contract liabilities are primarily the result of timing differences between our performance and the customer’s payment. The total amount of revenue recognized during the current year against contract liabilities is $40.9 million, including $22.6 million relating to contract liabilities at the beginning of the year.

Determining the Transaction Price

In most cases, the transaction price for each performance obligation is stated in the contract. In determining the variable amounts of consideration within the transaction price (such as volume-based customer rebates), we include an estimate of the expected amount of consideration as revenue. We apply the expected value method based on all of the information (historical, current, and forecast) that is reasonably available and identify reasonable estimates based on this information. We apply the method consistently throughout the contract when estimating the effect of an uncertainty on the amount of variable consideration to which we will be entitled.

Product Sales

We primarily manufacture and sell dispensing, sealing and active packaging solutions. The amount of consideration is typically fixed for such customers. At the time of delivery, the customer is invoiced the agreed-upon price. Revenue from product sales is typically recognized upon manufacture or shipment, when control of the goods transfers to the customer.

To determine when the control transfers, we typically assess, among other things, the shipping terms of the contract, shipping being one of the indicators of transfer of control. A majority of product sales are sold free on board (“FOB”) shipping point. For FOB shipping point shipments, control of the goods transfers to the customer at the time of shipment of the goods. Therefore, our performance obligation is satisfied at the time of shipment. We have elected to account for shipping and handling costs that occur after the customer has obtained control of a good as fulfillment costs rather than as a promised service. We do not have any material significant payment terms as payment is typically received shortly after the point of sale.

There also exist instances where we manufacture highly customized products that have no alternative use to us and for which we have an enforceable right to payment for performance completed to date. For these products, we transfer control and recognize revenue over time by measuring progress towards completion using the Output Method based on the number of products produced. As we normally make our products to a customer’s order, the time between production and shipment of our products is typically within a few weeks.

As a part of our customary business practice, we offer a standard warranty that the products will materially comply with the technical specifications and will be free from material defects. Because such warranties are not sold separately, do not provide for any service beyond a guarantee of a product’s initial specifications, and are not required by law, there is no revenue deferral for these types of warranties.

10

Table of Contents

Tooling Sales

We also build or contract to build molds and other tools (collectively defined as “tooling”) necessary to produce our products. As with product sales, we recognize revenue when control of the tool transfers to the customer. If the tooling is highly customized with no alternative use to us and we have an enforceable right to payment for performance completed to date, we transfer control and recognize revenue over time by measuring progress towards completion using the Input Method based on costs incurred relative to total estimated costs to completion. Otherwise, revenue for the tooling is recognized at the point in time when the customer approves the tool. We do not have any material significant payment terms as payment is typically either received during the mold-build process or shortly after completion.

In certain instances, we offer extended warranties on tools sold to our customers above and beyond the normal standard warranties. We normally receive payment at the inception of the contract and recognize revenue over the term of the contract. At December 31, 2018, $758 thousand of unearned revenue associated with outstanding contracts was reported in Accounts Payable and Other Liabilities. At September 30, 2019, the unearned amount was $504 thousand. We expect to recognize approximately $49 thousand of the unearned amount during the remainder of 2019, $260 thousand in 2020, and $195 thousand thereafter.

NOTE 3 - INVENTORIES

Inventories, by component, consisted of:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | September 30, | ​ | December 31, | ​
​ | ​ | 2019 | ​ | 2018 |
Raw materials | ​ | $ | 111,551 | ​ | $ | 110,720 | ​
Work in process | ​ |  | 129,753 | ​ |  | 131,091 | ​
Finished goods | ​ |  | 142,187 | ​ |  | 139,299 | ​
Total | ​ | $ | 383,491 | ​ | $ | 381,110 | ​

​

​

​

​

​

​

​

​

NOTE 4 – GOODWILL AND OTHER INTANGIBLE ASSETS

The changes in the carrying amount of goodwill by reporting segment since December 31, 2018 are as follows:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Beauty + |  | ​ | ​ |  | Food + |  | Corporate |  | ​ | ​ |
​ | ​ | Home | ​ | Pharma | ​ | Beverage | ​ | & Other | ​ | Total |
Goodwill | ​ | $ | 223,933 | ​ | $ | 359,883 | ​ | $ | 128,279 | ​ | $ | 1,615 | ​ | $ | 713,710 | ​
Accumulated impairment losses | ​ | ​ | — | ​ |  | — | ​ |  | — | ​ |  | (1,615) | ​ |  | (1,615) | ​
Balance as of December 31, 2018 | ​ | $ | 223,933 | ​ | $ | 359,883 | ​ | $ | 128,279 | ​ | $ | — | ​ | $ | 712,095 | ​
Acquisition | ​ | ​ | — | ​ | ​ | 28,138 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 28,138 | ​
Foreign currency exchange effects | ​ |  | (4,994) | ​ |  | (12,876) | ​ |  | (293) | ​ |  | — | ​ |  | (18,163) | ​
Goodwill | ​ | $ | 218,939 | ​ | $ | 375,145 | ​ | $ | 127,986 | ​ | $ | 1,615 | ​ | $ | 723,685 | ​
Accumulated impairment losses | ​ |  | — | ​ |  | — | ​ |  | — | ​ |  | (1,615) | ​ |  | (1,615) | ​
Balance as of September 30, 2019 | ​ | $ | 218,939 | ​ | $ | 375,145 | ​ | $ | 127,986 | ​ | $ | — | ​ | $ | 722,070 | ​

​

During the third quarter of 2019, we performed a separate quantitative impairment assessment using a discounted cash flow analysis of the Active Packaging reporting unit, which was formed as a result of the CSP Technologies Acquisition in the third quarter of 2018. We calculated the fair value of the Active Packaging reporting unit and compared it with the associated carrying amount (the “step one” approach”) as of July 1, 2019. Based on this quantitative analysis, the fair value of the reporting unit exceeded the carrying value and therefore no impairment loss was recognized.

11

Table of Contents

The table below shows a summary of intangible assets as of September 30, 2019 and December 31, 2018.

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | September 30, 2019 | ​ | ​ | December 31, 2018 | ​
Weighted Average | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Gross | ​ | ​ | ​ | ​ | ​ | ​ |
Amortization Period | ​ | Carrying | ​ | Accumulated | ​ | Net | ​ | Carrying | ​ | Accumulated | ​ | Net |
​ |  | (Years) |  | Amount |  | Amortization |  | Value |  | Amount |  | Amortization |  | Value |
Amortized intangible assets: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Patents |  | 3.0 | ​ | $ | 5,972 | ​ | ​ | (4,635) | ​ | $ | 1,337 | ​ | $ | 5,427 | ​ | $ | (5,294) | ​ | $ | 133 | ​
Acquired technology |  | 13.4 | ​ |  | 93,153 | ​ | ​ | (22,856) | ​ |  | 70,297 | ​ |  | 92,389 | ​ |  | (18,304) | ​ |  | 74,085 | ​
Customer relationships | ​ | 13.9 | ​ | ​ | 187,994 | ​ | ​ | (29,336) | ​ | ​ | 158,658 | ​ | ​ | 179,597 | ​ | ​ | (20,439) | ​ | ​ | 159,158 | ​
Trademarks and trade names | ​ | 7.2 | ​ | ​ | 33,026 | ​ | ​ | (9,564) | ​ | ​ | 23,462 | ​ | ​ | 21,243 | ​ | ​ | (5,914) | ​ | ​ | 15,329 | ​
License agreements and other |  | 11.0 | ​ |  | 14,830 | ​ | ​ | (8,872) | ​ |  | 5,958 | ​ |  | 13,852 | ​ |  | (7,653) | ​ |  | 6,199 | ​
Total intangible assets |  | 12.8 | ​ | $ | 334,975 | ​ | $ | (75,263) | ​ | $ | 259,712 | ​ | $ | 312,508 | ​ | $ | (57,604) | ​ | $ | 254,904 | ​

​

Aggregate amortization expense for the intangible assets above for the quarters ended September 30, 2019 and 2018 was $7,399 and $4,005, respectively. Aggregate amortization expense for the intangible assets above for the nine months ended September 30, 2019 and 2018 was $19,787 and $9,578, respectively.

Future estimated amortization expense for the years ending December 31 is as follows:

​ | ​ | ​ | ​ | ​ | ​
2019 | ​ | $ | 7,683 | ​ | (remaining estimated amortization for 2019)
2020 | ​ |  | 26,340 | ​ | ​
2021 | ​ |  | 25,484 | ​ | ​
2022 | ​ |  | 25,247 | ​ | ​
2023 and thereafter | ​ |  | 174,958 | ​ | ​

​

Future amortization expense may fluctuate depending on changes in foreign currency rates. The estimates for amortization expense noted above are based upon foreign exchange rates as of September 30, 2019.

​

NOTE 5 – INCOME TAXES

The effective tax rate for the three months ended September 30, 2019 of 31.0% reflects a $2.1 million charge from the increase in the tax rate in France, which is retroactive to the beginning of 2019, offset by a $2.0 million benefit from the excess tax benefits from employee stock-based compensation. The effective tax rate for the three months ended September 30, 2018 of 23.4% was favorably impacted by net tax benefits of $5.0 million from discrete events. This included a $4.5 million benefit from the excess tax benefits from employee stock-based compensation and a $1.9 million benefit related to U.S. tax reform legislation, offset by other discrete charges.

The effective tax rate for the nine months ended September 30, 2019 of 29.4% was favorably impacted by net tax benefits of $4.3 million from discrete events. This consisted of a favorable impact of $13.6 million from the excess tax benefits from employee stock-based compensation offset by, among other items, a $7.0 million charge recognized to record a valuation allowance to properly reflect the realization of recorded deferred tax assets and the $2.1 million charge from the French tax rate increase. The effective tax rate for the nine months ended September 30, 2018 of 25.6% was favorably impacted by net tax benefits of $15.1 million from discrete items. This included a favorable impact of $9.9 million from the excess tax benefits from employee stock-based compensation and a $5.4 million benefit related to U.S. tax reform legislation.

​

12

Table of Contents

NOTE 6 – DEBT

We hold U.S. dollar and euro-denominated debt to align our capital structure with our earnings base. At September 30, 2019, our long-term obligations consisted of the following:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Unamortized | ​ | ​ | ​
​ |  | ​ |  | Debt Issuance |  | ​ |
​ |  | Principal |  | Costs |  | Net |
Notes payable 0.00% – 10.90%, due in monthly and annual installments through 2028 | ​ | $ | 19,907 | ​ | $ | — | ​ | $ | 19,907 | ​
Senior unsecured notes 3.2%, due in 2022 | ​ |  | 75,000 | ​ |  | 70 | ​ |  | 74,930 | ​
Senior unsecured debts 3.8% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022 | ​ |  | 168,000 | ​ |  | 428 | ​ |  | 167,572 | ​
Senior unsecured notes 3.5%, due in 2023 | ​ | ​ | 125,000 | ​ | ​ | 153 | ​ | ​ | 124,847 | ​
Senior unsecured notes 1.0%, due in 2023 | ​ | ​ | 109,005 | ​ | ​ | 371 | ​ | ​ | 108,634 | ​
Senior unsecured notes 3.4%, due in 2024 | ​ |  | 50,000 | ​ |  | 66 | ​ |  | 49,934 | ​
Senior unsecured notes 3.5%, due in 2024 | ​ | ​ | 100,000 | ​ | ​ | 153 | ​ | ​ | 99,847 | ​
Senior unsecured notes 1.2%, due in 2024 | ​ | ​ | 218,010 | ​ | ​ | 782 | ​ | ​ | 217,228 | ​
Senior unsecured notes 3.6%, due in 2025 | ​ | ​ | 125,000 | ​ | ​ | 181 | ​ | ​ | 124,819 | ​
Senior unsecured notes 3.6%, due in 2026 | ​ | ​ | 125,000 | ​ | ​ | 181 | ​ | ​ | 124,819 | ​
Finance Lease Liabilities | ​ |  | 27,557 | ​ |  | — | ​ |  | 27,557 | ​
​ | ​ | $ | 1,142,479 | ​ | $ | 2,385 | ​ | $ | 1,140,094 | ​
Current maturities of long-term obligations | ​ |  | (64,941) | ​ |  | — | ​ |  | (64,941) | ​
Total long-term obligations | ​ | $ | 1,077,538 | ​ | $ | 2,385 | ​ | $ | 1,075,153 | ​

​

At December 31, 2018, our long-term obligations consisted of the following:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Unamortized | ​ | ​ | ​
​ | ​ | ​ | ​ | Debt Issuance | ​ | ​ | ​
​ | ​ | Principal | ​ | Costs | ​ | Net |
Notes payable 0.00% – 16.00%, due in monthly and annual installments through 2028 | ​ | $ | 15,531 | ​ | $ | — | ​ | $ | 15,531 | ​
Senior unsecured notes 3.2%, due in 2022 | ​ |  | 75,000 | ​ |  | 88 | ​ |  | 74,912 | ​
Senior unsecured debts 4.0% USD floating swapped to 1.36% EUR fixed, equal annual installments through 2022 | ​ |  | 224,000 | ​ |  | 541 | ​ |  | 223,459 | ​
Senior unsecured notes 3.5%, due in 2023 | ​ | ​ | 125,000 | ​ | ​ | 181 | ​ | ​ | 124,819 | ​
Senior unsecured notes 1.0%, due in 2023 | ​ | ​ | 114,535 | ​ | ​ | 432 | ​ | ​ | 114,103 | ​
Senior unsecured notes 3.4%, due in 2024 | ​ |  | 50,000 | ​ |  | 76 | ​ |  | 49,924 | ​
Senior unsecured notes 3.5%, due in 2024 | ​ | ​ | 100,000 | ​ | ​ | 181 | ​ | ​ | 99,819 | ​
Senior unsecured notes 1.2%, due in 2024 | ​ | ​ | 229,070 | ​ | ​ | 904 | ​ | ​ | 228,166 | ​
Senior unsecured notes 3.6%, due in 2025 | ​ | ​ | 125,000 | ​ | ​ | 207 | ​ | ​ | 124,793 | ​
Senior unsecured notes 3.6%, due in 2026 | ​ | ​ | 125,000 | ​ | ​ | 208 | ​ | ​ | 124,792 | ​
Capital lease obligations | ​ |  | 8,353 | ​ |  | — | ​ |  | 8,353 | ​
​ | ​ | $ | 1,191,489 | ​ | $ | 2,818 | ​ | $ | 1,188,671 | ​
Current maturities of long-term obligations | ​ |  | (62,678) | ​ | ​ | — | ​ | ​ | (62,678) | ​
Total long-term obligations | ​ | $ | 1,128,811 | ​ | $ | 2,818 | ​ | $ | 1,125,993 | ​

​

Aggregate long-term maturities, excluding finance lease liabilities, due annually from the current balance sheet date for the next five years are $61,085, $61,515, $135,217, $112,121, $494,402 and $250,582 thereafter.

We also maintain a multi-currency revolving credit facility with two tranches, providing for unsecured financing of up to $300 million that is available in the U.S. and up to €150 million that is available to our wholly-owned UK subsidiary. Each borrowing under the credit facility will bear interest at rates based on LIBOR, prime rates or other similar rates, in each case plus an applicable margin. A facility fee on the total amount of the facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. The December 31, 2018 outstanding balance of €69.0 million on the euro-based revolving credit facility was paid in the first quarter of 2019. €27.0 million was utilized as of September 30, 2019. Credit facility balances are included in notes payable, including revolving credit facilities on the Condensed Consolidated Balance Sheet.

13

Table of Contents

Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

​

​

​ | ​ | ​ | ​ | ​
​ |  | Requirement |  | Level at September 30, 2019
Consolidated Leverage Ratio (1) |  | Maximum of 3.50 to 1.00 |  | 1.68 to 1.00
Consolidated Interest Coverage Ratio (1) |  | Minimum of 3.00 to 1.00 |  | 16.07 to 1.00

(1) | Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.

​

​

NOTE 7 – LEASE COMMITMENTS

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating and finance leases expiring at various dates through the year 2028. Most of the operating leases contain renewal options and certain leases include options to purchase the related asset during or at the end of the lease term.

Amortization expense related to finance leases is included in depreciation expense while rent expense related to operating leases is included within cost of sales and selling research & development and administrative expenses (“SG&A”). Rent expense related to operating leases (including taxes, insurance and maintenance when included in the rent) amounted to $8.3 million and $24.2 million in the three and nine months ended September 30, 2018, respectively, under the old lease accounting standard.

The components of lease expense for the current period were as follows:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Three Months Ended | ​ | Nine Months Ended | ​
​ | ​ | September 30, 2019 |  | September 30, 2019 |
Operating lease cost | ​ | $ | 6,001 | ​ | $ | 17,442 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Finance lease cost: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of right-of-use assets | ​ | $ | 1,165 | ​ | $ | 3,041 | ​
Interest on lease liabilities | ​ | ​ | 344 | ​ | ​ | 984 | ​
Total finance lease cost | ​ | $ | 1,509 | ​ | $ | 4,025 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Short-term lease and variable lease costs | ​ | $ | 1,757 | ​ | $ | 6,027 | ​

​

Supplemental cash flow information related to leases was as follows:

​

​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, | ​ | 2019 |
Cash paid for amounts included in the measurement of lease liabilities: | ​ | ​ | ​ | ​
Operating cash flows from operating leases | ​ | $ | 15,874 | ​
Operating cash flows from finance leases | ​ | ​ | 877 | ​
Financing cash flows from finance leases | ​ | ​ | 3,365 | ​
​ | ​ | ​ | ​ | ​
Right-of-use assets obtained in exchange for lease obligations: | ​ | ​ | ​ | ​
Operating leases | ​ | $ | 11,673 | ​
Finance leases | ​ | ​ | 12,401 | ​

​

14

Table of Contents

Supplemental balance sheet information related to leases was as follows:

​

​ | ​ | ​ | ​ | ​
​ | ​ | September 30, 2019 | ​
Operating Leases | ​ | ​ | ​ | ​
Operating lease right-of-use assets | ​ | $ | 72,481 | ​
​ | ​ | ​ | ​ | ​
Accounts payable and accrued liabilities | ​ | $ | 16,351 | ​
Operating lease liabilities | ​ | ​ | 55,278 | ​
Total operating lease liabilities | ​ | $ | 71,629 | ​
​ | ​ | ​ | ​ | ​
Finance Leases | ​ | ​ | ​ | ​
Property, plant and equipment, gross | ​ | $ | 43,042 | ​
Accumulated depreciation | ​ | ​ | (3,125) | ​
Property, plant and equipment, net | ​ | $ | 39,917 | ​
​ | ​ | ​ | ​ | ​
Current maturities of long-term obligations, net of unamortized debt issuance cost | ​ | $ | 3,856 | ​
Long-term obligations, net of unamortized debt issuance cost | ​ | ​ | 23,701 | ​
Total finance lease liabilities | ​ | $ | 27,557 | ​
​ | ​ | ​ | ​ | ​
Weighted Average Remaining Lease Term (in years) | ​ | ​ | ​ | ​
Operating leases | ​ | ​ | 6.0 | ​
Finance leases | ​ | ​ | 7.1 | ​
​ | ​ | ​ | ​ | ​
Weighted Average Discount Rate | ​ | ​ | ​ | ​
Operating leases | ​ | ​ | 5.06 | %
Finance leases | ​ | ​ | 5.34 | %

​

Maturities of lease liabilities as of September 30, 2019, were as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Operating | ​ | Finance |
​ |  | Leases |  | Leases | ​
Year 1 | ​ | $ | 19,113 | ​ | $ | 5,028 | ​
Year 2 | ​ |  | 15,763 | ​ |  | 4,470 | ​
Year 3 | ​ |  | 11,167 | ​ |  | 3,659 | ​
Year 4 | ​ |  | 9,515 | ​ |  | 2,794 | ​
Year 5 | ​ |  | 7,177 | ​ |  | 2,340 | ​
Thereafter | ​ |  | 21,337 | ​ |  | 17,433 | ​
Total lease payments | ​ |  | 84,072 | ​ | ​ | 35,724 | ​
Less imputed interest | ​ |  | (12,443) | ​ | ​ | (8,167) | ​
Total | ​ | $ | 71,629 | ​ | $ | 27,557 | ​

​

Maturities of lease liabilities as of December 31, 2018 under the old lease accounting standard were as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Operating | ​ | Capital | ​
​ |  | Leases |  | Leases | ​
Year 1 | ​ | $ | 26,512 | ​ | $ | 1,828 | ​
Year 2 | ​ |  | 21,386 | ​ |  | 1,653 | ​
Year 3 | ​ |  | 16,529 | ​ |  | 1,546 | ​
Year 4 | ​ |  | 12,549 | ​ |  | 1,160 | ​
Year 5 | ​ |  | 10,225 | ​ |  | 880 | ​
Thereafter | ​ |  | 21,932 | ​ |  | 3,827 | ​
Total lease payments | ​ | $ | 109,133 | ​ | ​ | 10,894 | ​
Less imputed interest | ​ |  | ​ | ​ | ​ | (2,541) | ​
Present value of future lease payments | ​ | ​ | ​ | ​ | $ | 8,353 | ​

​

As of September 30, 2019, we have additional operating and finance leases, primarily for buildings, that have not yet commenced of $3.8 million. These operating and finance leases will commence in years 2019 and 2020 with lease terms of 3 to 10 years.

15

Table of Contents

NOTE 8 – RETIREMENT AND DEFERRED COMPENSATION PLANS

Components of Net Periodic Benefit Cost:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Domestic Plans | ​ | Foreign Plans |
Three Months Ended September 30, | ​ | 2019 | ​ | 2018 | ​ | 2019 | ​ | 2018 |
Service cost | ​ | $ | 2,772 | ​ | $ | 2,853 | ​ | $ | 1,429 | ​ | $ | 1,457 | ​
Interest cost | ​ |  | 1,845 | ​ |  | 1,713 | ​ |  | 491 | ​ |  | 445 | ​
Expected return on plan assets | ​ |  | (3,095) | ​ |  | (2,803) | ​ |  | (581) | ​ |  | (645) | ​
Amortization of net loss | ​ |  | 490 | ​ |  | 1,214 | ​ |  | 356 | ​ |  | 422 | ​
Amortization of prior service cost | ​ |  | — | ​ |  | — | ​ |  | 111 | ​ |  | 122 | ​
Net periodic benefit cost | ​ | $ | 2,012 | ​ | $ | 2,977 | ​ | $ | 1,806 | ​ | $ | 1,801 | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Domestic Plans | ​ | Foreign Plans | ​
Nine Months Ended September 30, | ​ | 2019 | ​ | 2018 | ​ | 2019 | ​ | 2018 |
Service cost | ​ | $ | 8,320 | ​ | $ | 8,546 | ​ | $ | 4,334 | ​ | $ | 4,479 | ​
Interest cost | ​ |  | 5,536 | ​ |  | 5,139 | ​ |  | 1,487 | ​ |  | 1,374 | ​
Expected return on plan assets | ​ |  | (9,284) | ​ |  | (8,409) | ​ |  | (1,759) | ​ |  | (1,982) | ​
Amortization of net loss | ​ |  | 1,468 | ​ |  | 3,642 | ​ |  | 1,078 | ​ |  | 1,301 | ​
Amortization of prior service cost | ​ |  | — | ​ |  | — | ​ |  | 337 | ​ |  | 376 | ​
Net periodic benefit cost | ​ | $ | 6,040 | ​ | $ | 8,918 | ​ | $ | 5,477 | ​ | $ | 5,548 | ​

​

The components of net periodic benefit cost, other than the service cost component, are included in the line “Miscellaneous, net” in the income statement.

​

EMPLOYER CONTRIBUTIONS

Although we have no minimum funding requirement, we contributed $365 thousand to our domestic defined benefit plans during the nine months ended September 30, 2019 and do not expect additional significant contributions during 2019. We expect to contribute approximately $4.3 million to our foreign defined benefit plans in 2019, and as of September 30, 2019, we have contributed approximately $1.5 million of that amount.

​

NOTE 9 – ACCUMULATED OTHER COMPREHENSIVE INCOME

Changes in Accumulated Other Comprehensive (Loss) Income by Component:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Foreign |  | Defined Benefit |  | ​ | ​ |  | ​ | ​ |
​ | ​ | Currency | ​ | Pension Plans | ​ | Derivatives | ​ | Total |
Balance - December 31, 2017 | ​ | $ | (185,503) | ​ | $ | (64,595) | ​ | $ | (3,204) | ​ | $ | (253,302) | ​
Other comprehensive (loss) income before reclassifications | ​ |  | (53,141) | ​ |  | — | ​ |  | 12,507 | ​ |  | (40,634) | ​
Amounts reclassified from accumulated other comprehensive income (loss) | ​ |  | — | ​ |  | 4,032 | ​ |  | (11,444) | ​ |  | (7,412) | ​
Net current-period other comprehensive (loss) income | ​ |  | (53,141) | ​ |  | 4,032 | ​ |  | 1,063 | ​ |  | (48,046) | ​
Balance - September 30, 2018 | ​ | $ | (238,644) | ​ | $ | (60,563) | ​ | $ | (2,141) | ​ | $ | (301,348) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Balance - December 31, 2018 | ​ | $ | (248,401) | ​ | $ | (60,463) | ​ | $ | (1,640) | ​ | $ | (310,504) | ​
Other comprehensive (loss) income before reclassifications | ​ |  | (42,725) | ​ |  | — | ​ |  | 11,806 | ​ |  | (30,919) | ​
Amounts reclassified from accumulated other comprehensive income (loss) | ​ |  | — | ​ |  | 2,150 | ​ |  | (12,399) | ​ |  | (10,249) | ​
Net current-period other comprehensive (loss) income | ​ |  | (42,725) | ​ |  | 2,150 | ​ |  | (593) | ​ |  | (41,168) | ​
Balance - September 30, 2019 | ​ | $ | (291,126) | ​ | $ | (58,313) | ​ | $ | (2,233) | ​ | $ | (351,672) | ​

​

16

Table of Contents

Reclassifications Out of Accumulated Other Comprehensive (Loss) Income:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Amount Reclassified from | ​ | ​ | ​
Details about Accumulated Other | ​ | Accumulated Other | ​ | Affected Line in the Statement | ​
Comprehensive Income Components | ​ | Comprehensive Income | ​ | Where Net Income is Presented | ​
Three Months Ended September 30, | ​ | 2019 | ​ | 2018 | ​ | ​ |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Defined Benefit Pension Plans | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of net loss | ​ | $ | 846 | ​ | $ | 1,636 |  | (1) | ​
Amortization of prior service cost | ​ |  | 111 | ​ |  | 122 |  | (1) | ​
​ | ​ |  | 957 | ​ |  | 1,758 |  | Total before tax | ​
​ | ​ |  | (244) | ​ |  | (425) |  | Tax benefit | ​
​ | ​ | $ | 713 | ​ | $ | 1,333 |  | Net of tax | ​
Derivatives | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Changes in treasury locks | ​ | $ | — | ​ | $ | 4 |  | Interest Expense | ​
Changes in cross currency swap: interest component | ​ | ​ | (1,309) | ​ | ​ | (1,337) | ​ | Interest Expense | ​
Changes in cross currency swap: foreign exchange component | ​ | ​ | (6,491) | ​ | ​ | (2,131) | ​ | Miscellaneous, net | ​
​ | ​ |  | (7,800) | ​ |  | (3,464) |  | Total before tax | ​
​ | ​ |  | — | ​ |  | 588 |  | Tax benefit | ​
​ | ​ | $ | (7,800) | ​ | $ | (2,876) |  | Net of tax | ​
Total reclassifications for the period | ​ | $ | (7,087) | ​ | $ | (1,543) | ​ | ​ | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Amount Reclassified from | ​ | ​ |
Details about Accumulated Other | ​ | Accumulated Other | ​ | Affected Line in the Statement |
Comprehensive Income Components | ​ | Comprehensive Income | ​ | Where Net Income is Presented |
Nine Months Ended September 30, | ​ | 2019 | ​ | 2018 | ​ | ​ |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Defined Benefit Pension Plans | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Amortization of net loss | ​ | $ | 2,546 | ​ | $ | 4,943 |  | (1) | ​
Amortization of prior service cost | ​ |  | 337 | ​ |  | 376 |  | (1) | ​
​ | ​ |  | 2,883 | ​ |  | 5,319 |  | Total before tax | ​
​ | ​ |  | (733) | ​ |  | (1,287) |  | Tax benefit | ​
​ | ​ | $ | 2,150 | ​ | $ | 4,032 |  | Net of tax | ​
Derivatives | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Changes in treasury locks | ​ | $ | — | ​ | $ | 26 |  | Interest Expense | ​
Changes in cross currency swap: interest component | ​ | ​ | (4,315) | ​ | ​ | (3,824) | ​ | Interest Expense | ​
Changes in cross currency swap: foreign exchange component | ​ |  | (8,084) | ​ |  | (9,984) |  | Miscellaneous, net | ​
​ | ​ |  | (12,399) | ​ |  | (13,782) |  | Total before tax | ​
​ | ​ |  | — | ​ |  | 2,338 |  | Tax benefit | ​
​ | ​ | $ | (12,399) | ​ | $ | (11,444) |  | Net of tax | ​
Total reclassifications for the period | ​ | $ | (10,249) | ​ | $ | (7,412) | ​ | ​ | ​

(1) | These accumulated other comprehensive income components are included in the computation of net periodic benefit costs, net of tax. See Note 8 – Retirement and Deferred Compensation Plans for additional details.

​

​

​

NOTE 10 – DERIVATIVE INSTRUMENTS AND HEDGING ACTIVITIES

We maintain a foreign exchange risk management policy designed to establish a framework to protect the value of our non-functional denominated transactions from adverse changes in exchange rates. Sales of our products can be denominated in a currency different from the currency in which the related costs to produce the product are denominated. Changes in exchange rates on such inter-country sales or intercompany loans can impact our results of operations. Our policy is not to engage in speculative foreign currency hedging activities, but to minimize our net foreign currency transaction exposure, defined as firm commitments and transactions recorded and denominated in currencies other than the functional currency. We may use foreign currency forward exchange contracts, options and cross currency swaps to economically hedge these risks.

17

Table of Contents

For derivative instruments designated as hedges, we formally document the nature and relationships between the hedging instruments and the hedged items, as well as the risk management objectives, strategies for undertaking the various hedge transactions, and the method of assessing hedge effectiveness at inception. Quarterly thereafter, we formally assess whether the derivatives that are used in hedging transactions are highly effective in offsetting changes in the fair value or cash flows of the hedged item. Additionally, in order to designate any derivative instrument as a hedge of an anticipated transaction, the significant characteristics and expected terms of any anticipated transaction must be specifically identified, and it must be probable that the anticipated transaction will occur. All derivative financial instruments used as hedges are recorded at fair value in the Condensed Consolidated Balance Sheets. See Note 11 - Fair Value for additional details.

CASH FLOW HEDGE

For derivative instruments that are designated and qualify as cash flow hedges, the changes in fair values are recorded in accumulated other comprehensive loss and included in changes in derivative gain/loss. The changes in the fair values of derivatives designated as cash flow hedges are reclassified from accumulated other comprehensive loss to net income when the underlying hedged item is recognized in earnings. Cash flows from the settlement of derivative contracts designated as cash flow hedges offset cash flows from the underlying hedged items and are included in operating activities in the Condensed Consolidated Statements of Cash Flows.

During 2017, our wholly-owned UK subsidiary borrowed $280 million in term loan borrowings under a new credit facility. In order to mitigate the currency risk of U.S. dollar debt on a euro functional currency entity and to mitigate the risk of variability in interest rates, we entered into a cross currency swap in the notional amount of $280 million to effectively hedge the foreign exchange and interest rate exposure on the $280 million term loan. This EUR/USD swap agreement fixed our U.S. dollar floating-rate debt to 1.36% euro fixed-rate debt. Related to this hedge, approximately $2.2 million of loss is included in accumulated other comprehensive loss at September 30, 2019. The amount expected to be recognized into earnings during the next 12 months related to the interest component of our cross currency swap based on prevailing foreign exchange and interest rates at September 30, 2019 is $4.2 million. The amount expected to be recognized into earnings during the next 12 months related to the foreign exchange component of our cross currency swap is dependent on fluctuations in currency exchange rates. As of September 30, 2019, the fair values of the cross currency swap were a $6.7 million asset. The swap contract expires on July 20, 2022.

HEDGE OF NET INVESTMENTS IN FOREIGN OPERATIONS

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our foreign subsidiaries. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we maintain debt in these subsidiaries to offset the net asset exposure. We do not otherwise actively manage this risk using derivative financial instruments. In the event we plan on a full or partial liquidation of any of our foreign subsidiaries where our net investment is likely to be monetized, we will consider hedging the currency exposure associated with such a transaction.

OTHER

As of September 30, 2019, we have recorded the fair value of foreign currency forward exchange contracts of $38 thousand in prepaid and other and $0.6 million in accounts payable and accrued liabilities on the balance sheet. All forward exchange contracts outstanding as of September 30, 2019 had an aggregate notional contract amount of $43.9 million.

18

Table of Contents

​

​

Fair Value of Derivative Instruments in the Condensed Consolidated Balance Sheets as of September 30, 2019 and December 31, 2018

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | ​ |  | September 30, 2019 |  | December 31, 2018 |
​ | ​ | ​ | ​ | ​ | ​ | Derivatives | ​ | ​ | ​ | Derivatives | ​
​ | ​ | ​ | ​ | Derivatives | ​ | not | ​ | Derivatives | ​ | not | ​
​ | ​ | ​ | ​ | Designated | ​ | Designated | ​ | Designated | ​ | Designated | ​
​ | ​ | Balance Sheet | ​ | as Hedging | ​ | as Hedging | ​ | as Hedging | ​ | as Hedging | ​
​ | ​ | Location | ​ | Instruments | ​ | Instruments | ​ | Instruments | ​ | Instruments |
Derivative Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
Foreign Exchange Contracts |  | Prepaid and other | ​ | $ | — | ​ | $ | 38 | ​ | $ | — | ​ | $ | 259 | ​
Cross Currency Swap Contract (1) |  | Prepaid and other | ​ |  | 6,673 | ​ |  | — | ​ |  | — | ​ |  | — | ​
​ | ​ | ​ | ​ | $ | 6,673 | ​ | $ | 38 | ​ | $ | — | ​ | $ | 259 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Derivative Liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign Exchange Contracts |  | Accounts payable and accrued liabilities | ​ | $ | — | ​ | $ | 597 | ​ | $ | — | ​ | $ | 331 | ​
Cross Currency Swap Contract (1) |  | Accounts payable and accrued liabilities | ​ |  | — | ​ |  | — | ​ |  | 1,040 | ​ |  | — | ​
​ | ​ | ​ | ​ | $ | — | ​ | $ | 597 | ​ | $ | 1,040 | ​ | $ | 331 | ​

(1) | This cross currency swap contract is composed of both an interest component and a foreign exchange component.

​

​

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Quarters Ended September 30, 2019 and 2018

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | Amount of Gain (Loss) | ​ | Total Amount | ​
​ | ​ | Amount of Gain (Loss) | ​ | Location of (Loss) | ​ | Reclassified from | ​ | of Affected | ​
Derivatives in Cash | ​ | Recognized in | ​ | Gain Recognized | ​ | Accumulated | ​ | Income | ​
Flow Hedging | ​ | Other Comprehensive | ​ | in Income on | ​ | Other Comprehensive | ​ | Statement | ​
Relationships | ​ | Income on Derivative | ​ | Derivatives | ​ | Income on Derivative | ​ | Line Item | ​
​ | ​ | 2019 | ​ | 2018 | ​ | ​ | ​ | 2019 | ​ | 2018 | ​ | ​ |
Cross currency swap contract: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest component |  | $ | 1,586 | ​ | $ | (68) | ​ | Interest expense | ​ | $ | 1,309 | ​ | $ | 1,337 | ​ | $ | (8,898) | ​
Foreign exchange component |  | ​ | 6,491 | ​ | ​ | 2,131 | ​ | Miscellaneous, net | ​ | ​ | 6,491 | ​ | ​ | 2,131 | ​ | ​ | (269) | ​
​ | ​ | $ | 8,077 | ​ | $ | 2,063 | ​ | ​ | ​ | $ | 7,800 | ​ | $ | 3,468 | ​ | ​ | ​ | ​

​

​

The Effect of Cash Flow Hedge Accounting on Accumulated Other Comprehensive Income (Loss) for the Nine Months Ended September 30, 2019 and 2018

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | Amount of Gain (Loss) | ​ | Total Amount | ​
​ | ​ | Amount of Gain (Loss) | ​ | Location of (Loss) | ​ | Reclassified from | ​ | of Affected | ​
Derivatives in Cash | ​ | Recognized in | ​ | Gain Recognized | ​ | Accumulated | ​ | Income | ​
Flow Hedging | ​ | Other Comprehensive | ​ | in Income on | ​ | Other Comprehensive | ​ | Statement | ​
Relationships | ​ | Income on Derivative | ​ | Derivatives | ​ | Income on Derivative | ​ | Line Item | ​
​ | ​ | 2019 | ​ | 2018 | ​ | ​ | ​ | 2019 | ​ | 2018 | ​ | ​ |
Cross currency swap contract: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Interest component |  | $ | 4,058 | ​ | $ | 5,084 | ​ | Interest expense | ​ | $ | 4,315 | ​ | $ | 3,824 | ​ | $ | (26,868) | ​
Foreign exchange component |  | ​ | 8,084 | ​ | ​ | 9,984 | ​ | Miscellaneous, net | ​ | ​ | 8,084 | ​ | ​ | 9,984 | ​ | ​ | 148 | ​
​ | ​ | $ | 12,142 | ​ | $ | 15,068 | ​ | ​ | ​ | $ | 12,399 | ​ | $ | 13,808 | ​ | ​ | ​ | ​

19

Table of Contents

​

​

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Quarters Ended September 30, 2019 and 2018

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Amount of (Loss) Gain | ​
Derivatives Not Designated | ​ | Location of (Loss) Gain Recognized | ​ | Recognized in Income | ​
as Hedging Instruments | ​ | in Income on Derivatives | ​ | on Derivatives | ​
​ | ​ | ​ | ​ | 2019 | ​ | 2018 |
Foreign Exchange Contracts |  | Other (Expense) Income: Miscellaneous, net | ​ | $ | (15) | ​ | $ | (1,011) | ​
​ | ​ | ​ | ​ | $ | (15) | ​ | $ | (1,011) | ​

​

​

The Effect of Derivatives Not Designated as Hedging Instruments on the Condensed Consolidated Statements of Income for the Nine Months Ended September 30, 2019 and 2018

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | Amount of (Loss) Gain | ​
Derivatives Not Designated | ​ | Location of (Loss) Gain Recognized | ​ | Recognized in Income | ​
as Hedging Instruments | ​ | in Income on Derivatives | ​ | on Derivatives | ​
​ | ​ | ​ | ​ | 2019 | ​ | 2018 |
Foreign Exchange Contracts |  | Other (Expense) Income: Miscellaneous, net | ​ | $ | (529) | ​ | $ | 102 | ​
​ | ​ | ​ | ​ | $ | (529) | ​ | $ | 102 | ​

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Gross Amounts not Offset | ​ | ​ | ​ |
​ | ​ | ​ | ​ | ​ | Gross Amounts | ​ | Net Amounts | ​ | in the Statement of | ​ | ​ | ​ |
​ | ​ | ​ | ​ | ​ | Offset in the | ​ | Presented in | ​ | Financial Position | ​ | ​ | ​ |
​ |  | Gross | ​ | Statement of | ​ | the Statement of | ​ | Financial | ​ | Cash Collateral | ​ | Net |
​ | ​ | Amount | ​ | Financial Position | ​ | Financial Position | ​ | Instruments | ​ | Received | ​ | Amount |
Description | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
September 30, 2019 | ​
Derivative Assets | ​ | $ | 6,711 |  | — | ​ | $ | 6,711 |  | — |  | — | ​ | $ | 6,711 | ​
Total Assets | ​ | $ | 6,711 |  | — | ​ | $ | 6,711 |  | — |  | — | ​ | $ | 6,711 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Derivative Liabilities | ​ | $ | 597 |  | — | ​ | $ | 597 |  | — |  | — | ​ | $ | 597 | ​
Total Liabilities | ​ | $ | 597 |  | — | ​ | $ | 597 |  | — |  | — | ​ | $ | 597 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
December 31, 2018 | ​
Derivative Assets | ​ | $ | 259 |  | — | ​ | $ | 259 |  | — |  | — | ​ | $ | 259 | ​
Total Assets | ​ | $ | 259 |  | — | ​ | $ | 259 |  | — |  | — | ​ | $ | 259 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Derivative Liabilities | ​ | $ | 1,371 |  | — | ​ | $ | 1,371 |  | — |  | — | ​ | $ | 1,371 | ​
Total Liabilities | ​ | $ | 1,371 |  | — | ​ | $ | 1,371 |  | — |  | — | ​ | $ | 1,371 | ​

​

​

​

​

​

​

​

NOTE 11 – FAIR VALUE

Authoritative guidelines require the categorization of assets and liabilities into three levels based upon the assumptions (inputs) used to price the assets or liabilities. Level 1 provides the most reliable measure of fair value, whereas Level 3 generally requires significant management judgment. The three levels are defined as follows:

| ● | Level 1: Unadjusted quoted prices in active markets for identical assets and liabilities.

| ● | Level 2: Observable inputs other than those included in Level 1. For example, quoted prices for similar assets or liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets.

| ● | Level 3: Unobservable inputs reflecting management’s own assumptions about the inputs used in pricing the asset or liability.

20

Table of Contents

As of September 30, 2019, the fair values of our financial assets and liabilities were categorized as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Total |  | Level 1 |  | Level 2 |  | Level 3 |
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign exchange contracts (1) | ​ | $ | 38 | ​ | $ | — | ​ | $ | 38 | ​ | $ | — | ​
Cross currency swap contract (1) | ​ | ​ | 6,673 | ​ | ​ | — | ​ | ​ | 6,673 | ​ | ​ | — | ​
Total assets at fair value | ​ | $ | 6,711 | ​ | $ | — | ​ | $ | 6,711 | ​ | $ | — | ​
Liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign exchange contracts (1) | ​ | $ | 597 | ​ | $ | — | ​ | $ | 597 | ​ | $ | — | ​
Contingent consideration obligation | ​ | ​ | 3,000 | ​ | ​ | — | ​ | ​ | — | ​ | ​ | 3,000 | ​
Total liabilities at fair value | ​ | $ | 3,597 | ​ | $ | — | ​ | $ | 597 | ​ | $ | 3,000 | ​

​

As of December 31, 2018, the fair values of our financial assets and liabilities were categorized as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Total | ​ | Level 1 | ​ | Level 2 | ​ | Level 3 |
Assets | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign exchange contracts (1) | ​ | $ | 259 | ​ | $ | — | ​ | $ | 259 | ​ | $ | — | ​
Total assets at fair value | ​ | $ | 259 | ​ | $ | — | ​ | $ | 259 | ​ | $ | — | ​
Liabilities | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Foreign exchange contracts (1) | ​ | $ | 331 | ​ | $ | — | ​ | $ | 331 | ​ | $ | — | ​
Cross currency swap contract (1) | ​ | ​ | 1,040 | ​ | ​ | — | ​ | ​ | 1,040 | ​ | ​ | — | ​
Total liabilities at fair value | ​ | $ | 1,371 | ​ | $ | — | ​ | $ | 1,371 | ​ | $ | — | ​

(1) | Market approach valuation technique based on observable market transactions of spot and forward rates.

​

​

The carrying amounts of our other current financial instruments such as cash and equivalents, accounts and notes receivable, notes payable and current maturities of long-term obligations approximate fair value due to the short-term maturity of the instruments. We consider our long-term obligations a Level 2 liability and utilize the market approach valuation technique based on interest rates that are currently available to us for issuance of debt with similar terms and maturities. The estimated fair value of our long-term obligations was $1.1 billion as of September 30, 2019 and December 31, 2018. As discussed in Note 18 – Acquisitions, we have a contingent consideration obligation to the selling equityholder of Gateway Analytical LLC (“Gateway”) in connection with the Gateway Acquisition (as defined herein) based on 2020 and 2022 performance targets defined in the purchase agreement. We consider this a Level 3 liability and on a quarterly basis we assess the projected results for the acquired business in comparison to the earnout targets and adjust the liability accordingly.

​

NOTE 12 - COMMITMENTS AND CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. While management believes the resolution of these claims and lawsuits will not have a material adverse effect on our financial position, results of operations or cash flows, claims and legal proceedings are subject to inherent uncertainties, and unfavorable outcomes could occur and could include amounts in excess of any accruals which management has established. Were such unfavorable final outcomes to occur, it is possible that they could have a material adverse effect on our financial position, results of operations and cash flows.

Under our Certificate of Incorporation, we have agreed to indemnify our officers and directors for certain events or occurrences while the officer or director is, or was, serving at our request in such capacity. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited; however, we have a directors and officers liability insurance policy that covers a portion of our exposure. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal. We have no liabilities recorded for these agreements as of September 30, 2019 and December 31, 2018.

An environmental investigation, undertaken to assess areas of possible contamination, was completed at our facility in Jundiaí, São Paulo, Brazil. The facility is primarily an internal supplier of anodized aluminum components for certain of our dispensing systems. The testing indicated that soil and groundwater in certain areas of the facility were impacted above acceptable levels established by local regulations. In March 2017, we reported the findings to the relevant environmental authority, the Environmental Company of the State of São Paulo – CETESB. Based upon our best estimate, we recorded a reserve of $1.5 million (operating expense) in the first quarter of 2017 related to this contingency. For the nine months ended September 30, 2019, we have paid approximately $0.6 million and made adjustments to the accrual based on our future anticipated expenditures. As of September 30, 2019, our outstanding reserve is $0.5 million. The ultimate loss associated with this environmental contingency is subject to the investigation and ongoing review of the CETESB. We will continue to evaluate the range of likely costs as the investigation proceeds and we have further clarity on the nature and extent of remediation that will be required. We note that the contamination, or any failure to complete any required remediation in a timely manner, could potentially result in fines or penalties.

21

Table of Contents

In March 2017, the Supreme Court of Brazil issued a decision that a certain state value added tax should not be included in the calculation of federal gross receipts taxes. The decision reduces our gross receipts tax in Brazil prospectively and, potentially, retrospectively. During the first quarter of 2019, we received a favorable court decision of $2.7 million for the retrospective right to recover part of our claim. This amount is recorded in cost of sales as a favorable impact of $1.7 million and $1.0 million was recognized as interest income. During the fourth quarter of 2018, we recorded an amount of $631 thousand based on the favorable court decision. If the Judicial Court grants full retrospective recovery, we estimate remaining potential recoveries of approximately $10 million, including interest. Due to uncertainties around our remaining court recovery claims, we have not recorded any further amounts relating to the retrospective nature of this matter. However, we anticipate decisions on our remaining claims in 2020.

​

NOTE 13 – STOCK REPURCHASE PROGRAM

On April 18, 2019, we announced a share repurchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

During the three and nine months ended September 30, 2019, we repurchased approximately 300 thousand and 493 thousand shares for approximately $35.8 million and $54.9 million, respectively. During the nine months ended September 30, 2018, we repurchased approximately 668 thousand shares for approximately $61.7 million. We did not repurchase any shares during the quarter ended September 30, 2018. As of September 30, 2019, there was $310.1 million of authorized share repurchases available to us.

​

NOTE 14 – STOCK-BASED COMPENSATION

Historically we have issued stock options and restricted stock units (“RSUs”), which consisted of time-based and performance-based awards, to employees under stock awards plans approved by stockholders. Beginning in 2019, we no longer issue stock options to employees. In addition, RSUs are issued to non-employee directors under a Restricted Stock Unit Award Agreement for Directors pursuant to the Company’s 2018 Equity Incentive Plan. Previously, non-employee directors were issued stock options under a Director Stock Option Plan. Stock options were awarded with the exercise price equal to the market price on the date of grant and generally vest over three years and expire 10 years after grant.

RSUs granted to employees vest according to a specified performance period and/or vesting period. Time-based RSUs generally vest over three years. Performance-based RSUs vest at the end of the specified performance period, generally three years, assuming required performance or market vesting conditions are met. Performance-based RSUs have one of two vesting conditions: (1) based on our internal financial performance metrics and (2) based on our total shareholder return (“TSR”) relative to total shareholder returns of an industrial peer group. At the time of vesting, the vested shares of common stock are issued in the employee’s name. In addition, RSU awards are generally net settled (shares are withheld to cover the employee tax obligation). RSUs granted to directors are only time-based and generally vest over one year.

Compensation expense attributable to employee stock options for the first nine months of 2019 was approximately $4.4 million ($3.6 million after tax). Approximately $3.7 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. Compensation expense attributable to stock options for the first nine months of 2018 was approximately $8.9 million ($6.9 million after tax). Approximately $7.1 million of the compensation expense was recorded in selling, research & development and administrative expenses and the balance was recorded in cost of sales. The reduction in stock option expense is due to our move to RSUs as discussed above.

For stock option grants, we used historical data to estimate expected life and volatility. The weighted-average fair value of stock options granted under the stock awards plans was $14.82 per share during the first nine months of 2018. This value was estimated on the grant date using the Black-Scholes option-pricing model with the following weighted-average assumptions:

​

​

​ | ​ | ​ | ​
Stock Awards Plans: |  | ​ | ​
Nine Months Ended September 30, | ​ | 2018 |
Dividend Yield |  | 1.5 | %
Expected Stock Price Volatility |  | 14.2 | %
Risk-free Interest Rate |  | 2.8 | %
Expected Life of Option (years) |  | 6.6 | ​

​

22

Table of Contents

A summary of option activity under our stock plans during the nine months ended September 30, 2019 is presented below:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Stock Awards Plans | ​ | Director Stock Option Plans |
​ |  | ​ | ​ |  | Weighted Average |  | ​ |  | Weighted Average |
​ | ​ | ​ | Options | ​ | Exercise Price | ​ | Options | ​ | Exercise Price |
Outstanding, January 1, 2019 |  | ​ | 6,761,055 | ​ | $ | 65.76 |  | 155,200 | ​ | $ | 58.13 | ​
Granted |  | ​ | — | ​ |  | — |  | — | ​ |  | — | ​
Exercised |  | ​ | (1,382,639) | ​ |  | 57.24 |  | (14,200) | ​ |  | 62.33 | ​
Forfeited or expired |  | ​ | (131,067) | ​ |  | 71.67 |  | — | ​ |  | — | ​
Outstanding at September 30, 2019 |  | ​ | 5,247,349 | ​ | $ | 67.96 |  | 141,000 | ​ | $ | 57.71 | ​
Exercisable at September 30, 2019 |  | ​ | 4,464,502 | ​ | $ | 65.61 |  | 141,000 | ​ | $ | 57.71 | ​
Weighted-Average Remaining Contractual Term (Years): | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding at September 30, 2019 |  | ​ | 5.6 | ​ | ​ | ​ | ​ | 3.3 | ​ |  | ​ | ​
Exercisable at September 30, 2019 |  | ​ | 5.1 | ​ | ​ | ​ | ​ | 3.3 | ​ |  | ​ | ​
Aggregate Intrinsic Value: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Outstanding at September 30, 2019 | ​ | $ | 263,304 | ​ | ​ | ​ | $ | 8,508 | ​ | ​ | ​ | ​
Exercisable at September 30, 2019 | ​ | $ | 234,118 | ​ | ​ | ​ | $ | 8,508 | ​ | ​ | ​ | ​
Intrinsic Value of Options Exercised During the Nine Months Ended: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
September 30, 2019 | ​ | $ | 76,797 | ​ | ​ | ​ | $ | 722 | ​ | ​ | ​ | ​
September 30, 2018 | ​ | $ | 62,895 | ​ | ​ | ​ | $ | 2,187 | ​ | ​ | ​ | ​

​

The grant date fair value of options vested during the nine months ended September 30, 2019 and 2018 was $12.2 million and $16.5 million, respectively. Cash received from option exercises was approximately $81.8 million and the actual tax benefit realized for the tax deduction from option exercises was approximately $17.2 million in the nine months ended September 30, 2019. As of September 30, 2019, the remaining valuation of stock option awards to be expensed in future periods was $3.8 million and the related weighted-average period over which it is expected to be recognized is 1.0 year.

The fair value of both time-based RSUs and performance-based RSUs pertaining to internal performance metrics is determined using the closing price of our common stock on the grant date. The fair value of performance-based RSUs pertaining to TSR is estimated using a Monte Carlo simulation. Inputs and assumptions used to calculate the fair value are shown in the table below. The fair value of these RSUs is expensed over the vesting period using the straight-line method or using the graded vesting method when an employee becomes eligible to retain the award at retirement.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, | ​ | ​ | 2019 | ​ | ​ | ​ | 2018 | ​ |
Fair value per stock award | ​ | $ | 134.97 | ​ | ​ | $ | 128.70 | ​ | ​
Grant date stock price | ​ | $ | 104.51 | ​ | ​ | $ | 89.42 | ​ | ​
Assumptions: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Aptar's stock price expected volatility | ​ | ​ | 16.50 | % | ​ | ​ | 12.30 | % | ​
Expected average volatility of peer companies | ​ | ​ | 31.90 | % | ​ | ​ | 27.50 | % | ​
Correlation assumption | ​ | ​ | 37.40 | % | ​ | ​ | 20.20 | % | ​
Risk-free interest rate | ​ | ​ | 2.19 | % | ​ | ​ | 2.42 | % | ​
Dividend yield assumption | ​ | ​ | 1.30 | % | ​ | ​ | 1.43 | % | ​

​

A summary of RSU activity as of September 30, 2019 and changes during the nine month period then ended is presented below:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Time-Based RSUs | ​ | Performance-Based RSUs |
​ |  |  |  | Weighted Average |  | ​ |  | Weighted Average | ​
​ | ​ | Units | ​ | Grant-Date Fair Value | ​ | Units | ​ | Grant-Date Fair Value | ​
Nonvested at January 1, 2019 | ​ | 261,487 | ​ | $ | 91.78 | ​ | 69,990 | ​ | $ | 111.55 | ​
Granted | ​ | 173,333 | ​ |  | 92.63 | ​ | 123,246 | ​ |  | 119.35 | ​
Vested | ​ | (46,912) | ​ | ​ | 87.38 | ​ | — | ​ | ​ | — | ​
Forfeited | ​ | (22,613) | ​ |  | 98.82 | ​ | (9,237) | ​ |  | 117.45 | ​
Nonvested at September 30, 2019 | ​ | 365,295 | ​ | $ | 92.32 | ​ | 183,999 | ​ | $ | 117.34 | ​

​

Included in the September 30, 2019 time-based RSUs are 11,490 units granted to non-employee directors and 14,257 units vested related to non-employee directors.

23

Table of Contents

Compensation expense recorded attributable to RSUs for the first nine months of 2019 and 2018 was approximately $13.7 million and $5.9 million, respectively. The actual tax benefit realized for the tax deduction from RSUs was approximately $719 thousand in the nine months ended September 30, 2019. The fair value of units vested during the nine months ended September 30, 2019 and 2018 was $4.1 million and $2.6 million, respectively. The intrinsic value of units vested during the nine months ended September 30, 2019 and 2018 was $4.9 million and $3.1 million, respectively. As of September 30, 2019, there was $32.3 million of total unrecognized compensation cost relating to RSU awards which is expected to be recognized over a weighted-average period of 2.3 years.

During 2017, we provided a long-term incentive program for certain employees. Each award is based on the cumulative TSR of our common stock during a three-year performance period compared to a peer group. The total expected expense related to this program for awards outstanding as of September 30, 2019 is approximately $3.0 million, of which $789 thousand and $1.0 million was recognized in the first nine months of 2019 and 2018, respectively.

​

​

NOTE 15 – EARNINGS PER SHARE

Basic net income per share is calculated by dividing net income attributable to Aptar by the weighted-average number of common shares outstanding during the period. Diluted net income per share is calculated by dividing the net income attributable to Aptar by the weighted-average number of common and common equivalent shares outstanding during the applicable period. The difference between basic and diluted earnings per share is attributable to stock-based compensation awards. Stock-based compensation awards for which total employee proceeds exceed the average market price over the applicable period would have an antidilutive effect on earnings per share, and accordingly, are excluded from the calculation of diluted earnings per share. The reconciliation of basic and diluted earnings per share for the three and nine months ended September 30, 2019 and 2018 is as follows:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended | ​
​ | ​ | September 30, 2019 | ​ | September 30, 2018 |
​ | ​ | Diluted | ​ | Basic | ​ | Diluted | ​ | Basic | ​
Consolidated operations | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income available to common stockholders | ​ | $ | 56,750 | ​ | $ | 56,750 | ​ | $ | 38,996 | ​ | $ | 38,996 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Average equivalent shares | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Shares of common stock | ​ |  | 64,010 | ​ |  | 64,010 | ​ |  | 62,378 | ​ |  | 62,378 | ​
Effect of dilutive stock-based compensation | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Stock options | ​ |  | 2,367 | ​ |  | — | ​ |  | 2,659 | ​ |  | — | ​
Restricted stock | ​ |  | 325 | ​ |  | — | ​ |  | 92 | ​ |  | — | ​
Total average equivalent shares | ​ |  | 66,702 | ​ | ​ | 64,010 | ​ | ​ | 65,129 | ​ | ​ | 62,378 | ​
Net income per share | ​ | $ | 0.85 | ​ | $ | 0.89 | ​ | $ | 0.60 | ​ | $ | 0.63 | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended | ​
​ | ​ | September 30, 2019 | ​ | September 30, 2018 | ​
​ | ​ | Diluted | ​ | Basic | ​ | Diluted | ​ | Basic |
Consolidated operations | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Income available to common stockholders | ​ | $ | 193,669 | ​ | $ | 193,669 | ​ | $ | 154,071 | ​ | $ | 154,071 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Average equivalent shares | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Shares of common stock | ​ |  | 63,485 | ​ |  | 63,485 | ​ |  | 62,304 | ​ |  | 62,304 | ​
Effect of dilutive stock-based compensation | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Stock options | ​ |  | 2,425 | ​ |  | — | ​ |  | 2,440 | ​ |  | — | ​
Restricted stock | ​ |  | 253 | ​ |  | — | ​ |  | 78 | ​ |  | — | ​
Total average equivalent shares | ​ |  | 66,163 | ​ | ​ | 63,485 | ​ | ​ | 64,822 | ​ | ​ | 62,304 | ​
Net income per share | ​ | $ | 2.93 | ​ | $ | 3.05 | ​ | $ | 2.38 | ​ | $ | 2.47 | ​

​

​

​

NOTE 16 – SEGMENT INFORMATION

We are organized into three reporting segments. Our Beauty + Home segment sells to the personal care, beauty and home care markets. Our Pharma segment serves customers in the prescription drug, consumer health care, injectables and active packaging markets. Our Food + Beverage segment sells to the food and beverage markets.

24

Table of Contents

The accounting policies of the segments are the same as those described in Part II, Item 8, Note 1 - Summary of Significant Accounting Policies in our Annual Report on Form 10-K for the year ended December 31, 2018. We evaluate performance of our business units and allocate resources based upon Adjusted EBITDA. Adjusted EBITDA is defined as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. All internal segment reporting and discussions of results with our Chief Operating Decision Maker (CODM) are based on segment Adjusted EBITDA.

Financial information regarding our reporting segments is shown below:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 | ​ | 2018 | ​ | 2019 | ​ | 2018 | ​
Total Sales: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beauty + Home | ​ | $ | 333,870 | ​ | $ | 346,040 | ​ | $ | 1,056,626 | ​ | $ | 1,103,664 | ​
Pharma | ​ |  | 271,608 | ​ |  | 227,691 | ​ |  | 830,679 | ​ |  | 699,105 | ​
Food + Beverage | ​ |  | 104,458 | ​ |  | 97,297 | ​ |  | 328,280 | ​ |  | 294,362 | ​
Total Sales | ​ | ​ | 709,936 | ​ | ​ | 671,028 | ​ | $ | 2,215,585 | ​ | $ | 2,097,131 | ​
Less: Intersegment Sales: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beauty + Home | ​ | $ | 5,688 | ​ | $ | 4,280 | ​ | $ | 18,705 | ​ | $ | 15,195 | ​
Pharma | ​ |  | 2,357 | ​ |  | 176 | ​ |  | 6,788 | ​ |  | 254 | ​
Food + Beverage | ​ |  | 613 | ​ |  | 797 | ​ |  | 1,693 | ​ |  | 1,949 | ​
Total Intersegment Sales | ​ | $ | 8,658 | ​ | $ | 5,253 | ​ | $ | 27,186 | ​ | $ | 17,398 | ​
Net Sales: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beauty + Home | ​ | $ | 328,182 | ​ | $ | 341,760 | ​ | $ | 1,037,921 | ​ | $ | 1,088,469 | ​
Pharma | ​ |  | 269,251 | ​ |  | 227,515 | ​ |  | 823,891 | ​ |  | 698,851 | ​
Food + Beverage | ​ |  | 103,845 | ​ |  | 96,500 | ​ |  | 326,587 | ​ |  | 292,413 | ​
Net Sales | ​ | $ | 701,278 | ​ | $ | 665,775 | ​ | $ | 2,188,399 | ​ | $ | 2,079,733 | ​
Adjusted EBITDA: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beauty + Home | ​ | $ | 41,475 | ​ | $ | 42,174 | ​ | $ | 143,411 | ​ | $ | 141,155 | ​
Pharma | ​ |  | 96,546 | ​ |  | 84,516 | ​ |  | 295,553 | ​ |  | 250,709 | ​
Food + Beverage | ​ |  | 18,728 | ​ |  | 15,482 | ​ |  | 56,363 | ​ |  | 46,284 | ​
Corporate & Other, unallocated | ​ |  | (9,943) | ​ |  | (7,954) | ​ |  | (33,328) | ​ |  | (28,576) | ​
Acquisition-related costs (1) | ​ | ​ | (1,355) | ​ | ​ | (10,369) | ​ | ​ | (2,636) | ​ | ​ | (12,932) | ​
Restructuring Initiatives (2) | ​ | ​ | (6,019) | ​ | ​ | (23,852) | ​ | ​ | (17,286) | ​ | ​ | (48,002) | ​
Depreciation and amortization | ​ | ​ | (49,218) | ​ | ​ | (41,857) | ​ | ​ | (144,574) | ​ | ​ | (123,133) | ​
Interest Expense | ​ | ​ | (8,898) | ​ | ​ | (8,735) | ​ | ​ | (26,868) | ​ | ​ | (24,754) | ​
Interest Income | ​ |  | 957 | ​ |  | 1,537 | ​ |  | 3,738 | ​ |  | 6,306 | ​
Income before Income Taxes | ​ | $ | 82,273 | ​ | $ | 50,942 | ​ | $ | 274,373 | ​ | $ | 207,057 | ​

(1) | Acquisition-related costs include transaction costs and purchase accounting adjustments related to inventory and backlog for acquisitions (see Note 18 – Acquisitions for further details).

(2) | Restructuring Initiatives includes expense items for the three and nine months ended September 30, 2019 and 2018 as follows (see Note 19 – Restructuring Initiatives for further details):

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 | ​ | 2018 | ​ | 2019 | ​ | 2018 | ​
Restructuring Initiatives by Segment | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beauty + Home | ​ | $ | 5,341 | ​ | $ | 18,854 | ​ | $ | 14,869 | ​ | $ | 38,501 | ​
Pharma | ​ |  | 168 | ​ |  | 2,008 | ​ |  | 381 | ​ |  | 3,596 | ​
Food + Beverage | ​ |  | 204 | ​ |  | 2,638 | ​ |  | 826 | ​ |  | 4,307 | ​
Corporate & Other | ​ | ​ | 306 | ​ | ​ | 352 | ​ | ​ | 1,210 | ​ | ​ | 1,598 | ​
Total Restructuring Initiatives | ​ | $ | 6,019 | ​ | $ | 23,852 | ​ | $ | 17,286 | ​ | $ | 48,002 | ​

​

​

​

Note 17 – INSURANCE SETTLEMENT RECEIVABLE

A fire caused damage to our facility in Annecy, France in June 2016. The fire was contained to one of three production units and there were no reported injuries. Aptar Annecy supplies anodized aluminum components for certain Aptar dispensing systems. We are insured for the damages caused by the fire, including business interruption insurance, and we do not expect this incident to have a material impact on our financial results.

25

Table of Contents

Losses related to the fire of $3.2 million and $14.1 million were incurred during the three and nine months ended September 30, 2018, respectively. For the nine months ended September 30, 2019, we received insurance proceeds of $3.4 million, and have no insurance receivable as of September 30, 2019. The final settlement continues to be negotiated. In many cases, our insurance coverage exceeds the amount of our recognized losses. However, no gain contingencies were recognized during the three and nine months ended September 30, 2019 as our ability to realize those gains remains uncertain. During the three and nine months ended September 30, 2019, profitability was not impacted. Profitability was negatively impacted by $1.5 million and $4.4 million during the three and nine months ended September 30, 2018, respectively. These 2018 losses negatively impacted the Beauty + Home and Pharma segments.

​

NOTE 18 – ACQUISITIONS

On August 2, 2019, we completed our asset acquisition (the “Bapco Acquisition”) of the remaining 80% ownership interest in the capital stock of Bapco Closures Holdings Limited (“Bapco”), for $3.8 million (net of $2.9 million of cash acquired). The 20% ownership investment previously held in Bapco is now included within the intangible assets acquired. Bapco, located in Horesell, UK, provides innovative closures sealing technology that provides package integrity and tamper evidence. The results of Bapco’s operations have been included in the Condensed Consolidated Financial Statements within our Food + Beverage segment since the date of acquisition.

During August 2019, we also invested an aggregate amount of $3.5 million in two preferred equity investments that are accounted for at cost less impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for identical or similar investments of the same issuer. There were no indications of impairment nor were there any changes from observable price changes noted in the three months ended September 30, 2019.

On June 5, 2019, we completed our acquisition (the “Nanopharm Acquisition”) of all of the outstanding capital stock of Nanopharm Ltd. (“Nanopharm”). Nanopharm, located in Newport, UK, is a science-driven, leading provider of orally inhaled and nasal drug product design and development services. The purchase price was approximately $38.1 million (net of $1.8 million of cash acquired) and was funded by cash on hand. The results of Nanopharm’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition. We are in the process of finalizing purchase accounting.

On May 31, 2019, we completed our acquisition (the “Gateway Acquisition”) of all of the outstanding equity interests of Gateway Analytical LLC (“Gateway”). Gateway, located in Gibsonia, PA, provides industry-leading particulate detection and predictive analytical services to customers developing injectable medicines. The purchase price was approximately $7.0 million and was funded by cash on hand. As part of the Gateway Acquisition, we are also obligated to pay to the selling equityholder of Gateway certain contingent consideration based on 2020 and 2022 performance targets defined in the purchase agreement. Based on projections as of the acquisition date, we estimated the aggregate fair value for this contingent consideration arrangement to be $3.0 million. We are in the process of finalizing purchase accounting. The results of Gateway’s operations have been included in the Condensed Consolidated Financial Statements within our Pharma segment since the date of acquisition.

On August 27, 2018, we completed our acquisition (the “CSP Technologies Acquisition”) of all of the outstanding capital stock of CSP Technologies S.à r.l. (“CSP Technologies”). CSP Technologies is a leader in active packaging technology based on proprietary material science expertise for the pharma and food service markets. CSP Technologies operates two manufacturing locations in the U.S. and one in France. The purchase price was approximately $553.5 million and was funded by cash on hand. At acquisition, we maintained $5.0 million in an escrow account and classified this amount as restricted cash pending the finalization of a working capital adjustment. These funds were released from restriction in January 2019, which resulted in a refund of $964 thousand and a corresponding reduction of our purchase price and the associated goodwill balance in the amount of the refund.

The following table summarizes the assets acquired and liabilities assumed related to the CSP Technologies Acquisition as of the acquisition date at estimated fair value.

26

Table of Contents

​

​ | ​ | ​ | ​ | ​
​ | ​ | August 27, 2018 |
Assets | ​ | ​ | ​ | ​
Cash and equivalents | ​ | $ | 24,053 | ​
Accounts receivable | ​ |  | 20,847 | ​
Inventories | ​ |  | 42,169 | ​
Prepaid and other | ​ |  | 3,995 | ​
Property, plant and equipment | ​ |  | 99,194 | ​
Goodwill | ​ |  | 278,020 | ​
Intangible assets | ​ |  | 177,120 | ​
Other miscellaneous assets | ​ |  | 1,039 | ​
Liabilities | ​ | ​ | ​ | ​
Current maturities of long-term obligations | ​ |  | 129 | ​
Accounts payable and accrued liabilities | ​ |  | 31,989 | ​
Long-term obligations | ​ |  | 6,037 | ​
Deferred income taxes | ​ |  | 38,442 | ​
Retirement and deferred compensation plans | ​ | ​ | 1,038 | ​
Deferred and other non-current liabilities | ​ |  | 15,344 | ​
Net assets acquired | ​ | $ | 553,458 | ​

​

The following table is a summary of the fair value estimates of the acquired identifiable intangible assets and weighted-average useful lives as of the acquisition date related to the CSP Technologies Acquisition:

​

​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Weighted-Average | ​ | Estimated |
​ | ​ | Useful Life | ​ | Fair Value |
​ | ​ | (in years) | ​ | of Asset |
Acquired technology |  | 12 | ​ | $ | 46,700 | ​
Customer relationships |  | 16 | ​ |  | 113,300 | ​
Trademarks and trade names | ​ | 9 | ​ | ​ | 14,600 | ​
License agreements and other |  | 11 | ​ |  | 2,520 | ​
Total | ​ | ​ | ​ | $ | 177,120 | ​

​

Goodwill, net of working capital settlement, in the amount of $277.1 million was recorded for the CSP Technologies Acquisition, of which $173.4 million and $103.7 million is included in the Pharma and Food + Beverage segments, respectively. Goodwill is calculated as the excess of the consideration transferred over the net assets acquired and represents the estimated future economic benefits arising from other assets acquired that could not be individually identified and separately recognized. Goodwill largely consists of leveraging our commercial presence in selling the CSP Technologies line of products in markets where CSP Technologies did not previously operate and the ability of CSP Technologies to maintain its competitive advantage from a technical viewpoint. Goodwill will not be amortized, but will be tested for impairment at least annually. We do not expect any of the goodwill will be deductible for tax purposes.

The unaudited pro forma results presented below include the effects of the CSP Technologies Acquisition as if it had occurred as of January 1, 2017. The unaudited pro forma results reflect certain adjustments related to the acquisition, such as intangible asset amortization, fair value adjustments for inventory and financing costs related to the change in our debt structure. The pro forma results do not include any synergies or other expected benefits of the acquisition. Accordingly, the unaudited pro forma financial information below is not necessarily indicative of either future results of operations or results that might have been achieved had the acquisition been completed on the date indicated.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | Three Months Ended | ​ | ​ | Nine Months Ended | ​
​ | ​ | ​ | September 30, 2018 | ​ | ​ | September 30, 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales | ​ | $ | 687,201 | ​ | $ | 2,172,737 | ​
Net Income Attributable to AptarGroup Inc. | ​ |  | 48,034 | ​ |  | 158,527 | ​
Net Income per common share — basic | ​ |  | 0.77 | ​ |  | 2.54 | ​
Net Income per common share — diluted | ​ |  | 0.74 | ​ |  | 2.45 | ​

​

27

Table of Contents

On May 1, 2018, we acquired 100% of the common stock of Reboul SAS (“Reboul”), a French manufacturer specializing in stamping, decorating and assembling metal and plastic packaging for the cosmetics and luxury markets, for a purchase price of approximately $3.6 million (net of $112 thousand of cash acquired). The results of Reboul’s operations have been included in the Condensed Consolidated Financial Statements within our Beauty + Home segment since the date of acquisition.

In May 2018, we invested $10.0 million in preferred equity stock of Reciprocal Labs Corporation, doing business as Propeller Health (“Reciprocal Labs”), which was accounted for at cost. No impairment charges were recorded during 2018 or 2019 against this investment. During the fourth quarter of 2018, we recorded a gain of approximately $6.5 million by adjusting the carrying amount to its expected proceeds as this investment was ultimately sold during January 2019.

​

NOTE 19 – RESTRUCTURING INITIATIVES

In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. For the three and nine months ended September 30, 2019, we recognized $6.0 million and $17.3 million of restructuring costs related to this plan, respectively. For the three and nine months ended September 30, 2018, we recognized $23.9 million and $48.0 million of restructuring costs related to this plan, respectively. Using current exchange rates, we estimate total implementation costs of approximately $90 million over three years, including costs that have been recognized to date. The cumulative expense incurred as of September 30, 2019 was $83.3 million. We also anticipate making capital investments related to the transformation plan of approximately $50 million, of which $32 million has been incurred to date.

As of September 30, 2019 we have recorded the following activity associated with the business transformation:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Beginning | ​ | Net Charges for | ​ | ​ | ​ | ​ | ​ | ​ | ​ | Ending |
​ | ​ | Reserve at | ​ | the Nine Months | ​ | ​ | ​ | ​ | Interest and | ​ | Reserve at |
​ | ​ | 12/31/2018 | ​ | Ended 9/30/2019 | ​ | Cash Paid | ​ | FX Impact | ​ | 9/30/2019 |
Employee severance | ​ | $ | 3,934 | ​ | $ | 7,566 | ​ | $ | (4,023) | ​ | $ | (258) | ​ | $ | 7,219 | ​
Professional fees and other costs | ​ |  | 11,101 | ​ |  | 9,720 | ​ |  | (18,958) | ​ |  | (71) | ​ |  | 1,792 | ​
Totals | ​ | $ | 15,035 | ​ | $ | 17,286 | ​ | $ | (22,981) | ​ | $ | (329) | ​ | $ | 9,011 | ​

​

​

​

NOTE 20 – SUBSEQUENT EVENTS

Subsequent to the quarter end, on October 1, 2019 we entered into a strategic definitive agreement to acquire 49% of the equity interests in three related companies: Suzhou Hsing Kwang, Suqian Hsing Kwang and Suzhou BTY, (collectively referred to as “BTY”), contingent on settlement date of the transaction. We have a call option to acquire an additional 26% to 31% of BTY’s equity interests following the initial lock-up period of 5 years based on a predetermined formula. Subsequent to the second lock-up period, which ends 3 years subsequent to the initial lock-up period, we have a call option to acquire the remaining equity interests of BTY based on a predetermined formula. Additionally, the selling shareholders of BTY have a put option for the remaining equity interest to be acquired by Aptar based on a predetermined formula. The BTY entities are leading Chinese manufacturers of high quality, decorative metal components, metal-plastic sub-assemblies, and complete color cosmetics packaging solutions for the beauty industry. The transaction, which is expected to close by the end of 2019 or early 2020, is subject to customary regulatory approvals and other customary closing conditions and the purchase will be funded with available cash on hand and/or borrowings under our revolving credit facilities.

Subsequent to the quarter end, on October 31, 2019 we acquired 100% of the equity interests of Noble International Inc., Genia Medical, Inc. and JBCB Holdings, LLC (collectively referred to as “Noble”), for approximately $62 million. Noble, based in Orlando, FL, is a leading provider in developing patient-centric advanced drug delivery system training devices including autoinjector, prefilled syringe, onbody and respiratory devices for the world’s leading biopharmaceutical companies and original equipment manufacturers. The purchase agreement also provides an earn-out provision providing for the payment of up to $31.3 million based on Noble’s financial performance during a 5 year measurement period.

​

​

​

​

28

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE AMOUNTS, OR AS OTHERWISE INDICATED)

​

RESULTS OF OPERATIONS

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ |  | Nine Months Ended September 30, | ​ | ​
​ | ​ | 2019 | ​ | 2018 | ​ | ​ | 2019 | ​ | ​ | 2018 | ​ | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net sales |  | ​ | 100.0 | % | ​ | 100.0 | % | ​ | 100.0 | % | ​ | 100.0 | % | ​
Cost of sales (exclusive of depreciation and amortization shown below) | ​ | ​ | 63.3 | ​ | ​ | 65.4 | ​ | ​ | 63.2 | ​ | ​ | 65.2 | ​ | ​
Selling, research & development and administrative | ​ | ​ | 15.9 | ​ | ​ | 15.5 | ​ | ​ | 15.8 | ​ | ​ | 15.5 | ​ | ​
Depreciation and amortization | ​ | ​ | 7.0 | ​ | ​ | 6.3 | ​ | ​ | 6.6 | ​ | ​ | 5.9 | ​ | ​
Restructuring initiatives | ​ | ​ | 0.9 | ​ | ​ | 3.6 | ​ | ​ | 0.8 | ​ | ​ | 2.3 | ​ | ​
Operating income | ​ | ​ | 12.9 | ​ | ​ | 9.2 | ​ | ​ | 13.6 | ​ | ​ | 11.1 | ​ | ​
Other expense | ​ | ​ | (1.2) | ​ | ​ | (1.5) | ​ | ​ | (1.1) | ​ | ​ | (1.1) | ​ | ​
Income before income taxes | ​ | ​ | 11.7 | ​ | ​ | 7.7 | ​ | ​ | 12.5 | ​ | ​ | 10.0 | ​ | ​
Net Income | ​ | ​ | 8.1 | ​ | ​ | 5.9 | ​ | ​ | 8.9 | ​ | ​ | 7.4 | ​ | ​
Effective tax rate | ​ | ​ | 31.0 | % | ​ | 23.4 | % | ​ | 29.4 | % | ​ | 25.6 | % | ​
Adjusted EBITDA margin (1) | ​ | ​ | 20.9 | % | ​ | 20.2 | % | ​ | 21.1 | % | ​ | 19.7 | % | ​

(1) | Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 36.

​

NET SALES

We reported net sales of $701.3 million for the quarter ended September 30, 2019, which represents a 5% increase compared to $665.8 million reported during the third quarter of 2018. The average U.S. dollar exchange rate strengthened compared to most major currencies we operate in, resulting in a negative currency translation impact of 3%. The acquisitions of CSP Technologies, Gateway and Nanopharm positively impacted sales by 4%. Therefore, core sales, which exclude acquisitions and changes in foreign currency rates, increased by 4% in the third quarter of 2019 compared to the third quarter of 2018. The consolidated core sales growth was primarily driven by strong demand for our drug delivery devices and components for injectable medicines produced by our Pharma segment. Our Food + Beverage segment also realized moderate core sales growth despite the negative effects of our pass-through of lower resin costs to our customers. Our Beauty + Home segment experienced volume declines in certain markets that resulted in a slight decrease in core sales. On a consolidated basis, an increase in tooling sales of $4.1 million in the Pharma segment was offset by the negative effect of $3.1 million related to the pass-through of lower resin prices to our customers.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Third Quarter 2019 | ​ | Beauty | ​ | ​ | ​ | Food + | ​ | ​ | ​
Net Sales Change over Prior Year |  | + Home |  | Pharma |  | Beverage |  | Total | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | (1) | % | 13 | % | 2 | % | 4 | %
Acquisitions | ​ | — | % | 9 | % | 8 | % | 4 | %
Currency Effects (1) | ​ | (3) | % | (4) | % | (2) | % | (3) | %
Total Reported Net Sales Growth | ​ | (4) | % | 18 | % | 8 | % | 5 | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

For the first nine months of 2019, we reported net sales of $2.2 billion, 5% above the first nine months of 2018 reported net sales of $2.1 billion. The average U.S. dollar exchange rate strengthened compared to all major currencies we operate in, resulting in a negative currency translation impact of 5%. The acquisitions of CSP Technologies, Reboul, Gateway and Nanopharm positively impacted sales by 5%. Core sales for the first nine months of 2019 increased 5% compared to the first nine months of 2018 as our Pharma and Food + Beverage segments reported strong growth over the first nine months of 2018. Core sales were negatively impacted by lower tooling sales of $6.8 million for the first nine months of 2019 compared to the same period in the prior year, primarily in our Beauty + Home segment.

29

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, 2019 | ​ | Beauty | ​ | ​ | ​ | Food + | ​ | ​ | ​
Net Sales Change over Prior Year |  | + Home |  | Pharma |  | Beverage |  | Total |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | — | % | 12 | % | 5 | % | 5 | %
Acquisitions | ​ | — | % | 12 | % | 10 | % | 5 | %
Currency Effects (1) | ​ | (5) | % | (6) | % | (3) | % | (5) | %
Total Reported Net Sales Growth | ​ | (5) | % | 18 | % | 12 | % | 5 | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

The following table sets forth, for the periods indicated, net sales by geographic location:

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 | ​ | % of Total | ​ | 2018 | ​ | % of Total | ​ | 2019 | ​ | % of Total | ​ | 2018 | ​ | % of Total | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Domestic | ​ | $ | 211,497 | ​ | 30% | ​ | $ | 181,349 | ​ | 27% | ​ | $ | 640,543 | ​ | 29% | ​ | $ | 528,210 | ​ | 25% |
Europe | ​ | ​ | 391,512 | ​ | 56% | ​ | ​ | 381,472 | ​ | 57% | ​ | ​ | 1,248,411 | ​ | 57% | ​ | ​ | 1,232,943 | ​ | 59% | ​
Latin America | ​ | ​ | 54,685 | ​ | 8% | ​ | ​ | 58,294 | ​ | 9% | ​ | ​ | 170,605 | ​ | 8% | ​ | ​ | 182,810 | ​ | 9% | ​
Asia | ​ | ​ | 43,584 | ​ | 6% | ​ | ​ | 44,660 | ​ | 7% | ​ | ​ | 128,840 | ​ | 6% | ​ | ​ | 135,770 | ​ | 7% | ​

​

For further discussion on net sales by reporting segment, please refer to the analysis of segment net sales and segment Adjusted EBITDA on the following pages.

COST OF SALES (EXCLUSIVE OF DEPRECIATION AND AMORTIZATION SHOWN BELOW)

Cost of sales (“COS”) as a percent of net sales decreased to 63.3% in the third quarter of 2019 compared to 65.4% in the third quarter of 2018. Our COS percentage was positively impacted by our mix of business and lower material costs. The mix of business positively impacted results as the sales growth of our higher margin Pharma products was greater than the sales growth of products in the other two segments. We also realized lower raw material input costs in the quarter and the associated positive impact from the timing of passing through resin cost reductions to our customers.

Cost of sales as a percent of net sales decreased to 63.2% in the first nine months of 2019 compared to 65.2% in the same period a year ago. As mentioned above, our COS was favorably impacted by the mix of Pharma business and the timing of resin pass-throughs to our customers. We also recognized lower custom tooling sales in the first nine months of 2019 compared to the prior year period. Sales of custom tooling typically generates lower margins than product sales, so lower tooling sales positively impacts cost of sales as a percentage of sales.

SELLING, RESEARCH & DEVELOPMENT AND ADMINISTRATIVE

Selling, research & development and administrative expenses (“SG&A”) increased by approximately $8.0 million to $111.6 million in the third quarter of 2019 compared to $103.6 million during the same period in 2018. Excluding changes in foreign currency rates, SG&A increased by approximately $10.6 million in the quarter. The increase is mainly due to $5.0 million of incremental operational costs during the third quarter of 2019 related to our acquired companies. We also recognized increases in professional fees and higher personnel costs in accordance with our growth strategy. SG&A as a percentage of net sales increased to 15.9% compared to 15.5% in the same period of the prior year due to the cost increases mentioned above.

SG&A increased by $23.4 million to $346.5 million in the first nine months of 2019 compared to $323.1 million during the same period a year ago. Excluding changes in foreign currency rates, SG&A increased by approximately $37.2 million in the first nine months of 2019 compared to the first nine months of 2018. As discussed above, the increase is related to $18.0 million of incremental costs from our acquired companies along with higher professional fees and personnel costs to implement our growth strategy. SG&A as a percentage of net sales increased to 15.8% compared to 15.5% in the same period of the prior year.

DEPRECIATION AND AMORTIZATION

Reported depreciation and amortization expenses increased by approximately $7.3 million to $49.2 million in the third quarter of 2019 compared to $41.9 million during the same period a year ago. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $8.5 million in the quarter compared to the same period a year ago. This increase is mainly due to $5.1 million of incremental costs related to our acquisitions. We also increased our capital spending during the current and prior year to support our growth strategy. Depreciation and amortization as a percentage of net sales increased to 7.0% in the third quarter of 2019 compared to 6.3% in the same period of the prior year primarily due to the incremental increase in expenses noted above.

30

Table of Contents

For the first nine months of 2019, reported depreciation and amortization expenses increased by approximately $21.4 million compared to the first nine months of 2018. Excluding changes in foreign currency rates, depreciation and amortization increased by approximately $26.9 million compared to the same period a year ago. As discussed above, this increase is mainly due to $17.9 million of incremental costs from our acquisitions and increased capital spending in the prior and current year to support the growth in our business. Depreciation and amortization as a percentage of net sales increased to 6.6% in the first nine months of 2019 compared to 5.9% in the same period of the prior year.

RESTRUCTURING INITIATIVES

In late 2017, we began a business transformation to drive profitable sales growth, increase operational excellence, enhance our approach to innovation and improve organizational effectiveness. The primary focus of the plan is the Beauty + Home segment; however, certain global general and administrative functions are also being addressed. Restructuring costs related to this plan for the three and nine months ended September 30, 2019 and 2018 are as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 |  | 2018 |  | 2019 |  | 2018 | ​
Restructuring Initiatives by Segment | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Beauty + Home | ​ | $ | 5,341 | ​ | $ | 18,854 | ​ | $ | 14,869 | ​ | $ | 38,501 | ​
Pharma | ​ |  | 168 | ​ |  | 2,008 | ​ |  | 381 | ​ |  | 3,596 | ​
Food + Beverage | ​ |  | 204 | ​ |  | 2,638 | ​ |  | 826 | ​ |  | 4,307 | ​
Corporate & Other | ​ | ​ | 306 | ​ | ​ | 352 | ​ | ​ | 1,210 | ​ | ​ | 1,598 | ​
Total Restructuring Initiatives | ​ | $ | 6,019 | ​ | $ | 23,852 | ​ | $ | 17,286 | ​ | $ | 48,002 | ​

​

We estimate total implementation costs of approximately $90 million over three years, including costs that have been recognized to date. We expect most of these costs to be incurred by the end of 2019. We also anticipate making capital investments related to the business transformation of approximately $50 million, of which $32 million has been incurred to date. Based on our ongoing restructuring initiatives, we are progressing towards our initial target of $80 million annualized incremental EBITDA by the end of 2020, principally within the Beauty + Home segment. Ongoing changes in customer and vendor negotiations, material indices, macro-economic trends and other factors subsequent to our initial restructuring initiatives may impact the consolidated net benefits from these initiatives.

OPERATING INCOME

Operating income increased approximately $29.1 million in the third quarter of 2019 compared to the same period a year ago. Excluding changes in foreign currency rates, operating income increased by approximately $32.4 million in the quarter compared to the same period a year ago. We incurred lower restructuring costs and realized improved margins related to our acquisitions in the third quarter of 2019 compared to the prior year period. Additionally, this increase is partly due to the shift in product sales to our more profitable Pharma products, thus leading to a lower cost of sales. Operating income as a percentage of net sales increased to 12.9% in the third quarter of 2019 compared to 9.2% for the same period in the prior year due to these improvements.

Operating income increased approximately $67.2 million to $297.2 million in the first nine months of 2019 compared to $230.0 million in the same period of the prior year. Excluding changes in foreign currency rates, operating income increased by approximately $81.8 million in the first nine months of 2019 compared to the same period a year ago. As discussed above, this increase is due to improvements in gross margin due to the change in our sales mix along with incremental margins associated with our acquisitions and lower restructuring costs reported during the first nine months of 2019. Operating income as a percentage of net sales increased to 13.6% in the first nine months of 2019 compared to 11.1% for the same period in the prior year.

NET OTHER EXPENSE

Net other expense in the third quarter of 2019 decreased $2.2 million to $8.0 million from $10.2 million in the same period of the prior year. For 2019, miscellaneous expenses decreased by approximately $2.7 million as a result of lower volatility in our forward contracts during 2019 compared to 2018.

Net other expenses for the nine months ended September 30, 2019 decreased slightly to $22.8 million from $23.0 million in the same period of the prior year. For 2019, miscellaneous expenses decreased $4.5 million due to lower volatility in our forward contracts, while net interest expense increased by approximately $4.7 million as a result of the CSP Technologies acquisition during the third quarter of 2018.

31

Table of Contents

EFFECTIVE TAX RATE

The effective tax rate for the three months ended September 30, 2019 of 31.0% reflects a $2.1 million charge from the increase in the tax rate in France, which is retroactive to the beginning of 2019, offset by a $2.0 million benefit from the excess tax benefits from employee stock-based compensation. The effective tax rate for the three months ended September 30, 2018 of 23.4% was favorably impacted by net tax benefits of $5.0 million from discrete events. This included a $4.5 million benefit from the excess tax benefits from employee stock-based compensation and a $1.9 million benefit related to U.S. tax reform legislation, offset by other discrete charges.

The effective tax rate for the nine months ended September 30, 2019 of 29.4% was favorably impacted by net tax benefits of $4.3 million from discrete events. This consisted of a favorable impact of $13.6 million from the excess tax benefits from employee stock-based compensation offset by, among other items, a $7.0 million charge recognized to record a valuation allowance to properly reflect the realization of recorded deferred tax assets and the $2.1 million charge from the French tax rate increase. The effective tax rate for the nine months ended September 30, 2018 of 25.6% was favorably impacted by net tax benefits of $15.1 million from discrete items. This included a favorable impact of $10.5 million from the excess tax benefits from employee stock-based compensation and a $5.3 million benefit related to U.S. tax reform legislation.

NET INCOME ATTRIBUTABLE TO APTARGROUP, INC.

We reported net income attributable to AptarGroup of $56.8 million and $193.7 million in the three and nine months ended September 30, 2019, respectively, compared to $39.0 million and $154.1 million for the same periods in the prior year.

BEAUTY + HOME SEGMENT

Operations that sell dispensing systems and sealing solutions to the personal care, beauty and home care markets form the Beauty + Home segment.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 | ​ | 2018 | ​ | 2019 | ​ | 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales | ​ | $ | 328,182 | ​ | $ | 341,760 | ​ | $ | 1,037,921 | ​ | $ | 1,088,469 |
Adjusted EBITDA (1) | ​ | ​ | 41,475 | ​ | ​ | 42,174 | ​ | ​ | 143,411 | ​ | ​ | 141,155 | ​
Adjusted EBITDA margin (1) | ​ | ​ | 12.6% | ​ | ​ | 12.3% | ​ | ​ | 13.8% | ​ | ​ | 13.0% | ​

(1) | Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 36.

Reported sales for the quarter ended September 30, 2019 decreased 4% to $328.2 million compared to $341.8 million in the third quarter of the prior year. Changes in currency rates negatively impacted net sales by 3%. Therefore, core sales decreased 1% in the third quarter of 2019 compared to the same quarter of the prior year. The majority of this decrease is due to reduced demand from the personal care market and a $1.5 million reduction of sales due to the pass-through of lower resin prices to our customers. Core sales to the personal care market decreased 8%. The decrease is mostly related to a general softening of demand across most of our major applications, especially body care and hair care products, as political and economic uncertainties are leading to some customer destocking. Core sales of our products to the beauty market increased 5% on strong growth in skin care and fragrance dispensing systems, primarily driven by the Chinese luxury market and retail travel. Higher sales of our products used on insecticide applications drove the 4% core sales growth in the home care market.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Third Quarter 2019 | ​ | Personal | ​ | ​ | ​ | Home | ​ | ​ | ​
Net Sales Change over Prior Year |  | Care |  | Beauty |  | Care |  | Total | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | (8) | % | 5 | % | 4 | % | (1) | %
Acquisitions | ​ | — | % | — | % | — | % | — | %
Currency Effects (1) | ​ | (2) | % | (3) | % | (2) | % | (3) | %
Total Reported Net Sales Growth | ​ | (10) | % | 2 | % | 2 | % | (4) | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

32

Table of Contents

Reported sales decreased 5% in the first nine months of 2019 to $1.0 billion compared to $1.1 billion in the first nine months of the prior year. Changes in currency rates negatively impacted net sales by 5%. Core sales were flat for the first nine months of 2019 compared to the same period in the prior year. Core sales to the personal care market were down 5% due to general softness in demand noted above and lower product and tooling sales related to large product launch for a specific North America customer during the second quarter of 2018. Consistent with the quarter results, sales were higher across the other two markets as beauty and home care increased by 5% and 4%, respectively, over the prior year period. Strong sales across all applications drove the strong results in the beauty market, while higher product and tooling sales used on air care and insecticide applications drove the improvements in the home care market.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, 2019 | ​ | Personal | ​ | ​ | ​ | Home | ​ | ​ | ​
Net Sales Change over Prior Year |  | Care |  | Beauty |  | Care |  | Total |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | (5) | % | 5 | % | 4 | % | — | %
Acquisitions | ​ | — | % | 1 | % | — | % | — | %
Currency Effects (1) | ​ | (4) | % | (6) | % | (4) | % | (5) | %
Total Reported Net Sales Growth | ​ | (9) | % | — | % | — | % | (5) | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Adjusted EBITDA in the third quarter of 2019 decreased 2% to $41.5 million compared to $42.2 million reported in the same period in the prior year. During the third quarter of 2019, we experienced favorable material cost impacts due to lower raw material input costs and the associated positive impact from the timing delay of passing through resin cost to our customers. We also realized improved profitability on our tooling projects, but this was not enough to overcome the soft demand from our personal care customers.

Adjusted EBITDA in the first nine months of 2019 increased 2% to $143.4 million compared to $141.2 million reported in the same period in the prior year. Targeted price increases and favorable material cost impacts discussed above were able to offset pockets of softening sales and manufacturing headwinds at certain facilities.

PHARMA SEGMENT

Operations that sell drug delivery, sealing and active packaging solutions primarily to the prescription drug, consumer health care, injectables and active packaging markets form the Pharma segment.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 | ​ | 2018 |  | 2019 | ​ | 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales | ​ | $ | 269,251 | ​ | $ | 227,515 | ​ | $ | 823,891 | ​ | $ | 698,851 | ​
Adjusted EBITDA (1) | ​ | ​ | 96,546 | ​ | ​ | 84,516 | ​ | ​ | 295,553 | ​ | ​ | 250,709 | ​
Adjusted EBITDA margin (1) | ​ | ​ | 35.9% | ​ | ​ | 37.1% | ​ | ​ | 35.9% | ​ | ​ | 35.9% | ​

(1) | Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 36.

Net sales for the Pharma segment increased 18% in the third quarter of 2019 to $269.3 million compared to $227.5 million in the third quarter of 2018. Changes in currencies negatively affected net sales by 4% while our acquisitions of CSP Technologies, Gateway and Nanopharm positively impacted sales by 9% in the third quarter of 2019. Therefore, core sales increased by 13% in the third quarter of 2019 compared to the third quarter of 2018. Core sales to the prescription drug market were particularly strong and increased 17% mainly driven by increased demand for our innovative drug delivery systems for allergic rhinitis, central nervous system and asthma. Core sales to the consumer health care market increased 3% as increased demand for our products used on nasal saline and eye care treatments more than compensated for some softness in demand for our cough & cold and nasal decongestant products. Core sales grew 12% to the injectables market from increased demand across a variety of components. Active packaging core sales comparisons are for the one month ended September 30 since our acquisition of CSP Technologies was at the end of August 2018. The increase is mostly due to strong sales of our products used for diabetes related products.

33

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Third Quarter 2019 | ​ | Prescription | ​ | Consumer | ​ | ​ | ​ | Active | ​ | ​ | ​
Net Sales Change over Prior Year |  | Drug |  | Health Care |  | Injectables |  | Packaging | ​ | Total | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | 17 | % | 3 | % | 12 | % | 19 | % | 13 | %
Acquisitions | ​ | 2 | % | — | % | 5 | % | 186 | % | 9 | %
Currency Effects (1) | ​ | (4) | % | (3) | % | (4) | % | (7) | % | (4) | %
Total Reported Net Sales Growth | ​ | 15 | % | — | % | 13 | % | 198 | % | 18 | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Net sales for the first nine months of 2019 increased by 18% to $823.9 million compared to $698.9 million in the first nine months of 2018. Changes in currencies negatively affected net sales by 6% while our acquisitions of CSP Technologies, Nanopharm and Gateway positively impacted sales by 12% in the first nine months of 2019. Therefore, core sales increased 12% in the first nine months of 2019 compared to the same period in the prior year. As discussed above, the prescription drug market core sales increase of 18% was mainly driven by strong demand for our products sold for central nervous system and allergic rhinitis treatments. We also benefitted from the realization of $1.8 million of revenue for achieving a development milestone related to a customer project. Core sales to the consumer health care market increased 6% as increased demand for our products used on eye care and nasal saline treatments more than offset lower tooling sales. Core sales of our products to the injectables markets grew 6% due to increased demand across a variety of components. Active packaging core sales comparisons are for the one month ended September 30 since our acquisition of CSP Technologies was at the end of August 2018. The increase is mostly due to strong sales of our products used for diabetes treatment and favorable timing of some of our customer orders.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, 2019 | ​ | Prescription | ​ | Consumer | ​ | ​ | ​ | Active | ​ | ​ | ​
Net Sales Change over Prior Year |  | Drug |  | Health Care |  | Injectables |  | Packaging | ​ | Total |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | 18 | % | 6 | % | 6 | % | 19 | % | 12 | %
Acquisitions | ​ | 1 | % | — | % | 2 | % | 805 | % | 12 | %
Currency Effects (1) | ​ | (6) | % | (7) | % | (6) | % | (21) | % | (6) | %
Total Reported Net Sales Growth | ​ | 13 | % | (1) | % | 2 | % | 803 | % | 18 | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Adjusted EBITDA in the third quarter of 2019 increased 14% to $96.5 million compared to $84.5 million reported in the same period of the prior year. The strong product sales growth discussed above along with incremental profit related to our acquisitions led to the increase in reported results for the third quarter of 2019 compared to the third quarter of 2018.

Adjusted EBITDA in the first nine months of 2019 increased 18% to $295.6 million compared to $250.7 million reported in the same period of the prior year. The increased sales and results of acquisitions discussed above offset higher overhead costs and lower profitability on some tooling projects.

FOOD + BEVERAGE SEGMENT

Operations that sell dispensing systems and sealing solutions to the food and beverage markets form the Food + Beverage segment.

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended September 30, | ​ | Nine Months Ended September 30, | ​
​ | ​ | 2019 | ​ | 2018 |  | 2019 | ​ | 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales | ​ | $ | 103,845 | ​ | $ | 96,500 | ​ | $ | 326,587 | ​ | $ | 292,413 | ​
Adjusted EBITDA (1) | ​ | ​ | 18,728 | ​ | ​ | 15,482 | ​ | ​ | 56,363 | ​ | ​ | 46,284 | ​
Adjusted EBITDA margin (1) | ​ | ​ | 18.0% | ​ | ​ | 16.0% | ​ | ​ | 17.3% | ​ | ​ | 15.8% | ​

(1) | Adjusted EBITDA is calculated as earnings before net interest, taxes, depreciation, amortization, unallocated corporate expenses, restructuring and acquisition-related costs. Adjusted EBITDA margins are calculated as Adjusted EBITDA divided by Reported Net Sales. See the reconciliation of non-U.S. GAAP measures starting on page 36.

34

Table of Contents

Net sales for the quarter ended September 30, 2019 increased approximately 8% to $103.8 million compared to $96.5 million in the third quarter of the prior year. Incremental sales from our CSP Technologies acquisition positively impacted sales by 8% while changes in foreign currency rates had an unfavorable impact of 2% on total segment sales. Therefore, core sales increased by 2% in the third quarter of 2019 compared to the third quarter of 2018. For the segment, we realized strong product sales growth offset by a $1.6 million decrease in the pass-through of resin price changes in the quarter ended September 30, 2019 compared to the third quarter of the prior year. Core sales to the food market increased 3% while core sales to the beverage market increased 1% in the third quarter of 2019 compared to the same period of the prior year. For the food market, we realized increased sales of our products used on dairy and granular/powder applications. For the beverage market, high demand for our bottled water products more than offset lower sales of our products used on functional drink and juice applications, mainly in China.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Third Quarter 2019 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales Change over Prior Year |  | ​ | ​ | Food |  | Beverage |  | Total | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | ​ | ​ | 3 | % | 1 | % | 2 | %
Acquisitions | ​ | ​ | ​ | 12 | % | — | % | 8 | %
Currency Effects (1) | ​ | ​ | ​ | (2) | % | (2) | % | (2) | %
Total Reported Net Sales Growth | ​ | ​ | ​ | 13 | % | (1) | % | 8 | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Net sales for the first nine months of 2019 increased by 12% to $326.6 million compared to $292.4 million in the first nine months of 2018. Incremental sales from our CSP Technologies acquisition positively impacted sales by 10% while changes in currency rates negatively impacted net sales by 3% in the first nine months of 2019. Therefore, core sales increased by 5% in the first nine months of 2019 compared to the same period in the prior year. Core sales to the food market increased 7% while core sales to the beverage market increased 3% in the first nine months of 2019 compared to the same period of the prior year. Sales to the food market increased due to strong sales of our products used on granular/powder and sauces/condiments applications, which more than offset lower tooling sales. For the beverage market, increased sales of our products used on bottled water and dairy applications compensated for a decrease in functional drink application sales in China and Europe, as the European region experienced lower temperatures early in the filling season. Lower tooling sales and the pass-through of resin price changes negatively impacted core sales compared to the first nine months of 2018 by $1.8 million and $1.4 million, respectively.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Nine Months Ended September 30, 2019 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Sales Change over Prior Year |  | ​ | ​ | Food |  | Beverage |  | Total |
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Core Sales Growth | ​ | ​ | ​ | 7 | % | 3 | % | 5 | %
Acquisitions | ​ | ​ | ​ | 16 | % | — | % | 10 | %
Currency Effects (1) | ​ | ​ | ​ | (3) | % | (4) | % | (3) | %
Total Reported Net Sales Growth | ​ | ​ | ​ | 20 | % | (1) | % | 12 | %

| (1) | Currency effects are calculated by translating last year’s amounts at this year’s foreign exchange rates.

Adjusted EBITDA in the third quarter of 2019 increased 21% to 18.7 million compared to $15.5 million reported in the same period of the prior year. This increase is due to incremental profit related to our CSP Technologies acquisition and solid core sales growth discussed above. We also benefitted from the positive timing delay of passing on resin cost decreases from previous quarters to our customers.

Adjusted EBITDA in the first nine months of 2019 increased 22% to $56.4 million compared to $46.3 million reported in the same period of the prior year. As discussed above, our profitability was favorably impacted by our strong core sales growth, pass-through of lower resin costs to our customers and incremental profit related to our CSP Technologies acquisition.

CORPORATE & OTHER

In addition to our three reporting segments, we assign certain costs to “Corporate & Other,” which is presented separately in Note 16 – Segment Information to the Notes to the Condensed Consolidated Financial Statements. For Corporate & Other, Adjusted EBITDA (which excludes net interest, taxes, depreciation, amortization, restructuring and acquisition-related costs) primarily includes certain professional fees, compensation and information system costs which are not allocated directly to our reporting segments. For the quarter ended September 30, 2019, Corporate & Other expenses increased to $9.9 million from $8.0 million in the third quarter of 2018. This increase is mainly due to higher professional fees and personnel costs as we continue to implement our growth strategy.

35

Table of Contents

Corporate & Other expenses in the first nine months of 2019 increased to $33.3 million compared to $28.6 million reported in the same period of the prior year. As discussed above, this increase is mainly due to higher costs as we continue to implement our growth strategy.

NON-U.S. GAAP MEASURE S

In addition to the information presented herein that conforms to U.S. GAAP, we also present financial information that does not conform to U.S. GAAP, which are referred to as non-U.S. GAAP financial measures. Management may assess our financial results both on a U.S. GAAP basis and on a non-U.S. GAAP basis. We believe it is useful to present these non-U.S. GAAP financial measures because they allow for a better period over period comparison of operating results by removing the impact of items that, in management’s view, do not reflect our core operating performance. These non-U.S. GAAP financial measures should not be considered in isolation or as a substitute for U.S. GAAP financial results, but should be read in conjunction with the unaudited Condensed Consolidated Statements of Income and other information presented herein. Investors are cautioned against placing undue reliance on these non-U.S. GAAP measures. Further, investors are urged to review and consider carefully the adjustments made by management to the most directly comparable U.S. GAAP financial measure to arrive at these non-U.S. GAAP financial measures.

In our Management’s Discussion and Analysis, we exclude the impact of foreign currency translation when presenting net sales information, which we define as “constant currency.” Changes in net sales excluding the impact of foreign currency translation is a non-U.S. GAAP financial measure. As a worldwide business, it is important that we take into account the effects of foreign currency translation when we view our results and plan our strategies. Consequently, when our management looks at our financial results to measure the core performance of our business, we may exclude the impact of foreign currency translation by translating our prior period results at current period foreign currency exchange rates. As a result, our management believes that these presentations are useful internally and may be useful to investors. We also exclude the impact of material acquisitions when comparing results to prior periods. Changes in operating results excluding the impact of acquisitions are non-U.S. GAAP financial measures. We believe it is important to exclude the impact of acquisitions on period over period results in order to evaluate performance on a more comparable basis.

We present adjusted earnings before net interest and taxes (“Adjusted EBIT”) and consolidated adjusted earnings before net interest, taxes, depreciation and amortization (“Adjusted EBITDA”), both of which exclude the business transformation charges (restructuring initiatives), acquisition-related costs and purchase accounting adjustments that affected inventory values. Our “Outlook” discussion below, as well as the estimated annual effective tax rate above, are also provided on a non-U.S. GAAP basis because certain reconciling items are dependent on future events that either cannot be controlled, such as exchange rates, or reliably predicted because they are not part of our routine activities, such as restructuring and acquisition-related costs.

Finally, we provide a reconciliation of Net Debt to Net Capital as a non-U.S. GAAP measure. “Net Debt” is calculated as interest bearing debt less cash and equivalents and short-term investments while “Net Capital” is calculated as stockholders’ equity plus Net Debt. Net Debt to Net Capital measures a company’s financial leverage, which gives users an idea of a company's financial structure, or how it is financing its operations, along with insight into its financial strength. We believe that it is meaningful to take into consideration the balance of our cash and equivalents, and short-term investments when evaluating our leverage. If needed, such assets could be used to reduce our gross debt position.

36

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended
​ | ​ | September 30, 2019
​ | ​ | ​ | ​
​ |  | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | ​ | $ | 701,278 | ​ | $ | 328,182 | ​ | $ | 269,251 | ​ | $ | 103,845 | ​ | $ | - | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported net income | ​ | $ | 56,769 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income taxes | ​ | ​ | 25,504 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income before income taxes | ​ | ​ | 82,273 | ​ | ​ | 15,413 | ​ | ​ | 78,418 | ​ | ​ | 9,323 | ​ | ​ | (12,940) | ​ | ​ | (7,941)
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring initiatives | ​ | ​ | 6,019 | ​ | ​ | 5,341 | ​ | ​ | 168 | ​ | ​ | 204 | ​ | ​ | 306 | ​ | ​ | ​
Transaction costs related to acquisitions | ​ | ​ | 708 | ​ | ​ | 34 | ​ | ​ | 520 | ​ | ​ | 154 | ​ | ​ | ​ | ​ | ​ | ​
Purchase accounting adjustments related to acquired companies' inventory and backlog | ​ | ​ | 647 | ​ | ​ | ​ | ​ | ​ | 647 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjusted earnings before income taxes | ​ | ​ | 89,647 | ​ | ​ | 20,788 | ​ | ​ | 79,753 | ​ | ​ | 9,681 | ​ | ​ | (12,634) | ​ | ​ | (7,941)
Interest expense | ​ | ​ | 8,898 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 8,898
Interest income | ​ | ​ | (957) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (957)
Adjusted earnings before net interest and taxes (Adjusted EBIT) | ​ | ​ | 97,588 | ​ | ​ | 20,788 | ​ | ​ | 79,753 | ​ | ​ | 9,681 | ​ | ​ | (12,634) | ​ | ​ | -
Depreciation and amortization | ​ | ​ | 49,218 | ​ | ​ | 20,687 | ​ | ​ | 16,793 | ​ | ​ | 9,047 | ​ | ​ | 2,691 | ​ | ​ | -
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | ​ | $ | 146,806 | ​ | $ | 41,475 | ​ | $ | 96,546 | ​ | $ | 18,728 | ​ | $ | (9,943) | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | ​ | ​ | 20.9% | ​ | ​ | 12.6% | ​ | ​ | 35.9% | ​ | ​ | 18.0% | ​ | ​ | ​ | ​ | ​ | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Months Ended
​ | ​ | September 30, 2018
​ | ​ | ​ | ​
​ |  | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | ​ | $ | 665,775 | ​ | $ | 341,760 | ​ | $ | 227,515 | ​ | $ | 96,500 | ​ | $ | - | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported net income | ​ | $ | 39,022 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income taxes | ​ | ​ | 11,920 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income before income taxes | ​ | ​ | 50,942 | ​ | ​ | 3,471 | ​ | ​ | 67,016 | ​ | ​ | 5,481 | ​ | ​ | (17,828) | ​ | ​ | (7,198)
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring initiatives | ​ | ​ | 23,852 | ​ | ​ | 18,854 | ​ | ​ | 2,008 | ​ | ​ | 2,638 | ​ | ​ | 352 | ​ | ​ | ​
Transaction costs related to acquisitions | ​ | ​ | 7,082 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 7,082 | ​ | ​ | ​
Purchase accounting adjustments related to acquired companies' inventory | ​ | ​ | 3,287 | ​ | ​ | ​ | ​ | ​ | 2,761 | ​ | ​ | 526 | ​ | ​ | ​ | ​ | ​ | ​
Adjusted earnings before income taxes | ​ | ​ | 85,163 | ​ | ​ | 22,325 | ​ | ​ | 71,785 | ​ | ​ | 8,645 | ​ | ​ | (10,394) | ​ | ​ | (7,198)
Interest expense | ​ | ​ | 8,735 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 8,735
Interest income | ​ | ​ | (1,537) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (1,537)
Adjusted earnings before net interest and taxes (Adjusted EBIT) | ​ | ​ | 92,361 | ​ | ​ | 22,325 | ​ | ​ | 71,785 | ​ | ​ | 8,645 | ​ | ​ | (10,394) | ​ | ​ | -
Depreciation and amortization | ​ | ​ | 41,857 | ​ | ​ | 19,849 | ​ | ​ | 12,731 | ​ | ​ | 6,837 | ​ | ​ | 2,440 | ​ | ​ | -
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | ​ | $ | 134,218 | ​ | $ | 42,174 | ​ | $ | 84,516 | ​ | $ | 15,482 | ​ | $ | (7,954) | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | ​ | ​ | 20.2% | ​ | ​ | 12.3% | ​ | ​ | 37.1% | ​ | ​ | 16.0% | ​ | ​ | ​ | ​ | ​ | ​

​

37

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended
​ | ​ | September 30, 2019
​ | ​ | ​ | ​
​ |  | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | ​ | $ | 2,188,399 | ​ | $ | 1,037,921 | ​ | $ | 823,891 | ​ | $ | 326,587 | ​ | $ | - | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported net income | ​ | $ | 193,689 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income taxes | ​ | ​ | 80,684 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income before income taxes | ​ | ​ | 274,373 | ​ | ​ | 66,407 | ​ | ​ | 244,101 | ​ | ​ | 29,234 | ​ | ​ | (42,239) | ​ | ​ | (23,130)
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring initiatives | ​ | ​ | 17,286 | ​ | ​ | 14,869 | ​ | ​ | 381 | ​ | ​ | 826 | ​ | ​ | 1,210 | ​ | ​ | ​
Transaction costs related to acquisitions | ​ | ​ | 1,767 | ​ | ​ | 34 | ​ | ​ | 1,579 | ​ | ​ | 154 | ​ | ​ | ​ | ​ | ​ | ​
Purchase accounting adjustments related to acquired companies' inventory and backlog | ​ | ​ | 869 | ​ | ​ | ​ | ​ | ​ | 869 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjusted earnings before income taxes | ​ | ​ | 294,295 | ​ | ​ | 81,310 | ​ | ​ | 246,930 | ​ | ​ | 30,214 | ​ | ​ | (41,029) | ​ | ​ | (23,130)
Interest expense | ​ | ​ | 26,868 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 26,868
Interest income | ​ | ​ | (3,738) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (3,738)
Adjusted earnings before net interest and taxes (Adjusted EBIT) | ​ | ​ | 317,425 | ​ | ​ | 81,310 | ​ | ​ | 246,930 | ​ | ​ | 30,214 | ​ | ​ | (41,029) | ​ | ​ | -
Depreciation and amortization | ​ | ​ | 144,574 | ​ | ​ | 62,101 | ​ | ​ | 48,623 | ​ | ​ | 26,149 | ​ | ​ | 7,701 | ​ | ​ | -
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | ​ | $ | 461,999 | ​ | $ | 143,411 | ​ | $ | 295,553 | ​ | $ | 56,363 | ​ | $ | (33,328) | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | ​ | ​ | 21.1% | ​ | ​ | 13.8% | ​ | ​ | 35.9% | ​ | ​ | 17.3% | ​ | ​ | ​ | ​ | ​ | ​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Nine Months Ended
​ | ​ | September 30, 2018
​ | ​ | ​ | ​
​ |  | Consolidated |  | Beauty + Home |  | Pharma |  | Food + Beverage |  | Corporate & Other |  | Net Interest
Net Sales | ​ | $ | 2,079,733 | ​ | $ | 1,088,469 | ​ | $ | 698,851 | ​ | $ | 292,413 | ​ | $ | - | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported net income | ​ | $ | 154,091 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income taxes | ​ | ​ | 52,966 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Reported income before income taxes | ​ | ​ | 207,057 | ​ | ​ | 40,688 | ​ | ​ | 208,915 | ​ | ​ | 21,736 | ​ | ​ | (45,834) | ​ | ​ | (18,448)
Adjustments: | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Restructuring initiatives | ​ | ​ | 48,002 | ​ | ​ | 38,501 | ​ | ​ | 3,596 | ​ | ​ | 4,307 | ​ | ​ | 1,598 | ​ | ​ | ​
Transaction costs related to acquisitions | ​ | ​ | 9,526 | ​ | ​ | 574 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 8,952 | ​ | ​ | ​
Purchase accounting adjustments related to acquired companies' inventory | ​ | ​ | 3,406 | ​ | ​ | 119 | ​ | ​ | 2,761 | ​ | ​ | 526 | ​ | ​ | ​ | ​ | ​ | ​
Adjusted earnings before income taxes | ​ | ​ | 267,991 | ​ | ​ | 79,882 | ​ | ​ | 215,272 | ​ | ​ | 26,569 | ​ | ​ | (35,284) | ​ | ​ | (18,448)
Interest expense | ​ | ​ | 24,754 | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | 24,754
Interest income | ​ | ​ | (6,306) | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | (6,306)
Adjusted earnings before net interest and taxes (Adjusted EBIT) | ​ | ​ | 286,439 | ​ | ​ | 79,882 | ​ | ​ | 215,272 | ​ | ​ | 26,569 | ​ | ​ | (35,284) | ​ | ​ | -
Depreciation and amortization | ​ | ​ | 123,133 | ​ | ​ | 61,273 | ​ | ​ | 35,437 | ​ | ​ | 19,715 | ​ | ​ | 6,708 | ​ | ​ | -
Adjusted earnings before net interest, taxes, depreciation and amortization (Adjusted EBITDA) | ​ | $ | 409,572 | ​ | $ | 141,155 | ​ | $ | 250,709 | ​ | $ | 46,284 | ​ | $ | (28,576) | ​ | $ | -
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Adjusted EBITDA margins (Adjusted EBITDA / Reported Net Sales) | ​ | ​ | 19.7% | ​ | ​ | 13.0% | ​ | ​ | 35.9% | ​ | ​ | 15.8% | ​ | ​ | ​ | ​ | ​ | ​

​

38

Table of Contents

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Debt to Net Capital Reconciliation | ​ | ​ | September 30, | ​ | ​ | December 31, |
​ | ​ | ​ | 2019 | ​ | ​ | 2018 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Notes payable, including revolving credit facilities | ​ | $ | 46,276 |  | $ | 101,293 |
Current maturities of long-term obligations, net of unamortized debt issuance costs | ​ | ​ | 64,941 | ​ | ​ | 62,678 | ​
Long-Term Obligations, net of unamortized debt issuance costs | ​ | ​ | 1,075,153 | ​ | ​ | 1,125,993 | ​
Total Debt | ​ | ​ | 1,186,370 | ​ | ​ | 1,289,964 | ​
Less: | ​ | ​ | ​ | ​ | ​ | ​ | ​
Cash and equivalents | ​ | ​ | 270,577 | ​ | ​ | 261,823 | ​
Net Debt | ​ | $ | 915,793 | ​ | $ | 1,028,141 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Total Stockholders' Equity | ​ | $ | 1,553,979 | ​ | $ | 1,422,871 | ​
Net Debt | ​ | ​ | 915,793 | ​ | ​ | 1,028,141 | ​
Net Capital | ​ | $ | 2,469,772 | ​ | $ | 2,451,012 | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
Net Debt to Net Capital | ​ | ​ | 37.1% | ​ | ​ | 41.9% | ​

​

FOREIGN CURRENCY

Because of our international presence, movements in exchange rates may have a significant impact on the translation of the financial statements of our foreign subsidiaries. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso, Swiss franc and other Asian, European and South American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial statements. Conversely, a weakening U.S. dollar has an additive effect. In some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. We manage our exposures to foreign exchange principally with forward exchange contracts to economically hedge recorded transactions and firm purchase and sales commitments denominated in foreign currencies. Changes in exchange rates on such inter-country sales could materially impact our results of operations. During the third quarter of 2019 the U.S. dollar strengthened compared to the euro. This resulted in a dilutive impact on our translated results during the third quarter of 2019 when compared to the third quarter of 2018. Beginning July 1, 2018, we have applied highly inflationary accounting for our Argentinian subsidiaries. We have changed the functional currency from the Argentinian peso to the U.S. dollar. Our Argentinian operations contributed less than 2% of consolidated net assets and revenues at and for the nine months ended September 30, 2019.

QUARTERLY TRENDS

Our results of operations in the last quarter of the year typically are negatively impacted by customer plant shutdowns in December. In the future, our results of operations in a quarterly period could be impacted by factors such as the seasonality of certain products within our segments, changes in foreign currency rates, changes in product mix, changes in material costs, changes in growth rates in the markets to which our products are sold and changes in general economic conditions in any of the countries in which we do business.

Historically, we have incurred higher employee stock compensation expense in the first quarter compared with the rest of the fiscal year due to the timing and recognition of stock option expense. During 2019, we transitioned from employee stock options to RSUs and PSUs and therefore we do not anticipate as much variability in expense between quarters in the future. Our estimated total stock-based compensation expense on a pre-tax basis (in $ millions) for the year 2019 compared to 2018 is as follows:

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | 2019 | ​ | 2018 |
First Quarter |  | $ | 6.5 |  | $ | 7.5 | ​
Second Quarter | ​ |  | 6.5 | ​ |  | 3.4 | ​
Third Quarter | ​ |  | 5.1 | ​ |  | 3.9 | ​
Fourth Quarter (estimated for 2019) | ​ |  | 6.1 | ​ |  | 4.8 | ​
​ |  | $ | 24.2 |  | $ | 19.6 | ​

​

39

Table of Contents

LIQUIDITY AND CAPITAL RESOURCES

We believe we are in a strong financial position and have the financial resources to meet our business requirements in the foreseeable future. We have historically used cash flow from operations, our revolving credit facilities and debt, as needed, as our primary sources of liquidity. Our primary uses of liquidity are to invest in equipment and facilities that are necessary to support our growth, cost efficiencies, and to make acquisitions that will contribute to the achievement of our strategic objectives. Other uses of liquidity include repurchasing shares of our common stock and paying dividends to stockholders. In the event that customer demand would decrease significantly for a prolonged period of time and negatively impact cash flow from operations, we would have the ability to restrict and significantly reduce capital expenditure levels, as well as evaluate our acquisition strategy and dividend and share repurchase programs. A prolonged and significant reduction in capital expenditure levels could increase future repairs and maintenance costs as well as have a negative impact on operating margins if we were unable to invest in new innovative products.

Cash and equivalents increased to $270.6 million at September 30, 2019 from $261.8 million at December 31, 2018. Total short and long-term interest bearing debt of $1.2 billion at September 30, 2019 decreased from the $1.3 billion at December 31, 2018 resulting from repayments made during the year on our group credit facilities and long-term debt obligations. The ratio of our Net Debt (interest bearing debt less cash and equivalents) to Net Capital (stockholders’ equity plus Net Debt) decreased to 37.1% at September 30, 2019 compared to 41.9% at December 31, 2018. See the reconciliation of non-U.S. GAAP measures starting on page 36.

In the first nine months of 2019, our operations provided approximately $380.4 million in net cash flow compared to $209.6 million for the same period a year ago. In both periods, cash flow from operations was primarily derived from earnings before depreciation and amortization. The increase in cash provided by operations during the first nine months of 2019 is primarily attributable to the lower restructuring costs, improved profitability and better working capital management.

We used $224.0 million in cash for investing activities during the first nine months of 2019 compared to $668.7 million during the same period a year ago. Our investment in capital projects increased $41.5 million during the first nine months of 2019 compared to the first nine months of 2018, which was driven by $19.3 million of additions related to our CSP Technologies and Nanopharm acquisitions. During the first nine months of 2019, $48.9 million of cash was utilized to fund our Gateway, Nanopharm and Bapco acquisitions; we also released $4.0 million relating to the final escrow settlement on our acquisition of CSP Technologies and invested $3.5 million in two preferred equity investments which are accounted for at cost. We received $16.5 million from the sale of our investment in Reciprocal Labs Corporation, doing business as Propeller Health. During the first nine months of 2018, approximately $553.5 million of our cash (net of $24.1 million of cash acquired) was utilized to fund our acquisition of CSP Technologies during 2018. $5.0 million was held in restricted cash pending the finalization of the working capital adjustment, which was completed during the first quarter of 2019. We also invested $10.0 million in preferred equity stock of Reciprocal Labs Corporation, which was accounted for at cost, and acquired Reboul, a French manufacturer specializing in stamping, decorating and assembling metal and plastic packaging for the cosmetics and luxury markets, for an initial purchase price of approximately $3.6 million (net of $112 thousand of cash acquired). Our 2019 estimated cash outlays for capital expenditures are expected to be in the range of approximately $240 to $260 million but could vary due to changes in exchange rates as well as the timing of capital projects.

Financing activities used $146.2 million in cash during the first nine months of 2019 compared to $50.3 million in cash provided by financing activities during the same period a year ago. During the first nine months of 2019, we received net proceeds from our stock option exercises of $81.8 million. We used cash on hand to pay $67.2 million of dividends, repay $47.3 million on our revolving credit facility and repurchase $54.9 million of treasury stock.

We hold U.S. dollar and euro-denominated debt to align our capital structure with our earnings base. We also maintain a multi-currency revolving credit facility with two tranches, providing for unsecured financing of up to $300 million that is available in the U.S. and up to €150 million that is available to our wholly-owned UK subsidiary. Each borrowing under the credit facility will bear interest at rates based on LIBOR, prime rates or other similar rates, in each case plus an applicable margin. A facility fee on the total amount of the facility is also payable quarterly, regardless of usage. The applicable margins for borrowings under the credit facility and the facility fee percentage may change from time to time depending on changes in our consolidated leverage ratio. The December 31, 2018 outstanding balance of €69.0 million on the euro-based revolving credit facility was paid in the first quarter of 2019. €27.0 million was utilized as of September 30, 2019. Credit facility balances are included in notes payable, including revolving credit facilities on the Condensed Consolidated Balance Sheet.

​

Our revolving credit facility and corporate long-term obligations require us to satisfy certain financial and other covenants including:

​ | ​ | ​ | ​ | ​
​ |  | Requirement |  | Level at September 30, 2019
Consolidated Leverage Ratio (1) |  | Maximum of 3.50 to 1.00 |  | 1.68 to 1.00
Consolidated Interest Coverage Ratio (1) |  | Minimum of 3.00 to 1.00 |  | 16.07 to 1.00

(1) | Definitions of ratios are included as part of the revolving credit facility agreement and the note purchase agreements.

​

40

Table of Contents

Based upon the above consolidated leverage ratio covenant, we have the ability to borrow approximately an additional $1.0 billion before the 3.50 to 1.00 maximum ratio requirement is exceeded.

Our foreign operations have historically met cash requirements with the use of internally generated cash or uncommitted short-term borrowings. We also have committed financing arrangements in both the U.S. and UK as detailed above. We manage our global cash requirements considering (i) available funds among the many subsidiaries through which we conduct business, (ii) the geographic location of our liquidity needs, and (iii) the cost to access international cash balances.

On October 17, 2019, the Board of Directors declared a quarterly cash dividend of $0.36 per share payable on November 20, 2019 to stockholders of record as of October 30, 2019.

CONTINGENCIES

The Company, in the normal course of business, is subject to a number of lawsuits and claims both actual and potential in nature. Please refer to Note 12 - Commitments and Contingencies of the Notes to Condensed Consolidated Financial Statements for a discussion of contingencies affecting our business.

OFF-BALANCE SHEET ARRANGEMENTS

We lease certain warehouse, plant and office facilities as well as certain equipment under noncancelable operating leases. Most of the operating leases contain renewal options and certain equipment leases include options to purchase during or at the end of the lease term. As a result of the adoption of ASU 2016-02 and subsequent amendments, which requires organizations to recognize leases on the balance sheet, we do not have significant off-balance sheet arrangements. Please refer to Note 7 – Lease Commitments of the Notes to Condensed Consolidated Financial Statements for lease arrangements that have not yet commenced and therefore are not included on the balance sheet.

RECENTLY ISSUED ACCOUNTING STANDARDS

We have reviewed the recently issued accounting standards updates to the FASB’s Accounting Standards Codification that have future effective dates. Standards that are effective for 2019 are discussed in Note 1 – Summary of Significant Accounting Policies of the Notes to Condensed Consolidated Financial Statements.

In June 2016, the FASB issued ASU 2016-13, which changes the accounting guidance for measurement of credit losses on financial instruments. The guidance replaces the incurred loss impairment methodology in current U.S. GAAP with a methodology that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information when recording credit loss estimates. The new standard is effective for fiscal years and interim periods beginning after December 15, 2019. We are currently evaluating the impact of adopting this guidance.

In January 2017, the FASB issued ASU 2017-04, which provides guidance to simplify how an entity is required to test goodwill for impairment by eliminating Step 2 from the goodwill impairment test. As a result, impairment charges will be required for the amount by which a reporting unit’s carrying amount exceeds its fair value up to the amount of its allocated goodwill. The new standard is effective for the annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019. We do not believe that this new guidance will have a material impact on our Condensed Consolidated Financial Statements.

In August 2018, the FASB issued ASU 2018-14, which amends disclosure requirements for defined benefit pension and other postretirement plans. The amendments in this update remove disclosures that are no longer considered cost beneficial, clarify the specific requirements of disclosures, and add disclosure requirements identified as relevant. The new standard is effective for fiscal years ending after December 15, 2020. As this update amends disclosure requirements, we do not expect any significant impact around adopting this guidance.

In August 2018, the FASB issued ASU 2018-15 to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. The amendments in this update align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the amendments require an entity (customer) in a hosting arrangement that is a service contract to follow the guidance in Subtopic 350-40 to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. The amendments also require the entity (customer) to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement, which includes reasonably certain renewals. The new standard is effective for fiscal years beginning after December 15, 2019. We are currently evaluating the impact of adopting this guidance.

41

Table of Contents

Other accounting standards that have been issued by the FASB or other standards-setting bodies that do not require adoption until a future date are not expected to have a material impact on our Condensed Consolidated Financial Statements upon adoption.

OUTLOOK

We expect earnings per share for the fourth quarter, excluding any restructuring costs and acquisition related expenses, to be in the range of $0.74 to $0.80 and this guidance is based on an effective tax rate range of 30% to 32%. The effective tax rate on adjusted earnings for the prior year fourth quarter was approximately 29%.

FORWARD-LOOKING STATEMENTS

Certain statements in Management’s Discussion and Analysis and other sections of this Form 10-Q are forward-looking and involve a number of risks and uncertainties, including certain statements set forth in the Restructuring Initiatives, Quarterly Trends, Liquidity and Capital Resources, Contingencies and Outlook sections of this Form 10-Q. Words such as “expects,” “anticipates,” “believes,” “estimates,” “future,” “potential” and other similar expressions or future or conditional verbs such as “will,” “should,” “would” and “could” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to:

● | economic conditions worldwide, including potential deflationary or inflationary conditions in regions we rely on for growth;

● | political conditions worldwide, including the impact of the UK leaving the European Union (Brexit) on our UK operations;

● | significant fluctuations in foreign currency exchange rates or our effective tax rate;

● | the impact of tax reform legislation, changes in tax rates and other tax-related events or transactions that could impact our effective tax rate;

● | financial conditions of customers and suppliers;

● | consolidations within our customer or supplier bases;

● | changes in customer and/or consumer spending levels;

● | loss of one or more key accounts;

● | the availability of raw materials and components (particularly from sole sourced suppliers) as well as the financial viability of these suppliers;

● | fluctuations in the cost of materials, components and other input costs (particularly resin, metal, anodization costs and transportation and energy costs);

● | our ability to successfully implement facility expansions and new facility projects;

● | our ability to offset inflationary impacts with cost containment, productivity initiatives or price increases;

● | changes in capital availability or cost, including interest rate fluctuations;

● | volatility of global credit markets;

● | the timing and magnitude of capital expenditures;

● | our ability to identify potential new acquisitions and to successfully acquire and integrate such operations and products, including the successful integration of the businesses we have acquired;

● | direct or indirect consequences of acts of war, terrorism or social unrest;

● | cybersecurity threats that could impact our networks and reporting systems;

● | the impact of natural disasters and other weather-related occurrences;

● | fiscal and monetary policies and other regulations;

● | changes or difficulties in complying with government regulation;

● | changing regulations or market conditions regarding environmental sustainability;

● | work stoppages due to labor disputes;

● | competition, including technological advances;

● | our ability to protect and defend our intellectual property rights, as well as litigation involving intellectual property rights;

● | the outcome of any legal proceeding that has been or may be instituted against us and others;

● | our ability to meet future cash flow estimates to support our goodwill impairment testing;

● | the demand for existing and new products;

● | the success of our customers’ products, particularly in the pharmaceutical industry;

● | our ability to manage worldwide customer launches of complex technical products, particularly in developing markets;

42

Table of Contents

● | difficulties in product development and uncertainties related to the timing or outcome of product development;

● | significant product liability claims;

● | the execution of our business transformation plan; and

● | other risks associated with our operations.

​

Although we believe that our forward-looking statements are based on reasonable assumptions, there can be no assurance that actual results, performance or achievements will not differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. We undertake no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Please refer to Item 1A (“Risk Factors”) of Part I included in our Annual Report on Form 10-K for the year ended December 31, 2018 for additional risk factors affecting the Company.

​

​

43

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

A significant number of our operations are located outside of the United States. Because of this, movements in exchange rates may have a significant impact on the translation of the financial condition and results of operations of our entities. Our primary foreign exchange exposure is to the euro, but we also have foreign exchange exposure to the Chinese yuan, Brazilian real, Mexican peso and Swiss franc, among other Asian, European, and South American currencies. A strengthening U.S. dollar relative to foreign currencies has a dilutive translation effect on our financial condition and results of operations. Conversely, a weakening U.S. dollar relative to foreign currencies has an additive translation effect on our financial condition and results of operations.

Additionally, in some cases, we sell products denominated in a currency different from the currency in which the related costs are incurred. Any changes in exchange rates on such inter-country sales may impact our results of operations.

We manage our exposures to foreign exchange principally with forward exchange contracts to hedge certain firm purchase and sales commitments and intercompany cash transactions denominated in foreign currencies.

The table below provides information as of September 30, 2019 about our forward currency exchange contracts. The majority of the contracts expire before the end of the third quarter of 2019.

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | ​ | Average |  | Min / Max | ​
​ |  | ​ | Contract Amount |  | Contractual | ​ | Notional | ​
Buy/Sell | ​ | ​ | (in thousands) |  | Exchange Rate |  | Volumes | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
EUR / USD | ​ | $ | 14,138 |  | 1.1164 |  | 13,919-28,394 | ​
EUR / BRL | ​ | ​ | 11,688 |  | 4.6254 |  | 11,646-12,814 | ​
CHF / EUR |  | ​ | 6,518 |  | 0.9079 |  | 6,518-6,792 | ​
EUR / IDR | ​ | ​ | 4,673 | ​ | 17.1408 | ​ | 4,409-4,673 | ​
EUR / INR | ​ | ​ | 4,042 |  | 78.6460 |  | 3,975-4,138 | ​
GBP / EUR | ​ | ​ | 1,360 |  | 1.1158 |  | 831-1,360 | ​
EUR / MXN | ​ | ​ | 613 |  | 22.1501 |  | 613-687 | ​
USD / EUR | ​ | ​ | 473 | ​ | 0.8940 | ​ | 473-7,245 | ​
CHF / USD | ​ | ​ | 352 | ​ | 1.0179 | ​ | 10-519 | ​
MXN / USD | ​ | ​ | 29 | ​ | 0.0518 | ​ | 9-29 | ​
Total |  | $ | 43,887 | ​ | ​ | ​ | ​ | ​

​

As of September 30, 2019, we have recorded the fair value of foreign currency forward exchange contracts of $0.04 million in prepaid and other and $0.6 million in accounts payable and accrued liabilities on the balance sheet. We also entered into a EUR/USD floating-to-fixed cross currency swap on July 20, 2017 to effectively hedge the foreign exchange and interest rate exposure on the $280 million bank term loan drawn by our wholly-owned UK subsidiary. The fair value of this cash flow hedge is $6.7 million reported in prepaid on the balance sheet.

​

ITEM 4. CONTROLS AND PROCEDURES

DISCLOSURE CONTROLS AND PROCEDURES

Management has evaluated, with the participation of the chief executive officer and chief financial officer of the Company, the effectiveness of our disclosure controls and procedures (as that term is defined in Rule 13a-15(e) under the Securities Exchange Act of 1934) as of September 30, 2019. Based on that evaluation, the chief executive officer and chief financial officer have concluded that these controls and procedures were effective as of such date.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

No changes in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Securities Exchange Act of 1934) occurred during our fiscal quarter ended September 30, 2019 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

​

44

Table of Contents

PART II - OTHER INFORMATION

​

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

​

RECENT SALES OF UNREGISTERED SECURITIES

Certain French employees are eligible to participate in the FCP Aptar Savings Plan (the “Plan”). An independent agent purchases shares of common stock available under the Plan for cash on the open market and we do not issue shares. We do not receive any proceeds from the purchase of common stock under the Plan. The agent under the Plan is Banque Nationale de Paris Paribas Fund Services. No underwriters are used under the Plan. All shares are sold in reliance upon the exemption from registration under the Securities Act of 1933 provided by Regulation S promulgated under that Act. During the quarter ended September 30, 2019, the Plan purchased 1,931 shares of our common stock on behalf of the participants at an average price of $118.55, for an aggregate amount of $229 thousand. The Plan sold 1,992 shares of our common stock on behalf of the participants at an average price of $122.38, for an aggregate amount of $244 thousand during the same period. At September 30, 2019, the Plan owned 85,550 shares of our common stock.

ISSUER PURCHASES OF EQUITY SECURITIES

On April 18, 2019, we announced a share purchase authorization of up to $350 million of common stock. This authorization replaces previous authorizations and has no expiration date. We may repurchase shares through the open market, privately negotiated transactions or other programs, subject to market conditions.

During the three months ended September 30, 2019, we repurchased approximately 300 thousand shares for approximately $35.8 million.

The following table summarizes our purchases of our securities for the quarter ended September 30, 2019:

​

​

​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ |  | ​ |  | ​ |  | Dollar Value Of |
​ | ​ | ​ | ​ | ​ | ​ | ​ | Total Number Of Shares | ​ | Shares that May Yet be |
​ | ​ | ​ | Total Number | ​ | ​ | ​ | Purchased as Part Of | ​ | Purchased Under The |
​ | ​ | ​ | Of Shares | ​ | Average Price | ​ | Publicly Announced | ​ | Plans or Programs |
Period | ​ | ​ | Purchased | ​ | Paid Per Share | ​ | Plans Or Programs | ​ | (in millions) | ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ |
7/1 – 7/31/19 | ​ |  | 38,721 | ​ | $ | 122.95 |  | 38,721 | ​ | $ | 341.1 | ​
8/1 – 8/31/19 | ​ |  | 82,462 | ​ |  | 119.27 |  | 82,462 | ​ |  | 331.3 | ​
9/1 – 9/30/19 | ​ |  | 178,938 | ​ |  | 118.37 |  | 178,938 | ​ |  | 310.1 | ​
Total | ​ |  | 300,121 | ​ | $ | 119.21 |  | 300,121 | ​ | $ | 310.1 | ​

​

​

​

45

Table of Contents

ITEM 6. EXHIBITS

​

​ | ​ | ​
​ | ​ | ​
​ | ​ | ​
Exhibit 31.1 | ​ | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 31.2 | ​ | Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 32.1 | ​ | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 32.2 | ​ | Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
​ | ​ | ​
Exhibit 101 | ​ | The following information from our Quarterly Report on Form 10-Q for the third quarter of fiscal 2019, filed with the SEC on November 1, 2019, formatted in Inline Extensible Business Reporting Language (XBRL): (i) the Cover Page, (ii) the Condensed Consolidated Statements of Income – Three and Nine Months Ended September 30, 2019 and 2018, (iii) the Condensed Consolidated Statements of Comprehensive Income – Three and Nine Months Ended September 30, 2019 and 2018, (iv) the Condensed Consolidated Balance Sheets – September 30, 2019 and December 31, 2018, (v) the Condensed Consolidated Statements of Changes in Equity – Three and Nine Months Ended September 30, 2019 and 2018, (vi) the Condensed Consolidated Statements of Cash Flows - Nine Months Ended September 30, 2019 and 2018 and (vii) the Notes to Condensed Consolidated Financial Statements. ​
Exhibit 104 | ​ | Cover Page Interactive Data File (embedded within the Inline XBRL document).
​ | ​ | ​
​ | ​

​

​

​

​

46

Table of Contents

SIGNATURE

​

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

​

​ | ​ | AptarGroup, Inc.
​ | ​ | (Registrant)
​ | ​ | ​
​ | By | /s/ ROBERT W. KUHN
​ | ​ | Robert W. Kuhn
​ | ​ | Executive Vice President,
​ | ​ | Chief Financial Officer and Secretary
​ | ​ | (Duly Authorized Officer and
​ | ​ | Principal Accounting and Financial Officer)
​ | ​ | ​
​ | ​ | ​
​ | ​ | Date: November 1, 2019

​

​

​

​

47